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ABSTRACT 
Metronomic cyclophosphamide (CPA) treatment activates robust anti-tumor 
immunity and induces regression of implanted tumors in mouse models of brain cancer 
when administered on an intermittent, every 6-day schedule (CPA/6d), but not on a daily 
low-dose or a maximum-tolerated dose schedule. Five intermittent metronomic CPA 
schedules were investigated in GL261 gliomas implanted in scid mice. Metronomic CPA 
treatments spaced 9 or 12 days apart induced extensive tumor regression, however, 
tumor-infiltrating natural killer cell responses were not sustained, and tumor growth 
rapidly resumed after treatment day 24. Increasing the CPA dose prolonged the period of 
tumor regression on the every 9-day schedule, but natural killer cell activation was 
markedly decreased. Thus, sustained immune and anti-tumor responses were only 
achieved on the CPA/6d schedule. Furthermore, CPA/6d treatment eradicated GL261 
tumors implanted in immunocompetent C57BL/6 mice by activating anti-tumor CD8-T 
cell responses and immune memory, which provides proof-of-concept that single agent 
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chemotherapy delivered on an optimized metronomic schedule can cure large established 
cancers. Transcriptomic profiling, KEGG pathway, and upstream regulator analysis were 
employed to compare CPA/6d-induced gene expression changes between: immune-
responsive GL261 tumors and immune-unresponsive Lewis lung carcinoma (LLC) and 
B16F10 melanoma tumors; between GL261 tumors implanted in immunocompetent mice 
versus in scid immunodeficient mice; and between GL261 tumors in scid mice treated 
with CPA every 6-days or every 9-days. CPA-treated LLC tumors were associated with 
inhibited VEGFA-targeted genes, down-regulated cell adhesion and transendothelial 
migration genes, and up-regulated drug metabolism pathways. In B16F10 tumors, CPA 
activated genes in chemokine signaling and antigen processing and presentation 
pathways, but no NK cell and T cell effector pathways were activated. GL261 tumors in 
scid mice were deficient in CPA activation of a subset of cytokine and cytokine receptor 
genes and T cell receptor signaling genes seen in immunocompetent mice. Cytokine gene 
expression was lower and drug metabolism gene expression was higher in every 9-day 
CPA-treated tumors versus CPA/6d-treated tumors. Together, these studies elucidate the 
dose, schedule, and adaptive immune-dependence of CPA-induced anti-tumor immune 
responses, giving new insight into the molecular signaling events underlying the 
deficiencies in immune responses seen in intermittent metronomic CPA-unresponsive 
tumor models. 
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Prf1 perforin 1 (pore forming protein) 
PRKAA1 protein kinase, AMP-activated, alpha 1 
PTGS2 prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and 
cyclooxygenase) 
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RIN RNA integrity number  
RIPK2 receptor-interacting serine-threonine kinase 2 
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SASP senescence associated secretory phenotype 
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TLR3 toll-like receptor 3 
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TRAF6 TNF receptor-associated factor 6, E3 ubiquitin protein ligase  
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CHAPTER ONE: RE-VISITING IMMUNOGENIC CHEMOTHERAPY: DOSE 
AND SCHEDULE DEPENDENCE AND A NEW DIRECTION  
1.1 Introduction 
In a healthy host the immune system can surveil and eliminate abnormal changes, 
such as nascent transformation [1]. Growing tumors can overcome immune surveillance 
by immunoediting, in which tumors evolve into or select for non-immunogenic tumor 
cell variants, or by immunosubversion, in which tumors develop mechanisms to actively 
suppress the immune system [1]. Tumor cells can also evade immune cell attack by 
secreting chemokines that preferentially recruit pro-tumor growth immune cells [2]. 
Accordingly, common approaches to cancer cellular immunotherapy involve the 
introduction of exogenous anti-tumor immune cells and the re-activation of endogenous 
immune surveillance mechanisms. However, the success of immunotherapy can be 
limited by immune escape mechanisms employed by cancer cells [2, 3]. Conventional 
cytotoxic chemotherapy is often immunosuppressive and associated with drug resistance 
leading to tumor regrowth after a short period of tumor shrinkage or tumor growth stasis 
[4]. However, several cytotoxic chemotherapeutics can induce immunogenic tumor cell 
death and activate robust anti-tumor immune responses that increase the efficacy of 
chemotherapy [5]. Here, we review how cancer chemotherapeutic drugs perturb the 
interactions between tumor cells and the host and induce immunogenic tumor cell death. 
We discuss how the choice of cytotoxic agent, and its dose and schedule impact immune 
responses. We present strategies to improve the design of combination chemo-
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immunotherapies. Finally, approaches to identify novel immunogenic chemotherapeutic 
drugs are discussed. 
Molecular interactions between tumor and host - The molecular interactions 
between tumor cells and the host may vary dramatically for different tumors due to 
factors such as tumor clonal heterogeneity [6], differentiation [7], driver gene mutations 
[8, 9], tumor cell immunogenicity [10], anatomical location and other factors [1, 6-14]. 
The interactions between tumor cells and the host can be considered at a local level, 
which includes the tumor cells, together with tumor-associated immune cells, endothelial 
cells, fibroblasts, and the extracellular matrix [7, 15-20]. Interactions can also be 
considered at the systemic level, involving the tumor local compartment/organ and its 
interactions with bone marrow (BM), spleen, lymph nodes, peripheral blood and other 
affected organs [11, 20-23]. A deeper understanding of the molecular interactions 
between tumor and host can help identify diagnostic markers, therapeutic targets and 
prognostic markers.  
Under normal, healthy conditions, malignant tumor cells are recognized as “non-
self” and are destroyed by immune cells in a process termed immune surveillance. For a 
tumor to expand, tumor cells must escape immune surveillance [1], for example by down 
regulating tumor-specific antigens and thereby hiding “non-self” tumor cell antigens from 
immune cells [1, 24]. Tumors can also escape immune surveillance by restricting their 
access to immune cells [21, 25]. A third way is to subvert the immune system. Many 
tumor cells and tumor-polarized stromal cells secrete growth factors that expand immune 
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suppressive cell populations, such as regulatory T cells (Tregs) and myeloid-derived 
immune suppressor cells (MDSCs) [26]. Tumor cells can directly inhibit the activation of 
immune cells by expressing inhibitory ligands for immune cells [11].  Tumor cells can 
also polarize (reprogram) immune cells that have plasticity, such as macrophages and 
neutrophils, converting them from the classically activated anti-tumor status into 
alternatively activated pro-tumor growth status [15, 27, 28]. The immunosubversion or 
immunoediting process is assisted by tumor-associated fibroblasts and endothelial cells 
[11], which combine with immune cells to generate a microenvironment that favors 
tumor growth [11]. 
Tumor cells can also interact with distant organs via signaling small molecules 
that are activated by chronic DNA damage responses resulting from the instability of the 
tumor cell genome [22], by chronic inflammatory responses to tumor cells [11], and by a 
senescence-associated secretory phenotype, which is associated with tumor cells and 
tumor-polarized stromal components [11, 22, 29]. Tumors produce soluble and other 
regulatory factors, including VEGF, PIGF, CXCL12, G-CSF, IL-6, TGF-beta, TNF-
alpha, MMP2, and MMP9, which regulate the trafficking, differentiation and activation 
of immune cells in blood, spleen, bone marrow, lung and liver, some of which are sites of 
tumor cell metastasis [11]. Tumor growth at local and metastatic sites can also be 
affected by bone marrow-derived myeloid cells, neutrophil precursors, macrophages and 
dendritic cells (DCs), endothelial precursor cells, as well as the growth factors, cytokines 
and chemokines that these immune cells produce [11, 30, 31].  
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Perturbation of interactions between tumor and host by chemotherapeutic 
drug treatment - Conventional cancer chemotherapeutic drugs are cytotoxic and 
cytostatic agents designed to reduce tumor cell number and overall tumor mass. Recent 
studies indicate that several such conventional cytotoxic drugs are able to kill tumor cells 
by activation of  anti-tumor immune responses, which can greatly increase the efficacy of 
chemotherapy [32, 33]. This immunogenic cell death pathway involves the early 
translocation of calreticulin to the tumor cell surface via exocytosis [34, 35] and post-
apoptotic release of HMGB1 and ATP into the extracellular matrix [32]. Calreticulin on 
the tumor cell surface can serve as an essential “eat-me” signal for DCs. Tumor surface 
molecules such as CD31, CD46, and CD47, which serve as “don’t eat me” signals for 
DCs, are down regulated, allowing the “eat-me” signals to prevail and phagocytosis of 
apoptotic cell to occur [36]. Molecular chaperones such as heat-shock protein 90 appear 
on the tumor cell surface, enhancing DC-tumor cell adhesion and stimulating DC 
maturation [37]. High-mobility group box 1 (HMGB1) translocates from the nucleus to 
the cytoplasm, and is then released into the extracellular matrix when tumor cells undergo 
necrosis. This release enables HMGB1 to interact with Toll-like receptor 4 (TLR4) 
expressed on DCs, thereby stimulating the antigen presentation function of DCs as well 
as DC production of IL-1beta, which activates CD8
+
 T cells [32, 38]. ATP secreted by 
dying tumor cells can act on DC purinergic P2RX7 receptors to activate CD8
+
 T cells 
[32, 39]. Consistent with the importance of chemotherapy-induced immunogenic tumor 
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cell death, loss-of-function alleles of TLR4 and P2RX7 have been associated with low 
efficacy of chemotherapy or radiotherapy [33, 38, 39].   
Chemotherapy can also increase tumor cell immunogenicity by inducing the 
expression of MHC I molecules or tumor-specific antigens on the tumor cell surface [40]. 
Chemotherapy-induced stress can also induce expression of stimulatory ligands, such as 
Nkg2d activating ligands [41], while decreasing tumor cell surface levels of inhibitory 
ligands, such as Clr-b, increasing the activation of natural killer (NK) cells [42, 43]. 
Chemotherapy can also increase tumor cell surface expression of death receptors, such as 
TRAIL receptor and mannose-6-phosphate receptor,, rendering tumor cells susceptible to 
immune cell attack [44, 45]. In some cases, bystander tumor cells are also killed by 
activated immune cells [44].  
Cytotoxic cancer chemotherapeutic drugs, such as cyclophosphamide (CPA), 
induce transient lymphopenia, which is well-documented in both preclinical animal 
models and in the clinic [46]. Lymphopenia is often associated with up regulation of host 
danger-sensing and repair mechanisms, which leads to a “storm” of cytokines and 
chemokines, DC differentiation, maturation and homeostatic proliferation, T cell 
activation, and anti-tumor immune cell recruitment into tumors [47, 48]. Immune 
suppressive cells, such as Tregs and MDSCs, are also sensitive to cytotoxic 
chemotherapy. Low dose CPA given to advanced cancer patients (50 mg orally, twice a 
day, 1 week on and 1 week off, for 1 month or more) selectively depletes circulating Treg 
cells, which restores  NK cell effector function and conventional T-cell proliferation [49].  
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1.2 Factors affecting chemotherapy-activated immune responses 
Chemotherapeutic drug type - Several classical cancer chemotherapeutic drugs, 
including doxorubicin, epirubicin, idarubicin, mitoxantrone, and oxaliplatin and CPA, 
have been shown to induce immunogenic tumor cell death and anti-tumor immune 
responses [33, 50-52]. For example, vaccination of immune competent mice by injection 
of tumor cells treated with the immunogenic drugs mitoxantrone, doxorubicin or 
idarubicin, conferred immunity against live tumor cell challenge on the opposite flank 
[34]. In contrast, tumor cells treated with other DNA-damaging agents, such as etoposide 
and mitomycin C, show little vaccine activity in the same setting and thus are considered 
non-immunogenic [34]. Further study indicates that a protein kinase-like endoplasmic 
reticulum kinase (PERK)-mediated endoplasmic reticulum stress response leads to 
calreticulin exposure, which dictates the immunogenicity of dying cancer cells [34]. 
Indeed, over expression of calreticulin or knock down of 1/GADD34, a negative 
regulator of calreticulin, restores the immunogenicity of cancer cells treated with 
etoposide and mitomycin C [34]. In a mouse study, oxaliplatin and cisplatin both 
triggered HMGB1 release from murine and human colon cancer cells, while oxaliplatin, 
but not cisplatin, stimulated calreticulin exposure and induced anticancer immunity [53]. 
In a study of three human tumor cells with different histologies, REH acute 
lymphoblastic leukemia cells, OV90 ovarian cancer cells and DU145 prostate cancer 
cells, doxorubicin and idarubicin, but not gemcitabine and etoposide, activated tumor cell 
immunogenic cell death markers, as well as tumor cell uptake by DC, maturation of DCs, 
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and in vitro T-cell activation [54]. These findings suggest that some chemotherapeutic 
drugs fail to elicit immunogenic cell death due to intrinsic features.  
In contrast, the immunogenic cancer drug CPA, when given on an every 6-day 
repeating schedule, induces robust anti-tumor immune responses in several gliomas 
implanted in scid immunodeficient mice [55-58]. In contrast, KM12 colon cancer 
xenografts do not show these responses, even though KM12 tumor cells show an intrinsic 
sensitivity to the cytotoxicity of activated CPA that is similar to that of the glioma cells 
[59]. A similar phenomenon was observed in immune-competent C57BL/6 mice (B6 
mice), where studies presented in Chapter 3 of this thesis show that an every 6-day 
repeating CPA schedule cured GL261 tumors by a CD8
+
 T cell-dependent mechanism 
but effected only a modest delay in the growth of LLC and B16F10 tumors with little or 
no immune responses (unpublished data, CS Chen and M Jordan, Waxman lab). This 
suggests that in some cases tumor cell-intrinsic features resist immunogenic cell death, or 
have deficiencies in critical factors required for drug-induced immunogenic cell death. 
There is thus a need for studies, such as those presented in Chapter 4 of this thesis, to 
identify biomarkers that distinguish immune-responsive from immune non-responsive 
tumors, and to match chemotherapeutic drugs with responsive tumor cell type to elicit 
immunogenic cell death. 
Several cancer chemotherapeutic agents found to be non-immunogenic in one 
study can nevertheless exert immune stimulatory functions in another. For example, 
cisplatin, which has been defined as non-immunogenic [53], can eliminate MDSCs and 
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thus relieve tumor immune suppression and augment the homing ability of exogenous 
and endogenous immune effector cells in a murine B16 melanoma xenograft model [60]. 
Similarly, etoposide, a non-immunogenic cancer chemotherapeutic agents as defined by 
the work of Obeid et al. [34], can facilitate DC maturation at doses that cause only 
marginal DC death [61]. Thus, it is likely that more drugs are capable of inducing anti-
tumor immune responses than currently recognized, and in some cases, that immune 
effects vary from one tumor to another. A systematic investigation to determine which 
drugs can or cannot elicit immunogenic cell death or other anti-tumor immune responses 
is thus warranted. Further, chemotherapy that is given at a suboptimal dose or schedule 
may fail to elicit significant immunogenic cell death or immune responses, as discussed 
below.  
Impact of chemotherapeutic drug dose and schedule - Given the right match 
between chemotherapeutic drug and tumor, there are many factors that can affect the 
strength and duration of immune anti-tumor responses and thus overall anti-tumor 
efficacy.  The studies presented in this thesis along with other published studies 
summarized below establish the striking importance of chemotherapy dose and schedule. 
Treatment with cancer chemotherapeutic drugs administered at a maximum 
tolerated dose (MTD) is associated with high host toxicity, tumor vasculature regrowth, 
and the selection of drug-resistant cell populations during the prolonged drug-free breaks 
required for recovery from host toxicity [46]. In contrast, metronomic schedules of 
chemotherapy deliver drugs at a lower dose but on a more frequent, or even a continuous 
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(daily) schedule, which is usually less toxic to the host. Consider CPA, a widely used and 
well-studied cancer chemotherapeutic drug [62] that is used in 43% of metronomic drug 
trials for cancer [52, 63]. Wada et al. found that a single injection of CPA at a dose of 50 
- 100 mg/kg induced tumor-specific T cell infiltration in autochthonous prostate tumors, 
while doses higher than 200 mg/kg are highly cytotoxic to circulating CD4
+
 T, CD8
+
 T 
and CD19
+
 B cells in a mouse model [64]. In studies from this laboratory, CPA delivered 
on an MTD schedule induced transient innate immune responses in implanted glioma 
models, whereas when CPA was given on an intermittent, 6-day repeating metronomic 
schedule, immune responses were sustained and a prolonged period of tumor regression 
was achieved, as seen in several mouse glioma models [55-57].  
In related studies, a 6-day repeating metronomic schedule of CPA was more 
effective in activating anti-tumor innate immune responses than an exposure dose-
equivalent daily low-dose metronomic schedule of CPA in a 9L brain tumor xenograft-
bearing scid mice [56]. In other studies, tumor-specific T cells were increased in tumor 
draining lymph nodes when CPA was given at 100 mg/kg as a bolus dose on an every 8 
day-repeating schedule, but were suppressed when the same total CPA dose was given at 
50 mg/kg CPA repeated every 4 days  [65]. Metronomic CPA treatments at either 10 
mg/kg per day or 50 mg/kg per week act synergistically with tumor vaccines to induce 
tumor regression in an HPV tumor-bearing C57BL/6 (B6) mouse model, however, the 
daily administration schedule tends to decrease tumor-specific CD8
+
 T cells in 
comparison to the weekly schedule [66]. Similarly, in CT26 colorectal carcinoma tumor-
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bearing BALB/c mice given CPA in combination with IL-12 gene therapy, a single 
injection of CPA at 50 mg/kg induced a superior anti-tumor response compared to when 
CPA was given three times per week at a dose of 25 mg/kg [67].  
In contrast, CPA given on a 14-day repeating schedule inhibits tumor regression 
and long-term immune response activated by the TLR7/TLR8 agonist resiquimod (R488) 
in a syngeneic rat CNS-1 glioma model [68]. We have found that halting CPA treatment 
after two 6-day CPA cycles in a GL261 tumor-bearing B6 mice led to a significant 
increase in Treg cells marked by Foxp3 in the tumor compartment 9 days later [69]. This 
increase correlated with the decreased expression of the immune effector marker Prf1, 
indicating that in this model, a CPA schedule with a drug-free break longer than 6 days 
may be subject to robust immune suppression [69]. Similarly, a metronomic CPA 
schedule with a drug-free break > 6 days induced a transient NK cell responses in 
comparison to that induced by every 6-day CPA treatment [70]. These results highlight 
the importance of chemotherapeutic dose and schedule optimization for activation of 
anti-tumor immune responses.   
1.3 Chemotherapy combined with immunotherapy  
Despite the aforementioned strong, beneficial anti-tumor immune responses that 
can be achieved in some tumor models by mono-chemotherapy is usually transient and 
followed by tumor regrowth [71]. This indicates a need to better optimize 
chemotherapeutic doses and schedules and to develop effective combination therapies. 
Combinations of chemotherapy with immunotherapy are particularly attractive, given the 
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intrinsic immunostimulatory capacity of certain classical cancer chemotherapeutic drugs, 
discussed above, and the distinct killing mechanisms employed by immunotherapy and 
chemotherapy.  
Immunotherapy that may be synergistic with chemotherapy – There are 
several ways to implement immunotherapy. One common approach uses tumor vaccines, 
which can prime and stimulate anti-tumor T cell responses with or without co-
administration of antigen-presenting cells, such as DCs [72]. Another approach is to 
adoptively transfer back to the host ex vivo-activated and expanded anti-tumor immune 
cells [73]. T cells are the most frequently used immune cells in adoptive transfer studies. 
T cells can be engineered to express T cell receptors that recognize specific tumor 
antigens and Fc fragment of an antibody targeting tumor cells. Co-administration of 
immune-stimulatory cytokines, such as GM-CSF, IL1-beta, IL2, and IL12, can improve 
the efficacy of immunotherapy. Tumor vaccines and adoptive transfer are both subject to 
multiple tumor-derived immune suppressive mechanisms [74]. Thus, anti-tumor immune 
cells will eventually undergo either anergy or apoptosis. In some cases, peripheral 
immune cells cannot access the tumor [2]. Since chemotherapy can deplete or inhibit 
immune suppressive cells, as well as produce immune-stimulatory cytokines and immune 
cell recruiting chemokines while increasing the exposure of tumor antigen [32], tumor 
vaccine- and adoptive transfer-based immunotherapies may be ideally suited for 
combination with chemotherapy.  
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New emerging immunotherapies target immune checkpoint molecules, such as 
CTLA-4 and PD-1, which are inhibitory receptors expressed on T cells and other immune 
cells [75]. Blocking the activity of these T cell-expressed receptors using antagonist 
antibodies can stimulate anti-tumor immune responses that are otherwise suppressed. 
Cytotoxic drugs are expected to be effective when administered after checkpoint 
blockade, when tumor cells are already under T cell attack and may be particularly 
sensitive to cytotoxics. Chemotherapy may also kill tumor cells that escape T cell attack. 
However, in this scenario, chemotherapy may kill the proliferating/tumor-infiltrating T 
cells. Thus, it requires careful schedule optimization. Checkpoint blockade applied after a 
cycle of chemotherapy is also expected to be effective, in particular for chemotherapeutic 
drugs that induce immunogenic cell death: as chemotherapy-derived cytotoxicity and 
anti-tumor responses wane and pro-tumor immune responses start to rebound, the 
checkpoint inhibitors may suppress the pro-tumor immune responses and thereby 
prolong, and augment, immune responses activated by chemotherapy. 
Immunotherapeutic agents, such as anti-KIR to enhance NK cell cytotoxicity and anti-
TGF-β [76] to inhibit immune suppression, can be expected to interface with 
chemotherapy in a similar manner. 
Finally, oncolytic viruses might benefit from a short immune suppressive window 
induced by chemotherapy to reduce the host anti-viral immune response and thereby 
facilitate oncolytic virus replication [77]. Chemotherapy-resistant tumor cells may be 
subject to infection and lysis by oncolytic viruses. Danger signals released following 
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oncolytic virus-mediated tumor cell lysis may lead to a rebound in anti-tumor immunity, 
which may in turn increase chemotherapy efficacy [77].  
Combination chemotherapy and immunotherapy in mouse models - Immune 
suppressive cells in the tumor microenvironment, such as Treg, MDSCs, and 
macrophages, can counter otherwise effective immunotherapies. Chemotherapeutic 
agents capable of eliminating or modulating these factors are thus good candidates as 
preconditioning agents for immunotherapy [50, 51, 78]. CPA and paclitaxel are both 
active at eliminating or inhibiting Treg [51], while gemcitabine and 5-flurouracil are 
effective at depleting MDSCs [79]. Doxorubicin (5 mg/kg) boosts anti-tumor responses 
when given 7 days after vaccination in neu-transgenic FVB/n female mice, potentially by 
polarizing macrophage into anti-tumor M1 activation state [80]. Chemotherapeutic drug 
dose and schedule can also have a large effect on immunomodulatory activity. For 
example, CPA can deplete Treg when administered at a low dose on a daily schedule (10-
20 mg/kg per day is commonly used in mice; 50 mg/day per os in humans) or at a higher 
dose as a single injection (50-100 mg/kg ip in mice; 200-300 mg/m
2 
iv in humans) [50, 
78]. High-dose CPA may limit tumor-reactive T cell responses, in addition to depleting 
Treg [66, 78]. Likewise, in a rat glioma model, temozolomide decreases the Treg/CD4
+
 T 
cell ratio when given at a low dose (0.5 or 2 mg/kg per day, 5 days per week for 3 
weeks), but not at a high dose (30 mg/kg per day for a total of 5 days, or 10 mg/kg per 
day, 5 days per week for 3 weeks). This is most likely due to the non-selective toxicity of 
high doses of temozolomide on lymphocyte populations [81].  
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Treg cell depletion by CPA is typically transient [64, 66], which necessitates 
repeated CPA administration or direct follow-up with an active immunotherapy regimen. 
In an autochthonous prostate cancer mouse model, a single injection of CPA at 50 mg/kg 
induced transient depletion of Treg cells in the prostate tumor draining lymph nodes [64]. 
Further, when a GM-CSF-secreting tumor vaccine was given one day after CPA 
treatment, the depletion of Treg cells by CPA was prolonged compared to CPA treatment 
in the absence of the vaccine [64]. Two cycles of combination therapy (CPA on day -1, 
vaccine injection on day 0, followed by a second cycle of CPA then vaccine on days 6 
and 7, respectively) gave much stronger tumor-specific CD8 T cell responses compared 
to a single cycle [64].  
In addition to depleting or inhibiting pro-tumor growth or immune suppressive 
cells, low-dose CPA can stimulate host danger-sensing and repair mechanisms, which 
generate immune-stimulatory cytokines and chemokines and thereby facilitate DC 
maturation, anti-tumor T cell proliferation and the infiltration of cytotoxic immune cells 
to tumors [47, 78]. Therefore, the timing of immunotherapy needs to be optimal to take 
advantage of the “space” previously occupied by tumor tolerant or pro-tumor immune 
cells, as well as dynamic production of cytokines and chemokines generated by 
chemotherapy [47, 48]. Adoptive immunotherapy given either 5 hr or one day after a 
single injection of CPA at 83 mg/kg showed maximum anti-tumor activity in 3Cl-8 
Friend leukemia-bearing DBA/2 mice, whereas splenocytes derived from tumor-
immunized mice and transferred at least 3 days after CPA treatment showed no anti-
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tumor activity [47]. In other studies, vaccines given one day after a single injection of 
CPA at a dose of 50 mg/kg induced the highest level of tumor-specific CD8 T cells in the 
autochthonous prostate cancer mouse model [64].  
CPA delivered at higher doses may have different immune modulatory effects. 
For example, immature DCs that rebound and peak 12 days after a single injection of 
CPA at a lympho-depleting dose (4 mg per mouse, or 160 mg/kg for a 25 gr mouse) are 
functional and can mediate enhanced prime-boost vaccination anti-tumor responses when 
stimulated with a TLR3 agonist in a tolerogenic pmel-1 TCR transgenic B6 mouse model 
12 days after CPA treatment [82]. This suggests that the restoration phase (days 5 to 18) 
following the early lymphopenic phase (days 1 to 4) has a distinct immune stimulation 
value, which should be taken into account in the design of a combination chemo-
immunotherapy. Single low-dose injection of CPA (100 mg/kg) can also spare bone 
marrow DC precursors and stimulate DC differentiation and activation beginning 3 days 
after CPA injection [35]. In contrast, when given at a myeloablative dose of 200 mg/kg, 
CPA depletes bone marrow DC precursors [83]. A comparable prime-boost vaccination 
study across different CPA dosages has not been carried out. Nevertheless, the above 
studies indicate that the immune perturbation function of CPA is highly dose-dependent 
and that the timing of combinational immunotherapy needs to be optimized based on the 
chemotherapy dose. 
Combination of chemotherapy and immunotherapy in clinical trials – The 
discovery of immune stimulatory functions of cancer chemotherapy has led to many 
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clinical trials exploring the immune modulation potential of chemotherapy. Consistent 
with mouse studies, low-dose CPA was found to be immunostimulatory in several 
clinical trials. For example, treatment of end stage patients with low-dose metronomic 
CPA (50 mg orally, twice daily, 1 week on, and 1 week off, for 1 month or more) 
strongly curtails immunosuppressive Treg cells leading to a restoration of peripheral T 
cell proliferation and innate killing activities [49].  
Several successful clinical trials have examined low-dose metronomic 
chemotherapy as an immune induction regimen. In a prospective, randomized trial, 
patients with advanced, unresectable pancreatic adenocarcinomas, non-small cell lung 
cancer, or prostate cancer were divided into two groups [84]. The control group was 
given standard chemotherapy (gemcitabine, 1,000 mg/m
2
 I.V., on days 1, 8, 15 every 4 
weeks for pancreatic cancer; cisplatin, 75 mg/m
2
 I.V., plus docetaxel 75 mg/m
2
 I.V., 
every 3 weeks for NSCLC; and docetaxel 75 mg/m
2
 I.V., every 3 weeks for prostate 
cancer) and the experimental group was treated with chemotherapy plus low-dose 
metronomic CPA (oral 50 mg daily,  a high dose of Cox-2 inhibitor (400 mg twice daily), 
G-CSF, a sulfhydryl (SH) donor (oral N-acetyl- cysteine, 400 mg twice daily), and a 
hemoderivative that contained autologous tumor antigens every 4 weeks.  The 
experimental group demonstrated higher anti-tumor immunity three months after the start 
of treatment and had significantly longer mean survival compared with the control group 
given standard chemotherapy [84]. In another study, 28 progressive metastatic melanoma 
patients were treated with low-dose metronomic CPA (50 mg orally, twice daily, 1 week 
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on, and 1 week off) together with celecoxib (200 mg daily), followed by DC vaccines 
(first 4 vaccines weekly, then 6 vaccine every other week and IL2 (2 MIU, s.c., daily, day 
1-5 after each vaccination except the first) [85]. A general increase in immune responses 
was observed. Induction of antigen-specific immune responses was seen in 9 out of 15 
patients screened for HLA-A2(+). The number of patients with stable disease more than 
doubled and 6-month survival was increased significantly compared to a previous trial 
without CPA and celecoxib [85].  
In several clinical trials, low-dose cancer chemotherapeutic agents were used as 
preconditioning agents for immunotherapy. For example, Emens et al. conducted a 3 x 3 
factorial (response surface) dose-ranging study of CPA, doxorubicin, and HER2-positive, 
allogeneic, GM-SCF-secreting tumor vaccine in 28 metastatic breast cancer patients. 
HER2-specific antibody responses were enhanced by 200 mg/m
2
 CPA (1 day prior to 
vaccination) and 35 mg/m
2
 doxorubicin (7 days after vaccination), but were suppressed 
by higher CPA doses (250 or 350 mg/m
2
) [86]. In another study, a cohort of patients with 
advanced pancreatic cancer was treated with CPA at 250 mg/m
2
 i.v. one day before 
treatment with a GM-CSF-secreting tumor vaccine [87]. This combination regimen 
induced tumor specific CD8
+
 T cells and led to longer median survival (4.3 months vs. 
2.3 months in patients treated by tumor vaccine alone) [87].  
However, in other cases, low-dose CPA in combination with immunotherapy did 
not result in any objective responses. For example, CPA (300 mg/m
2
, on day 1) plus 
escalating doses of huKS-IL2 (an IL2 conjugate consisting of a humanized antibody 
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specific for epithelial cell adhesion molecule, EpCAM, 0.5 – 4.0 mg/m2 IV over 4 hours, 
on days 2, 3, 4 of each 21-day cycle), were used to treat EpCAM-positive advanced solid 
tumors. Among 26 patients treated for up to 6 cycles, 10 patients (38%) had stable 
disease as the best response, which lasted more than four cycles in only three patients 
[88].  In a randomized phase II trial, four mixed modified HLA-class I tumor vaccines 
were given in combination with CPA (300 mg/m
2
) and low-dose IL2 to early melanoma 
patients. While vaccination induced a rapid and persistent increase in specific effector 
memory CD8 T cells, cross-recognition of native vaccine and reaction  to melanoma cells 
was limited [89]. In one phase II trial, advanced hepatocellular carcinoma patients were 
treated with CPA (300 mg/m
2
, day -3) in combination with GM-CSF and a telomerase 
peptide vaccine, GV101, on days 1, 3, 5, 8, 15, 22, 36, followed by 4-weekly injections. 
This regimen did not induce a complete or partial response in any patients and no 
GV101-specific immune responses were detected after vaccination [90].  
While different reasons might account for each failed clinical trial, the overall 
performance of low-dose chemotherapy, either given as a single injection or in a 
metronomic manner, is moderate, even though statistically significant increases in 
immune responses may be associated with some low-dose metronomic or single 
chemotherapy treatments. A systematic review of low-dose metronomic chemotherapy 
based on 80 published clinical trials up to 2012 (64.5% involving combination therapy) 
found that the mean response rate was only 26% (95% confidence interval 21.4 - 30.7) 
with median progression free survival 4.6 months (interquartile range: 2.9 – 7.0) [63]. 
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Since in many cases low-dose metronomic chemotherapeutic agents are used as 
“maintenance” or “consolidation” treatment for elderly and frail patients because of their 
ease of administration and comparatively low-degree of toxicity [91], randomized phase 
III trials are needed to better assess the immune modulation function of low-dose 
chemotherapy. However, based on available results, we would not expect that low-dose 
chemotherapy based therapy will lead to substantial improvement in cancer treatment. In 
addition, potent immunotherapy is often associated with severe side-effects, likely due to 
immune tolerance breakdown [92]. These findings indicate a need for new treatment 
strategies.  
1.4 Combination of medium-dose, intermittent metronomic chemotherapy with 
immunotherapy  
We propose combining immunotherapy with medium-dose chemotherapy given 
on an intermittent metronomic schedule as a therapeutic regimen with two goals: 1) to 
impart strong and repeated cytotoxic insult to tumors, in order to kill a large fraction of 
tumor cells; and 2) to activate a sustained anti-tumor immune response. A key goal for 
immunotherapy is to eliminate residual tumor cells that are potentially chemotherapy-
resistant. By combining two therapies with different killing mechanisms, the chance of 
achieving synergism leading to sustained tumor regression and long-lived immunity is 
greatly improved. Our rationale is explained below. 
To obtain a synergistic response, the first consideration is to select a 
chemotherapeutic drug capable of inducing immunogenic cell death and/or depleting 
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immune suppressive cells at a dose that can eradicate a majority of tumor cells [81] (See 
diagram in Fig. 1-1). In the absence of immunogenic cell death and the associated 
immune responses, mono-chemotherapy can be expected to induce tumor cell resistance 
and fail to effectively reduce the tumor burden [33] (Fig. 1-1; orange rectangle). Some 
chemotherapy regimens can only perturb immune cell populations, e.g., decreasing the 
Treg/CD4
+
 T cell ratio, when given at a dose that is too low to inhibit tumor growth [81] 
(Fig. 1-1; blue rectangle). Tumor burden is often negatively correlated with the potency 
of immunotherapy, presumably because immune suppressive signals derived from the 
expanding tumor mass are sufficiently strong to override immunotherapy [93]. Therefore, 
non-immunogenic drug treatment or immunogenic drug regimens that use a dose too low 
to inhibit tumor growth are not ideal candidates to combine with immunotherapy.  
For chemo-immunotherapy to be effective, the dose of chemotherapy needs to be 
lower than the threshold dose for severe myeloablation and toxicity to host (Fig. 1-1; 
green rectangle), to circumvent the need for a prolonged drug-free break, such as the 
break required in MTD drug schedules. This long drug-free break may allow for the 
development of immune suppression, overriding the transient anti-tumor immune 
responses [55] and allowing drug resistant tumor cell clones to emerge [94]. Once drug-
resistant tumor cells expand and a relatively large tumor mass forms, the growing tumor 
cells can evolve additional mechanisms to subvert or escape the immune system and 
abrogate immunotherapy.  
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The drug-free break needs to be appropriately spaced to maintain a good balance 
between cytotoxicity to tumor cells and sustained immune responses (Fig. 1-2). An 
optimized drug-free break will allow for the rebound of endogenous tumor-reactive 
immune cells and sufficient time to expand the immunotherapy-derived immune response 
(Fig. 1-2B). As discussed above, a drug-free break that is too long may facilitate the 
acquisition of immune suppression and emergence of drug resistance (Fig. 1-2C), while a 
drug-free break that is too short may ablate anti-tumor immune cells together with tumor 
cells (Fig. 1-2D). Multiple combination treatment cycles will likely be required to 
eradicate sufficient tumor cells while preventing the development of immune suppressive 
mechanisms and emergence of drug resistant tumor cell populations.  
Our mouse studies indicate that an intermittent, every 6-day repeating medium 
dose CPA schedule (140 mg/kg per injection) (CPA/6d) can activate robust and sustained 
innate and adaptive immune responses following transient lymphopenia (Fig. 1-1; red 
rectangle) [69]. The CPA/6d regimen is well tolerated in the mouse model. The effective 
daily dose of this CPA/6d regimen is similar to that used in MTD CPA schedules in 
mouse models [55, 95], except that the length of the drug-free break is much shorter. 
Whereas MTD schedules induce transient immune responses associated with substantial 
tumor growth rebound [55], the CPA/6d schedule provides a good balance between 
maximizing tumor cell toxicity and minimizing the frequency of immune cell ablation 
[69]. Other studies from our laboratory and others support the use of intermittent 
metronomic chemotherapy schedules [55-57, 65, 66], as summarized above under 
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“Chemotherapeutic drug dose and schedule”. Findings in our preclinical mouse studies, 
and the moderate performance of many low-dose chemotherapy trials, discussed above, 
indicate the importance of new clinical trials to determine the efficacy of combination of 
medium-dose, intermittent metronomic chemotherapy with immunotherapy. 
1.5 Combination chemotherapy-based chemo-immunotherapy strategy  
The combination of two cancer chemotherapeutic drugs can be more effective 
than a single drug-based treatment by minimizing the selection of drug-resistant tumor 
cell clones (Fig. 1-3A). Further, different anti-cancer chemotherapeutic drugs can 
stimulate different anti-tumor immune populations. For example, while CPA and 
paclitaxel can each boost tumor vaccine-mediated T cell responses when given at 
lympho-depleting doses one day prior to vaccination, doxorubicin can spare T cells and 
activate macrophages when given 7 days after vaccine injection (Fig. 1-3B) [80]. 
Alternatively, one drug may inhibit tumor growth by an anti-angiogenic mechanism or 
reduce tumor burden by its intrinsic tumor cell cytotoxicity, while a second drug may 
complement the first drug by activating immunogenic cell death (Fig. 1-3C). However, 
caution should be exercised when using such a strategy, since VEGFR2-targeting anti-
angiogenesis agents can block CPA/6d-induced immune cell recruitment [55, 58]. In 
addition, the tumor vasculature is often leaky, which results in a high interstitial pressure 
and a low rate of drug penetration [96]. Therefore, one drug may normalize the tumor 
vasculature and thereby improve the uptake of a second chemotherapeutic agent, 
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resulting in more effective tumor cell kill and altering the tumor microenvironment in 
way that favors anti-tumor immune responses (Fig. 1-3D). 
1.6 Implications for drug development 
In vitro tumor cell cytotoxicity assays are commonly used to screen for novel 
anti-tumor drugs [97]. This approach can be effective in identifying potent cytotoxic 
agents, but is not designed to identify drugs that activate immunogenic cell death. 
Stromal cells may also be an important target in treating cancers. The clinical efficacy of 
imatinib mesylate (Gleevec) in gastrointestinal stromal tumors (GISTs) lacking activating 
mutations in KIT and PDGFRA supports this rationale [98]. These GIST cells do not 
respond to imatinib in vitro due to the absence of mutation in the imatinib targets c-Kit 
and PDGF-R. Rather, imatinib blocking of KIT signaling in host DCs leads to DC-
mediated NK cell activation, which inhibits tumor cell growth [98]. For some KIT-
expressing GIST tumors, imatinib functions in a non-cell autonomous manner by 
restoring the anti-tumor functions of CD8
+
 T cells and NK cells by inhibition of the KIT-
ETV4-IDO-Treg axis between tumor cells and Treg cells [99]. In both cases, without the 
responses from stromal cell components, the efficacy of imatinib is negligible. Therefore, 
in addition to direct tumor cell cytotoxicity, it is important to incorporate new criteria, 
such as immune modulation or immunogenic cell death, when screening for anticancer 
drugs.  
There are two ways to assess the capacity of chemotherapeutic agents to modulate 
immune cell function and induce immunogenic tumor cell death. One way is to engineer 
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a fluorescent marker to track the expression of immunogenic tumor cell death. For 
example, U2OS cells that stably express a CRT-GFP fusion protein can be used to 
monitor the cellular location of CRT protein [100]. This system was used to verify that 
cisplatin, which does not induce immunogenic tumor cell death, failed to induce 
translocation of CRT from the endoplasmic reticulum (ER) to the cell surface that was 
seen with oxaliplatin or mitoxantrone, which are both immunostimulatory. This system 
was also used in a screen that led to the identification of thapsigargin, an ER stress 
inducer, as a drug that can synergize with cisplatin to induce translocation of CRT to the 
plasma membrane and activate immunogenic cell death [100]. Reporters for HMGB1 
release can also be developed and used for immunogenic chemotherapeutic drug screen 
and development. 
Assays for chemotherapy-mediated immune cell modulation can also be 
implemented for use in high throughput in vitro screens. In one example, an engineered 
IL1 promoter was used to drive the expression of a fluorescent protein in a murine DC 
cell line [61]. The fluorescent protein reporter was then used as a surrogate marker of DC 
maturation to screen for immune stimulatory chemotherapeutic drugs. 15 out of 54 drugs 
tested were found to activate DCs. However, DC function can be affected by many non-
cell autonomous factors, including eat-me signals from immunogenic tumor cell death 
and cytokines secreted by tumor cells or other stromal cells [35]. Therefore, the 
effectiveness of such a screen might be greatly improved by adding tumor cell-
conditioned medium or tumor cells and other stromal cells to mimic the in vivo 
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composition of a specific type of tumors. Further, by adding tumor cells, immunogenic 
tumor cell death may be indirectly read out by the high-throughput reporter of DC 
activation. Promising candidates identified in an initial  screen can be further examined 
mechanistically using other markers of immunogenic cell death, such as calreticulin and 
HSP90 expressed on the tumor cell surface, HMGB1 in the cytoplasm, and ATP and 
HMGB1 released from dying tumor cells, to determine whether the observed 
immunomodulation results from immunogenic tumor cell death or from direct action on 
stromal cells [33]. Mixed cell populations comprised of tumor cells, stromal cells, and 
immune cells and designed to mimic the in vivo tumor composition may also be used to 
screen other immune modulatory features of cancer chemotherapeutic drugs. These 
include the ability to induce critical immune stimulatory cytokines or chemokines, 
activate NK cell or T cell effectors, deplete immune suppressive cells, or increase death 
receptor expression on tumor cells. Gene profiles of untreated tumors that reflect the 
immunogenicity of tumor cells, the composition of stromal cells, and the immune cell 
activation status may help identify targets of immunotherapy and design suitable in vitro 
screens for chemotherapy drugs [10, 13, 14, 101].  
1.7 Overview of thesis  
In chapter two of this thesis I present studies showing the CPA schedule 
dependence for induction of NK cell responses in GL261 glioma tumor-bearing scid 
immunodeficient mice [57]. These studies demonstrate that CPA administered at a bolus 
dose of 140 mg/kg on a 6-day repeating schedule can induce sustained NK cell responses 
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and tumor regression, whereas CPA schedules with drug-free intervals 9-day or longer 
cannot. The findings presented are discussed in terms of the impact of metronomic CPA 
scheduling on the emergence of drug or immune cell resistant tumor cell populations. 
Chapter three of this thesis investigates metronomic CPA-induced NK cell and 
cytotoxic T lymphocyte (CTL) responses in immune competent B6 mice transplanted 
with same GL261 glioma tumors [69]. The work presented demonstrates the importance 
of using optimized chemotherapeutic doses, and schedules and illustrates the feasibility 
of using mono-chemotherapy to cure cancers and establish long-term, tumor-specific 
immunity. 
In chapter four of this thesis, transcriptomic profiling (RNA-seq) was performed, 
and KEGG pathway and upstream regulator (UPR) analysis were employed to compare 
gene expression changes induced by CPA/6d treatment in an immune-responsive GL261 
glioma model to those in unresponsive LLC and B16F10 tumors. I also compared 
CPA/6d-induced gene responses in GL261 tumors implanted in immune-competent B6 
mice, where CPA/6d treatment is curative and induces long-term immunity, to gene 
responses in GL261 tumors implanted in scid (adaptive immune-deficient) mice, where 
regression is incomplete and often followed by tumor growth rebound. Finally, the 
impact of lengthening the treatment interval from 6 to 9 days (CPA/9d) was studied.  
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Fig. 1-1. Diagrams for different outcomes of non-immunogenic or immunogenic 
cancer chemotherapy with different dose and schedules. 
Cancer chemotherapeutic drugs can be non-immunogenic (yellow rectangle) or can induce 
immunogenic cell death. The latter agents can be divided into three categories based on the dose 
and schedule, i.e., low-dose (blue rectangle), medium-dose and intermittent schedule (red 
rectangle), and high-dose with long drug-free breaks (green rectangle). In the absence of 
immunogenic cell death and associated immune responses (yellow rectangle), mono-
chemotherapy can be expected to induce tumor cell-evolved resistance and fail to effectively 
reduce the tumor burden. As a consequence, tumor regression that results from a non-
immunogenic mechanism can be expected to be followed by tumor regrowth. Low-dose 
immunogenic chemotherapy (blue rectangule) can only kill a portion of the tumor cell population. 
The remaining, large fraction of tumor cells may escape or subvert anti-tumor immune responses, 
leading to tumor growth rebound. Medium-dose immunogenic chemotherapy (red rectangle) 
given on a schedule with appropriate, medium drug-free break may kill most of tumor cells and 
activate robust anti-tumor immune responses. The residual tumor cells, which are potentially 
chemotherapy-resistant, will be killed by immune responses. In contrast, high-dose immunogenic 
chemotherapy (green rectangle) may kill most tumor cells, similar to medium-dose 
chemotherapy. However, myeloabaltion induced by high-dose chemotherapy may necessitate a 
long drug-free break, during which immune suppression mechanisms or pro-tumor immune cells 
will develop and drug-resistant tumor cells will be selected. Thus, anti-tumor immune responses 
will be overridden or subverted and tumor growth will resume. 
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Fig. 1-2. Diagrams showing dynamic changes in pro- or anti-tumor immune signals 
induced by different chemo-immunotherapy schedules  
(A) Time course for various responses activated by a single injection of a chemotherapeutic agent 
(arrow along X-axis). Shown are the level of tumor tolerant immune cells before chemotherapy 
(a), chemotherapy treatment-derived drug cytotoxicity (b), which is followed by lymphopenia (c) 
and activation of immune-stimulatory signals (d). The immunostimulatory signals activate anti-
tumor immune responses (e), which are followed by a gradual increase in immune suppression 
and drug resistance (f). (B) An appropriate drug-free break (interval between arrows along X-
axis) allows a sufficient increase in anti-tumor immune responses (e) before being overridden by 
immune suppression. The second chemotherapy treatment may have greater efficacy than the first 
one (b) due to a synergistic effect between anti-tumor immune responses and chemotherapy; (C) 
Too long a drug-free break facilitates the acquisition of immune suppression and drug resistance 
(f), which may dampen the efficacy of the second chemotherapy treatment (b); (D) Too short a 
drug-free break ablates the anti-tumor immune responses, thereby reducing the efficacy of the 
second chemotherapy treatment.         
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Fig. 1-3. Diagram showing four different chemotherapeutic drug combination 
strategies.   
(A) Drug B synergizes with drug A by minimizing the selection of drug-resistant tumor cell 
clones. (B) Drug A and drug B each stimulate different anti-tumor immune populations, e.g., drug 
A activates anti-tumor T cells while drug B activates anti-tumor macrophages, in addition to 
synergize by minimizing the selection of drug-resistant tumor cell clones as shown in (A) . (C) 
Drug A inhibits tumor growth by an intrinsic anti-tumor cytotoxicity or an anti-angiogenic 
mechanism, while drug B complements drug A by activating immunogenic cell death. (D) Drug 
A normalizes the tumor vasculature and thereby improves the uptake of drug B and facilitates the 
anti-tumor immune responses activated by drug B.  
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CHAPTER TWO: METRONOMIC CYCLOPHOSPHAMIDE SCHEDULE-
DEPENDENCE OF INNATE IMMUNE CELL RECRUITMENT AND TUMOR 
REGRESSION IN AN IMPLANTED GLIOMA MODEL 
2.1 Abstract 
Metronomic cyclophosphamide (CPA) treatment activates robust innate anti-
tumor immunity and induces major regression of large, implanted brain tumor xenografts 
when administered on an intermittent, every 6-day schedule, but not on a daily low-dose 
or a maximum-tolerated dose CPA schedule. Here, we used an implanted GL261 glioma 
model to compare five intermittent metronomic CPA schedules to elucidate the kinetics 
and schedule dependence of innate immune cell recruitment and tumor regression. 
Tumor-recruited natural killer cells induced by two every 6-day treatment cycles were 
significantly ablated 1 day after a third CPA treatment, but largely recovered several days 
later. Natural killer and other tumor-infiltrating innate immune cells peaked 12 days after 
the last CPA treatment on the every 6-day schedule, suggesting that drug-free intervals 
longer than 6 days may show increased efficacy. Metronomic CPA treatments spaced 9 or 
12 days apart, or on an alternating 6 and 9 day schedule, induced extensive tumor 
regression, similar to the 6-day schedule; however, the tumor-infiltrating natural killer 
cell responses were not sustained, leading to rapid resumption of tumor growth after day 
24, despite ongoing metronomic CPA treatment. Increasing the CPA dose prolonged the 
period of tumor regression on the every 9-day schedule, but natural killer cell activation 
was markedly decreased. Thus, while several intermittent metronomic CPA treatment 
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schedules can activate innate immune cell recruitment leading to major tumor regression, 
sustained immune and anti-tumor responses are only achieved on the 6-day schedule. 
However, even with this schedule, some tumors eventually relapse, indicating a need for 
further improvements in this immunogenic metronomic therapy. 
2.2 Introduction 
The alkylating agent cyclophosphamide (CPA; NSC 26271) was first approved by 
the FDA for cancer treatment in 1959 and is currently used to treat a variety of diseases, 
including breast and ovarian cancer, hematological malignancies, and autoimmune 
diseases [1]. CPA and other cytotoxic agents are commonly delivered to cancer patients 
on a maximum-tolerated dose schedule, but often show modest anti-cancer activity [2,3]. 
This limited efficacy is in part due to high toxicity to the host, which necessitates a long 
drug-free break, during which chemotherapy-resistant tumor cell populations may emerge 
and residual tumors can neovascularize, leading to tumor regrowth [3,4]. This limitation 
can be addressed, in part, by administration of CPA on a metronomic schedule [5,6], 
which augments CPA cytotoxicity to tumor-associated endothelial cells and can increase 
overall therapeutic activity while reducing host toxicity [7–9]. Daily, oral low dose 
metronomic CPA schedules have shown promising results in preclinical models [10,11] 
and are currently being tested in clinical trials [12–14]. 
CPA has substantial immunomodulatory activity [15,16]. CPA can deplete 
immune suppressive regulatory T cells [17,18], stimulate dendritic cell maturation [18], 
rescue tumor-driven CD4+ T-cell differentiation [19] and activate anti-tumor CD8+ T 
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cell responses [20]. Furthermore, in studies from our laboratory, CPA was shown to 
activate a potent, innate anti-tumor immune response in several implanted glioma models 
grown in immune competent or immune deficient (scid) mice when delivered on an 
intermittent, 6-day repeating metronomic schedule, leading to strong innate immune-
based tumor regression [21]. This regression is dependent on natural killer (NK) cells, as 
demonstrated by antibody depletion experiments and using mouse models deficient in 
NK cells or in the NK cell cytotoxic effector perforin 1 [21]. CPA administration on a 
more frequent metronomic schedule, e.g., daily low-dose CPA treatment, failed to 
activate a robust anti-tumor immune response or induce tumor regression [22]. Thus, an 
intermittent, 6-day repeating metronomic schedule of CPA is most effective in activating 
the anti-tumor innate immune response leading to tumor regression. Metronomic 
schedules that administer CPA or other cytotoxic drugs too frequently may hamper 
immune cell proliferation or suppress intratumoral accumulation of chemotherapy-
sensitive immune cell populations. Consistent with these findings, bone marrow 
myelopoiesis suppressed by CPA requires ~10 days for recovery [23,24], and in a 
myeloma model, CPA administered at long intervals elicited strong immune responses 
and better anti-tumor activity than CPA given at shorter intervals [18]. However, a drug-
free break that is too long may increase the risk of tumor regrowth, as can occur with 
maximum-tolerated dose drug schedules [2]. Other studies indicate that a threshold level 
of tumor cell and/or stromal cell DNA damage may be required to activate cytokine and 
chemokine responses [21,22], which can stimulate immune cell recruitment [25]. 
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Although CPA is not typically used to treat gliomas, our prior findings indicate 
that CPA can be very active in multiple glioma models when administered on an 
intermittent metronomic schedule [21,22,26], suggesting that CPA may have greater 
clinical potential for glioma treatment than recognized previously. Here, we investigate 
whether the efficacy of intermittent CPA treatment on an every 6-day schedule (CPA/6d) 
can be improved by extending the time between CPA treatments to allow for a longer 
drug-free interval. Four other schedules were investigated: CPA treatment every 9 days 
(CPA/ 9d) or every 12 days (CPA/12d), CPA treatment on a 6-day and 9-day alternating 
schedule (CPA/6–9d), and CPA treatment on an every 9 day schedule, but with an 
increase in CPA dose from the standard dose of 140 mg/kg/injection to 210 
mg/kg/injection (CPA(210)/ 9d schedule). We found that all five intermittent CPA 
schedules initially induce strong tumor regression, which proceeds with strong 
momentum for ~24 days, after which many of the tumors treated at 9 or 12 day intervals 
rapidly regrow in association with a major decrease in the expression of NK cell 
activation markers. These findings are discussed in terms of the impact of metronomic 
CPA scheduling on the emergence of drug or immune cell resistant tumor cell 
populations. 
2.3 Materials and methods 
Tumor cell lines and mouse xenografts 
Mouse GL261 glioma cells were authenticated by and obtained from the 
Developmental Therapeutics Program Tumor Repository (National Cancer Institute, 
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Frederick, MD, USA). Cells were grown at 37 °C in a humidified 5% CO2 atmosphere in 
RPMI-1640 culture medium containing 10% fetal bovine serum, 100 Units/ml penicillin 
and 100 μg/ml streptomycin. Six-week-old (26–28 g) male ICR/Fox Chase immune 
deficient scid mice (Taconic Farms, Germantown, NY, USA) were housed and treated 
under approved protocols and federal guidelines. GL261 glioma cells (4 × 106) were 
injected s.c. on each posterior flank in 0.2 ml serum-free RPMI using a U-100 insulin 
syringe with a 28.5 gauge needle (BD Biosciences, Cat.# 329461). Tumor areas (length × 
width) were measured twice weekly using Vernier calipers (VWR International, Cat# 
62379-531) and tumor volumes were calculated based on the formula Vol = (π/6) × (L × 
W)3/2. Tumors were monitored and drug treatment was initiated when the mean tumor 
volumes reached ~500– 700 mm3. The measured volume of each tumor was normalized to 
the drug treatment starting point (=100%) to obtain a normalized tumor volume. Mouse 
body weights were normalized in the same manner. Mice were treated with CPA given 
on the following intermittent metronomic schedules: CPA/6d (140 mg CPA/ kg-body 
weight (BW), repeated every 6 days); CPA/6–9d (140 mg CPA/kg-BW, alternating 
between an every 6 day and an every 9 day schedule); CPA/9d (140 mg CPA/kg-BW, 
repeated every 9 days); CPA/12d (140 mg CPA/kg-BW, repeated every 12 days); and 
CPA(210)/9d (210 mg CPA/kg-BW, repeated every 9 days), on the days marked in each 
figure using vertical arrows. CPA was administered as a mono-hydrate (Sigma, Cat. # 
C0768), with the CPA doses reported here based on the non-hydrated molecular weight 
of 261. Tumor sizes and mouse body weights were measured at least twice a week. 
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Fisher’s exact test and Student’s t-test were used to assess the differential tumor 
responses (regression vs. rebound) and tumor growth rate observed with each CPA 
schedule, respectively: *p < 0.05; **p < 0.01; and ***p < 0.001. 
qPCR analysis of immune cell and other marker genes 
Changes in tumor-infiltrating innate immune cells were monitored by changes in 
the expression of innate immune marker genes, as determined by qPCR analysis of tumor 
RNA. Changes in the immune cell marker genes used here are indicative of changes in 
the corresponding immune marker protein levels and immune cell numbers, as shown by 
immunohistochemistry and/or FACS analysis of metronomic CPA-treated 9L and U251 
gliomas implanted in the same scid mouse model [21,22,26]. Further, NK cell marker 
gene expression levels show a close association with the extent of tumor regression 
induced by metronomic CPA treatment [22]. Isolation of total tumor RNA, reverse 
transcription, and qPCR were carried out as described [21]. Primers designed using 
Primer Express software (Applied Biosystems, Carlsbad, CA, USA) are described in 
[21,22] or presented in Table 2-1. qPCR data were analyzed using the comparative CT 
method and are presented as relative levels of each RNA compared to the RNA level in 
untreated tumors after normalization to the 18S RNA content of each sample. qPCR data 
are expressed as mean values ± S.E. for n = 4–6 tumors per time point for each treatment 
group unless indicated otherwise. Statistically significant differences between mean 
values of different treatment groups were determined by one-way ANOVA (for more 
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than two group comparisons) or two-tailed Student’s t-test (for two group comparisons). 
Significance is indicated by: *p < 0.05; **p < 0.01; and ***p < 0.001. 
2.4 Results 
CPA/6d schedule induces GL261 glioma regression with strong momentum 
GL261 gliomas were implanted subcutaneously in scid mice to investigate 
sensitivity to CPA treatment and innate immune cell recruitment using the same 6-day 
repeating metronomic schedule (CPA/6d schedule) shown to be efficacious in treating 
two other implanted brain tumors (9L gliosarcoma and U251 glioblastoma) [21].single 
CPA injection induced only a transient pause in GL261 tumor growth, from day 9 to day 
12 after treatment; however, a prolonged period of regression, lasting 15–18 days, was 
induced by a second and also by a third CPA injection when given on the CPA/ 6d 
schedule (Fig. 2-1). Thus, CPA/6d treatment activates an anti-tumor response with strong 
momentum for continued regression once the second CPA injection is given. The time to 
initiate GL261 tumor regression was intermediate compared to two other gliomas 
investigated in the same mouse model: GL261 tumor regression began just after the 
second CPA/6d injection on day 6, whereas U251 tumor regression begins shortly after 
the first CPA injection, and 9L tumor regression begins after three to four CPA injections 
[21]. We used this experimental model to investigate the efficacy of other intermittent 
metronomic CPA schedules in which the drug-free interval is longer than 6 days. 
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CPA ablation of tumor-infiltrating NK cells 
GL261 tumors treated with 1, 2 or 3 CPA injections on the CPA/ 6d schedule, as 
in Fig. 2-1, were sampled 1, 3, 6, and 12 days after the last CPA injection, and then again, 
after robust tumor growth resumed (i.e., on treatment days 18, 30 and 40, respectively, in 
Fig. 2-1). Tumor-infiltrating innate immune cells were assayed by qPCR analysis of 
innate immune cell marker genes, whose changes in expression are indicative of changes 
in the corresponding tumor-associated immune cell populations [21,22,26]. We examined 
the NK cell marker genes Nkp46 and Nkg2d, NK cell activation markers Prf1 and Gzmb, 
dendritic cell markers CD207 and CD74, and macrophage markers CD68 and Emr1 
(F4/80). All of the marker genes showed their highest expression 12 days after the last 
CPA injection (c.f., peaks of expression on days 12, 18 and 24) (Fig. 2-2). In addition, 
there were significant decreases in the NK cell markers 1 day after the third CPA 
injection (75% decrease in Nkp46 levels, and 62% decrease in Nkg2d levels from day 12 
to day 13; Fig. 2-2A and Table 1), consistent with CPA cytotoxicity to the tumor-
infiltrating NK cell population. Similar decreases were seen for the NK cell activation 
markers Prf1 and Gzmb (Fig. 2-2B and Table 1). Markers for the tumor-associated 
dendritic cells and macrophages did not show significant changes (Table 1), suggesting 
those cells are less sensitive to CPA cytotoxicity than the tumor-associated NK cells. The 
preferential loss of NK cells following CPA treatment on day 13 (Table 1) is consistent 
with reports that CPA is preferentially cytotoxic to NK cells [27,28], depletes fewer 
granulocyte precursors than lymphocytes in mouse spleen and bone marrow [29], and 
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does not affect peritoneal macrophage cytolytic activity [30]. Given the functional 
importance of NK cells for metronomic CPA-induced tumor regression [21], our findings 
further suggest that the efficacy of intermittent metronomic CPA might be improved by 
lengthening the 6 day interval between CPA treatments to decrease the frequency with 
which CPA ablates the tumor-associated NK cell population. 
CPA/6d-responsive cytokine, chemokine and adhesion molecule gene signatures 
We investigated expression patterns for several other genes found to be 
responsive to intermittent CPA treatment to ascertain whether they also favor a 
metronomic CPA drug-free interval longer than 6 days. These genes include: IL15 and 
IL18, which are important for NK cell development, proliferation, and cytotoxicity [31–
34]; Fas and its ligand Fasl, which are expressed on tumor cells and NK cells, 
respectively, and together elicit NK cell-mediated tumor cell death [35,36]; Cxcl12, a 
pleiotropic chemokine that recruits neutrophils and monocytic cells [37]; and Tlr7, which 
induces dendritic cell maturation and anti-tumor inflammatory immune responses 
[38,39]. Gene responses were generally maximal 12 days after each CPA injection (Fig. 
2-3). Similar patterns of response were seen for three other genes that may contribute to 
the strong innate immune responses seen in the metronomic CPA-treated tumors: Csf1, 
which induces macrophage and monocyte development and proliferation [40], and Icam2 
and Vcam1, which are expressed on endothelial cells and immune cells and are important 
for immune cell transendothelial cell migration toward inflammation sites and tumors 
[41,42] (see Fig. 2-3). Vegfa, which is a strong pro-angiogenic tumor factor with 
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immune-suppressive and wound-healing activity [43–47], showed a distinct response 
pattern: Vegfa expression decreased progressively with each cycle of CPA treatment 
through at least day 24. This decrease in Vegfa could favor the activation of anti-tumor 
immunity [46,47].distinct response pattern was seen for Icam1, as well as for the 
chemokines Cxcl9, Cxcl10 and Cxcl11 (Fig. 2-3), whose expression is driven by 
interferon-γ and is important for NK cell trafficking and recruitment into tumors [48]. 
These three chemokines were maximally expressed between day 6 and day 12 and 
thereafter declined, independent of the second or the third CPA treatment (Fig. 2-3). In 
the 9L glioma model, metronomic CPA treatment induces strong expression of Cxcl10 
and Cxcl11, but those gene responses do not correlate with the efficacy of different 
metronomic CPA schedules or with the extent of activation of anti-tumor immune 
responses [22]. 
Impact of longer drug-free breaks on anti-tumor activity 
Based on the findings above, we investigated the efficacy of metronomic CPA 
treatment on an every 12-day schedule (CPA/12d). CPA/ 12d treatment induced tumor 
regression over an 18–21 day period that was indistinguishable from that of the CPA/6d 
schedule. However, by the third CPA treatment, on day 24, the ability of CPA to sustain 
tumor regression was lost (Fig. 2-4) and a rapid rebound in tumor growth was seen in 12 
out of 14 tumors (Table 2-3). 
Next, we considered three alternative schedules: CPA/9d (every 9 day dosing), 
CPA/6–9d (alternate between every 6 day and every 9 day CPA dosing), and 
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CPA(210)/9d (every 9 day dosing, with an increase in the CPA dose from 140 to 210 
mg/kg per injection). The CPA(210)/9d schedule delivers the same total CPA dose over 
time as the CPA/6d schedule when calculated on a per day basis. Fig. 2-5A shows that 
CPA/9d and CPA/6–9d treatment induced GL261 tumor regression comparable to the 
CPA/6d or CPA(210)/9d schedules until day 24, at which time several of the CPA/9d and 
CPA/6–9d treated tumors began to regrow rapidly (Fig. 2-5B). The CPA/6d and 
CPA(210)/ 9d schedules were significantly more efficacious than CPA/9d treatment (for 
both schedules, p < 0.05 on days 30, 33, and 36; Fig. 2-5A). Schedule-dependent patterns 
of response were also evident when only the rebounding tumors were considered (Fig. 2-
5B). Whereas the tumors treated on the CPA/6–9d and CPA/9d schedules rapidly regrew 
beyond their tumor volume prior to drug treatment (i.e., tumor volume on day 0; dashed 
line, Fig. 2-5B), the CPA/6d and CPA(210)/9d rebounding tumors required substantially 
longer time to return to their initial size (Fig. 2-5B and Table 2-3). No major difference 
between schedules was seen in the tumor regression curves when considering only the 
regressing tumors (Fig. 2-5C). However, the frequency of tumor rebound was 
substantially greater with the CPA/12d and CPA/9d schedules (Table 2-3; Fig. 2-5D). 
Thus, increasing the CPA treatment interval to longer than 6 days without a change in 
CPA dose (i.e. CPA/6–9d, CPA/9d, and CPA/12d schedules) does not alter the kinetics or 
the extent of tumor regression through ~day 24, but increases both the rate and the 
frequency of the subsequent rebound in tumor growth. Examination of changes in 
normalized mouse body weight as a marker for host toxicity did not reveal significant 
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differences between the CPA schedules (see Fig. 2-8). In particular, body weights in the 
CPA/6d or CPA(210)/9d groups were stable through the end of each study, indicating 
that CPA is well tolerated on both schedules. 
NK cell activation is maximally sustained by the CPA/6d schedule 
The NK cell responses stimulated by each metronomic CPA schedule were 
investigated to help understand the distinct regression profiles of each schedule. NK cell 
markers were analyzed in tumors excised 6 days after the second CPA injection (Fig. 2-
5A: day 12 for CPA/6d; day 15 for CPA/9d and CPA(210)/9d), at which times all of the 
tumors in each group were actively regressing. The NK cell marker Nkp46 was 
significantly increased in all three CPA treatment groups (Fig. 2-6A). However, CPA 
induction of the NK cell activation markers Prf1 and Gzmb was significantly lower on 
the CPA/9d and CPA(210)/9d schedules than with CPA/6d treatment (Fig. 2-6A). This 
suggests that although all three schedules induce strong NK cell tumor recruitment, the 
CPA/6d schedule is significantly more efficacious at NK cell activation. This finding was 
confirmed in separate sets of analyses of NK cell activation markers 6 days and 9 days 
after three injections on each of metronomic CPA schedule. Again, induction of the NK 
cell activity markers Prf1 and Gzmb was significantly lower in tumors treated on the 
CPA/9d and CPA(210)/9d schedules compared to the CPA/6d schedule (Fig. 2-6B, 
6C).third NK cell activation marker, Fasl, showed the same schedule-dependent 
expression pattern as Prf1 and Gzmb (Fig. 2-6D). In contrast, dendritic cell marker CD74 
and macrophage marker Emr1 did not show differential expression between the CPA/6d, 
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CPA/9d, and CPA(210)/ 9d treated tumors (Fig. 2-6D). Thus, NK cell activation is 
particularly sensitive to the metronomic schedule employed. In the case of the 
CPA(210)/9d schedule, the induction of Nkp46 seen after two treatment cycles (Fig. 2-
6A) was not sustained through the third cycle (Fig. 2-6B), consistent with the sensitivity 
of NK cells to the higher circulating drug levels under this schedule. 
Finally, we compared immune responses between regressing tumors and 
rebounding tumors (Fig. 2-7). The expression of all of the innate immune cell markers 
examined, including Nkp46, Prf1, Gzmb, CD74, Emr1, Fasl, was significantly lower in 
the rebounding tumors than in the regressing tumors (Fig. 2-7). Similar immune response 
profiles were seen 12 days after three CPA injections on the CPA/12d schedule (data not 
shown), at which point the tumors were rapidly regrowing (Fig. 2-4). 
2.5 Discussion 
There is increasing clinical interest in metronomic chemotherapy as an alternative 
to traditional maximum-tolerated dose cancer chemotherapy; however, there is little 
understanding of how the choice of metronomic schedule, in particular the dosing 
interval, impacts anti-tumor responses. Previous studies using B6 mice have shown that 
metronomic CPA treatment on an every 6-day schedule (CPA/6d) induces regression of 
large implanted gliomas by a mechanism that is at least in part dependent on tumor 
recruitment of anti-tumor NK cells [21]. Immune responses are substantially reduced and 
glioma regression is abolished by a moderate reduction of CPA dose, or by metronomic 
administration of CPA at more frequent intervals, including low-dose daily CPA 
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scheduling [22]. Here, our investigation of the time-dependent changes in tumor-
infiltrating NK cell, dendritic cell and macrophage markers revealed that the CPA/6d 
schedule is preferentially toxic to NK cells recruited to the treated tumors. Moreover, all 
of the immune cell and NK cell activation markers examined peaked on day 12, rather 
than on day 6 after each CPA treatment, as did several cytokines, chemokines and 
adhesion molecules that favor immune cell recruitment and activation. Tumor responses 
peaked much earlier for the chemokines Cxcl9, Cxcl10, and Cxcl11, whose induction by 
CPA does not correlate with anti-tumor immune responses and tumor regression [22]. In 
contrast, expression of the pro-angiogenic tumor factor VEGFA decreased progressively 
with each cycle of CPA treatment through at least day 24. These findings led us to 
compare the CPA/6d schedule to four metronomic schedules with longer intervals 
between CPA treatments, namely, CPA/12d, CPA/9d, CPA/6–9d, and CPA(210)/9d 
schedules. 
We found that all five metronomic CPA schedules initially drive tumor regression 
with similar kinetics and to a similar maximal extent, even though the total dose of CPA 
administered over the first 21 days is substantially lower with the CPA/12d, CPA/9d and 
CPA/6–9d schedules than with the CPA/6d and CPA(210)/9d schedules. However, after 
day 24, many of the tumors treated on the CPA/ 12d, CPA/9d, and CPA/6–9d schedules 
showed robust regrowth despite continued CPA treatment. In contrast, a large majority of 
the tumors treated on the CPA/6d and CPA(210)/9d schedules remained regressed long-
term. The rapid rebound of tumors treated on the CPA/6–9d schedule, which has only one 
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9-day drug-free interval through day 24 (Fig. 2-5B), highlights the importance of the 
duration of the drug-free interval. We conclude that the efficacy of metronomic CPA 
treatment in this model is not dependent on the extent of initial tumor regression, which 
was similar for all five metronomic CPA schedules, but rather is dependent on the 
effectiveness of each schedule at inducing a strong and prolonged anti-tumor immune 
response. In particular, the ineffectiveness of the every 9-day and every 12-day 
metronomic CPA schedules at sustaining tumor regression is associated with the inability 
of those schedules to sustain strong NK cell activity (Fig. 2-6). This, in turn, could 
facilitate the emergence of resistant tumor cell populations leading to the tumor relapse 
frequently seen after day 24. 
Increasing the dose of CPA given on the every 9 day schedule from 140 to 210 
mg/kg-BW (i.e., CPA/9d versus CPA(210)/9d treatment) did not augment immune 
responses, but nevertheless, was effective at reducing the frequency of tumor regrowth. 
NK cell activation markers were decreased in the CPA(210)/9d treated tumors, which 
may result from weak dendritic cell mobilization at high doses of CPA, which can 
decrease tumor NK cell activation [49,50]. Alternatively, there might be increased DNA 
repair during drug-free intervals longer than 6 days, which may promote selection of 
resistance to chemotherapy and reduce tumor cell sensitivity to subsequent CPA 
injections. In this scenario, increasing the CPA dose per injection on an every 9-day 
schedule, as in the CPA(210)/9d treatment, may result in an effective anti-tumor 
response, despite the longer drug-free break. These findings demonstrate that increasing 
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the dose of CPA can at least in part compensate for the decreased anti-tumor immune 
response of the 9-day repeating CPA schedule. Increasing the CPA dose used in 
metronomic CPA regimens may be one option to improve efficacy, in particular in 
immune-deficient or immune-compromised patients. 
NK cell marker levels are closely correlated with the extent of tumor regression 
induced by metronomic CPA treatment [22]. Here, we found a close association between 
the reduced effectiveness of metronomic CPA schedules with a 9-day or 12-day drug-free 
interval and a decrease in NK cell activation marker expression leading to rapid tumor 
regrowth after treatment day 24.drug-free interval longer than 6 days could favor the 
expression of immunosuppressive factors compared to immune-stimulatory factors. 
Moreover, host immune reservoirs may become exhausted and immune resistance 
mutants may be selected by metronomic CPA treatment for prolonged periods of time 
[22]. Reduced NK cell recruitment was also seen in CPA(210)/9d-treated tumors, where 
the elevated CPA dose was able to compensate for the reduced innate immune response. 
Resistance to metronomic CPA has been associated with dormant stem-cell foci in 
hepatocellular carcinoma [51], ischemia-dependent K-ras mutations in colorectal 
carcinoma [52] and increased annexin A3 expression in prostate cancer [53,54]. Different 
resistance mechanisms may be activated in different tumor models and by different CPA 
doses and schedules [55,56]; these mechanisms could include immune-based resistance, 
as well as repopulation of quiescent tumor cells that are distal of blood vessel and 
deprived of oxygen and nutrients, selection of tumor cell populations with increased drug 
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efflux and detoxification ability, increased DNA damage repair between metronomic 
CPA treatments, metabolic adaptation, and emergence of resistance to apoptosis [57,58]. 
In preliminary studies of regressing GL261 tumors, we have seen ~two-fold higher 
expression of ALDH1A1 6 days after two CPA injections on the CPA/9d compared to the 
CPA/6d schedule (J Wu and DJ Waxman, unpublished results, 2014); ALDH1A1 
inactivates CPA-derived aldophosphamide and can confer CPA resistance [59].  
In summary, the innate immune stimulatory CPA/6d schedule described 
previously [21] is shown to be more efficacious than intermittent metronomic CPA 
schedules having longer drug-free breaks. CPA schedules with 9 day or 12 day drug-free 
intervals induced major regression of implanted gliomas through treatment day 24 in a 
manner very similar to the CPA/6d schedule, but this initial response period was followed 
by rapid tumor regrowth and a high frequency of rebounding tumors showing 
significantly reduced levels of NK cell activation. These findings complement our recent 
studies showing that more frequent CPA scheduling – either daily low dose or every 3 
day CPA treatment with the same net drug exposure as the every 6 day schedule – is 
ineffective with regard to induction of robust NK cell recruitment and tumor regression 
[22]. Overall, these findings are consistent with the empirical finding of Browder et al. 
that an every 6-day metronomic CPA schedule is more active than every 3, 4, 5, 7, or 8-
day CPA scheduling in a CPA-resistant Lewis lung carcinoma model [7]. Additional 
studies are needed to establish the effectiveness of every 6-day metronomic CPA 
treatment in orthotopic glioma models, and in brain cancer patients, where metronomic 
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CPA may potentially be combined with current standard of care treatments, such as 
temozolomide, as an associated immunotherapy. Further, our finding that increasing the 
CPA dose in the 9-day schedule substantially prolongs tumor regression suggests that 
while low dose metronomic drug treatment can be effective at inducing immune-based 
tumor regression, increases in drug doses may sometimes be needed for metronomic 
therapy to reduce the potential for relapse. Finally, further investigation is required to 
elucidate the mechanisms leading to the emergence of resistance to immunogenic 
metronomic scheduling, as well as to translate these findings to improve the efficacy of 
CPA-based metronomic immunotherapies in the clinic. 
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Table 2-1. Primer sets used for qPCR for the indicated mouse gene transcripts 
Gene names are shown in parentheses. f: forward; r: reverse. Sequences for the following primer 
sets were reported previously [21]: TNF receptor superfamily member 6 (Fas), natural 
cytotoxicity triggering receptor 1 (Nkp46), perforin 1 (Prf1), granzyme B (Gzmb), killer cell 
lectin-like receptor subfamily K, member 1 (Nkg2d or Klrk1), CD68 antigen (CD68), CD74 
antigen (CD74), CD207 antigen (CD207), EGF-like module containing, mucin -like, hormone 
receptor-like sequence 1 (Emr1). Fas ligand (Fasl) was reported in [22]. 
Gene Primer# Primer Sequence (5’ to 3’) 
interleukin 15 (IL15) 
5095 f: GAAGGCTGAGTTCCACATCTAACA 
5096 r: CTGCTGACATGGGTTTCTGTGTT 
interleukin 18 (IL18) 
5099 f: TGTGACCCTCTCTGTGAAGGATAGT 
5100 r: GTTTCTGAAAGAATATGAGATCACTTTG 
colony stimulating factor 1 
(Csf1) 
5089 f: GAGGCTCCAGGAACTCTCCAAT 
5090 r: CAAGGAGATTCTTTGTTTCATTAAAGAAG 
intercellular adhesion 
molecule 1 (Icam1) 
4842 f: CAAGGGCTGGCATTGTTCTCT 
4843 r: GGGTGTCGAGCTTTGGGATG 
vascular endothelial growth 
factor(VEGFA) 
3612 f: CGACAGAAGGAGAGCAGAAGTCC 
3613 r: GACGGCAGTAGCTTCGCTGG 
chemokine (C-X-C motif) 
ligand 10 (Cxcl10) 
3373 f: ACCATGAACCCAAGTGCTGCC 
3374 r: CTATGGCCCTCATTCTCACTGGCC 
Toll-like receptor 7 (Tlr7) 
5141 f: GGATGATCCTGGCCTATCTCTGA 
5142 r: TCTCTTCCGTGTCCACATCGA 
intercellular adhesion 
molecule 2 (Icam2) 
4846 f: TTGCTGGAGCCTGTCTCTTCTTA 
4847 r: GCAGTTGGTGCTGCAGTTGAT 
vascular cell adhesion 
molecule 1 (Vcam1) 
4840 f: TCTGGGAAGCTGGAACGAAGT 
4841 r: CAGCCTGTAAACTGGGTAAATGTCT 
chemokine (C-X-C motif) 
ligand  9 (Cxcl9) 
5076 f: GAAGAAGCTGATGAAAGAATGGGAA 
5077 r: ATTCAGGGTGCTTGTTGGTAAAGTAA 
chemokine (C-X-C motif) 
ligand 11(Cxcl11) 
4878 f: GCTGAGATGAACAGGAAGGTCACA 
4879 r: TGCCATTTTGACGGCTTTCAT 
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Table 2-2. Comparison of immune cell marker gene expression on day 13 vs. day 12. 
Changes in innate immune cell marker genes in CPA/6d-treated tumors on day 13 (i.e., 1 day 
after a third CPA injection) compared to day 12 (i.e., 6 days after two injections of CPA), based 
on data in Fig. 2-2. Values shown in columns 3 and 4 are fold-changes ± SE in the expression 
level of each immune marker gene compared to drug-free (untreated control) tumors. The 
percentage values shown in column 5 indicate the extent to which the immune marker gene 
declines within 1 day of a third CPA injection given on day 12, and is calculated using the 
formula: 100% × (day 12 − day 13) / day 12. The significance of the change was assessed by one 
tailed t-test. NS, not significant (p > 0.05). 
Cell type Genes Day 12 Day 13 Day 13 vs. p-value 
  (2-CPA) (3-CPA) day 12  
  fold-change fold-change (% decrease)  
        
NK cells Nkp46 4.8 ± 1.0 1.2 ± 0.4 75.4 <0.01 
 Nkg2d 6.0 ± 1.1 2.3 ± 0.5 61.5 <0.02 
NK cell activation Prf1 4.1 ± 1.2 1.6 ± 0.6 60.1 0.06 
 Gzmb 5.5 ± 1.5 2.2 ± 0.6 59.3 <0.05 
Dendritic cells CD74 5.2 ± 0.8 4.5 ± 1.0 13.7 NS 
 CD207 2.3 ± 0.9 3.0 ± 0.8 −29.9 NS 
Macrophages CD68 5.2 ± 0.7 4.7 ± 0.4 10.9 NS 
 Emr1 13.2 ± 2.8 9.1 ± 0.8 31.4 NS 
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Table 2-3. Impact of different metronomic CPA schedules on the number of 
rebounding and regressing tumors, the frequency of tumor rebound, and the rate of 
growth of rebounding tumors. 
Data shown are based on growth curves presented in Fig. 2-4 and Fig. 2-5. Rebounding tumor 
growth rates were estimated from Fig. 2-5B based on the number of days required for regressing 
tumors to return to the mean initial tumor volume prior to CPA treatment (day 0). Tumors in the 
CPA/6d and CPA(210)/9d groups were combined for these analyses; both groups were treated 
with the same CPA dose calculated on a per day basis, and they exhibited similar tumor rebound 
growth frequency (18–25%; mean value for combined group 21%) and rebound growth rate (45–
48 days for rebound to initial tumor volume). a, p-value obtained by Fisher’s exact test comparing 
each group to the combined CPA/6d and CPA(210)/9d group. NS, not significant. b, p = 0.008 
and p = 0.0011 for separate comparisons to the CPA/6d and CPA(210)/9d treatment groups, 
respectively. 
CPA 
schedule 
Rebounding 
tumors 
Regressing 
tumors 
p-value
a
 Rebound 
Time to rebound 
to initial tumor 
volume 
  (number) (number)   
frequency 
(%) 
(number of days) 
CPA/12d 12 2 0.00030
b
 85.7 21–24 
CPA/9d 8 6 0.033 57.6 27–33 
CPA/6d–9d 3 7 NS 30 27–33 
CPA/6d + 
CPA(210)/9d 
4 15 – 21.1 45–48 
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Fig. 2-1. Growth curves of GL261 tumors that were untreated, or were given 1, 2, or 
3 CPA injections on the CPA/6d schedule.  
Data shown are tumor volumes normalized to 100% on the first day of drug treatment (=day 0), 
mean ± SEM, for n = 6–8 tumors/group, except for 1 cycle CPA, where n = 4. Arrows at the 
bottom indicate days of CPA treatment at 140 mg/kg-BW. The measured tumor volumes on day 0 
were 685 ± 55 
mm3
, 785 ± 370 
mm3
, 715 ± 105 
mm3
 (mean ± SEM) for the groups given 1, 2, and 3 
CPA injections, respectively. 
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Fig. 2-2. Time courses of changes in innate immune cell marker gene expression 
assayed by qPCR in GL261 tumors treated as in Fig. 2-1.  
Tumors were sampled 1, 3, 6 and 12 days after the last CPA injection, and at one additional time 
point, when strong tumor regrowth was evident (treatment days 18, 30 and 40, for 1, 2 and 3 CPA 
injections, respectively; see Fig. 2-1). (A) NK cell markers Nkp46 and Nkg2d, (B) NK cell 
activation markers Prf1 and Gzmb, (C) dendritic cell markers CD207 and CD74, and (D) macro-
phage markers CD68 and Emr1 (F4/80). The third CPA injection reduced NK cell marker 
expression compared to the level just prior to injection (day 13 vs. day 12; see Table 2-2). Gene 
expression levels relative to 18S rRNA over the time course (X-axis) were normalized to the 
mean of untreated tumors on day 1. Y-axis values are relative expression levels of each gene, 
mean ± SEM, for n = 4–8 tumors per time point. 
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Fig. 2-3. Time courses for changes in cytokine, chemokine and adhesion molecule 
gene expression in GL261 tumors treated as in Fig. 2-1.  
Tumor samples were the same as in Fig. 2-2. Error bars, mean expression values ± SEM, for n = 
4–8 tumors per time point, except that Icam2 and Vcam1 were assayed using pooled cDNA from 
n = 4 to 6 individual tumors 
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Fig. 2-4. Growth curves for GL261 tumors in mice given a total of three CPA 
injections on the CPA/12d schedule (upper set of arrows).  
Data are directly compared to the growth curve for three cycles of CPA/6d treatment (lower set of 
arrows), re-produced from Fig. 2-1, to highlight the divergence of responses beginning on day 24. 
Data shown are normalized tumor volumes, mean ± SEM, n = 8 for tumors in the CPA/ 6d group, 
n = 9 for tumors in the CPA/12d group. Tumor volume on the first day of CPA/12d treatment 
(day 0) = 610 ± 130 
mm3
 (=100%). Normalized tumor volumes in the CPA/12d group on days 24, 
27, and 30 were significantly larger than in the CPA/6d group (*p < 0.05; **p < 0.01, by one-
tailed t-test). 
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Fig. 2-5. Growth curves for GL261 tumors in mice treated with CPA on four 
different metronomic schedules.  
Data shown are normalized tumor volumes, mean ± SEM. (A) Data shown are for all tumors 
included in the study: n = 4, 8, 14, 11, and 10 tumors for the untreated, CPA/6d, CPA/9d, 
CPA(210)/9d, and CPA/6–9d treatment groups, respectively. Normalized tumor volumes in the 
CPA/9d treatment group were significantly greater than in the CPA/6d group, and also the 
CPA(210)/9d treatment group, on day 30, on day 33, and also on day 36 (p < 0.05 by one tailed t-
test). (B) Data are shown for untreated tumors (n = 4) and for regrowing tumors only: n = 2, 8, 2, 
and 3, for CPA/6d, CPA/9d, CPA(210)/9d, and CAP/6–9d, respectively. Normalized tumor 
volumes in CPA/9d group were significantly greater than those in the CPA/6d group on days 27 
and 30, and those in the CPA(210)/9d group on days 30, 33, and 36, respectively (p < 0.05 by one 
tailed t-test). (C) Data are shown for untreated tumors (n = 4) and for long-term regressing tumors 
only: n = 6, 6, 9, and 7, for CPA/6d, CPA/ 9d, CPA(210)/9d, and CAP/6–9d, respectively. (D) 
Individual GL261 tumor growth curves from four metronomic CPA treatment schedules 
(CPA/6d, CPA/9d, CAP/6-9d, and CPA(210)/9d). Rebounding and regressing tumor numbers are 
as indicated. 
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Fig.2-5 
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Fig. 2-6. NK cell recruitment and NK cell activation status in metronomic CPA-
treated GL261 tumors.  
qPCR analysis of the indicated marker genes in tumors collected 6 days after two CPA injections 
(A), 6 days after three CPA injections (B and D), or 9 days after three injections (C) given on the 
indicated schedules: CPA/6d, CPA/9d and CPA(210)/ 9d. Data shown are relative expression 
levels, mean ± SEM: (A) n = 18 (untreated), n = 20 (CPA/6d), n = 24 (CPA/9d), and n = 4 
(CPA(210)/9d); (B and C) n = 5–8 tumors per group. Significance when compared to untreated 
tumors: *p < 0.05; **p < 0.01; ***p < 0.001 (one-way ANOVA). Significance when compared to 
CPA/6d treatment: +p < 0.05; ++p < 0.01; +++p < 0.001 (one-way ANOVA for comparisons 
involving three or more groups; two-tailed t-test for comparisons limited to two groups).       
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Fig. 2-7. NK cell marker Nkp46, NK cell activation markers Prf1, Gzmb, and Fasl, 
dendritic cell marker CD74, and macrophage marker Emr1 in regressing GL261 
tumors compared to rebounding GL261 tumors.  
Data shown are relative expression levels normalized to the mean values for untreated tumors, 
mean ± SEM. n = 4 untreated tumors, n = 5 regressing tumors, and n = 18 rebounding tumors, as 
in Fig. 2-5B. Significance when compared to untreated tumors: *p < 0.05; **p < 0.01; ***p < 
0.001. Significance when comparing regressing tumors vs. rebounding tumors: +p < 0.05; ++p < 
0.01; +++p < 0.001 (one-way ANOVA). 
 
 
 
 
 60 
 
Fig. 2-8. Body weights for GL261-bearing mice treated on the indicated metronomic 
CPA schedules.  
Data are normalized to the first treatment day (day 0). Body weight data are mean ± SEM, n = 2, 
4, 6, 5, 7 mice for untreated, CPA/6d, CPA/9d, CPA(210)/9d, CAP/6-9d, CPA/12d treatment 
groups, respectively. The CPA/12d and CPA/9d schedules were associated with higher total body 
weight than the CPA/6d or CPA(210)/9d schedules; however, these increases primarily reflect the 
increased tumor sizes in the CPA/12d and CPA/9d treated mice. 
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CHAPTER THREE: METRONOMIC CYCLOPHOSPHAMIDE ERADICATES 
LARGE IMPLANTED GL261 GLIOMAS BY ACTIVATING ANTI-TUMOR 
CD8
+ 
T CELL RESPONSES AND IMMUNE MEMORY  
3.1 Abstract 
Cancer chemotherapy using cytotoxic drugs can induce immunogenic tumor cell 
death, however, dosing regimens and schedules that enable single agent chemotherapy to 
induce adaptive immune-dependent ablation of large, established tumors with activation 
of long-term immune memory have not been identified. Here, we investigate this issue in 
a syngeneic, implanted GL261 glioma model in immune competent mice given 
cyclophosphamide on a 6-day repeating metronomic schedule. Two cycles of 
metronomic cyclophosphamide treatment induced sustained up regulation of tumor-
associated CD8
+
 cytotoxic T lymphocyte (CTL) cells, natural killer (NK) cells, 
macrophages and other immune cells. Expression of CTL and NK cell-shared effectors 
peaked on day 6 then declined by day 9 after the second cyclophosphamide injection and 
correlated inversely with expression of the Treg cell marker Foxp3. Sustained tumor 
regression leading to tumor ablation was achieved after several cyclophosphamide 
treatment cycles. Tumor ablation required CD8
+
 T cells, as shown by immunodepletion 
studies, and was associated with immunity to re-challenge with GL261 glioma cells, but 
not B16-F10 melanoma or Lewis lung carcinoma cells. Rejection of GL261 tumor re-
challenge was associated with elevated CTLs in blood and increased CTL infiltration in 
tumors, consistent with the induction of long-term, specific CD8
+
 T cell anti-GL261 
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tumor memory. Co-depletion of CD8
+
 T cells and NK cells did not inhibit tumor 
regression beyond CD8+ T cell depletion alone, suggesting that the metronomic 
cyclophosphamide-activated NK cells function via CD8a+ T cells. Taken together, these 
findings provide proof-of-concept that single agent chemotherapy delivered on an 
optimized metronomic schedule can eradicate large, established tumors and induce long-
term immune memory. 
3.2 Introduction 
Chemotherapy is widely used for cancer treatment, however, it is less than 
optimally effective, with drug resistance leading to tumor regrowth after a short period of 
tumor shrinkage or tumor growth stasis, as commonly seen with difficult to treat tumors, 
such as glioblastoma [102]. Tumor cell drug resistance is difficult to avoid due to the 
heterogeneous nature of tumor cell populations and their high mutation rate [103, 104]. 
Cancer-directed immune-based therapies offer an attractive alternative, however, many 
such therapies, including cancer vaccines and adoptive transfer of anti-tumor T cells, are 
only modestly effective in the clinic [2, 105-107]. Immune escape mechanisms vary 
between tumor types and stages [10, 108], and potent immunotherapeutic regimens often 
are associated with severe toxicities [92, 109]. The goal of effective personalized 
immunotherapy has been elusive, despite important recent successes, such as anti-CTLA-
4 treatment for metastatic melanoma [110]. One approach to this problem is to employ 
therapies based on traditional cancer chemotherapeutic drugs, which can directly kill 
 63 
 
tumor cells, and repurpose them to activate anti-tumor immune responses that enhance 
tumor regression and prevent tumor regrowth.  
Several cancer chemotherapeutic drugs have intrinsic capacity to induce 
immunogenic cell death [52]. Tumor cells treated by chemotherapeutic drugs can be used 
as a tumor vaccine to confer immunity against subsequent live tumor cell challenge [52, 
53, 100, 111], and intratumoral injection of antineoplastic agents can elicit short-term 
primary immunity [34, 111]. However, it is unclear whether single agent chemotherapy, 
when delivered systemically in the absence of immunotherapy, can effect robust, immune 
cell-dependent ablation of large, well-established tumors with activation of long-term 
immune memory. Further, even for drugs that can induce immunogenic cell death [52], 
chemotherapeutic drug doses and schedules that preserve the intrinsic potential for 
immune activation without ablating responding immune cells need to be identified so as 
to avoid the immunosuppressive responses commonly seen with conventional maximum 
tolerated dose chemotherapy (MTD) schedules [50, 112]. 
Cyclophosphamide (CPA) is a bifunctional alkylating agent prodrug used to treat 
oncogenic and autoimmune diseases [62]. CPA can induce immunogenic tumor cell death 
by inducing tumor surface expression of the “eat-me” signal calreticulin and by releasing 
HMGB1, which stimulates cross-presentation of tumor antigens to T cells [35]. CPA also 
depletes Treg immune suppressive cells and can induce a cytokine storm, which includes 
the production of type I interferons that boost the differentiation and mobilization of 
mature dendritic cells and expand T cells with a memory phenotype [35, 64, 78, 113, 
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114]. For CPA and certain other cytotoxic anticancer drugs, immunogenic responses can 
be achieved when using metronomic drug delivery schedules[55, 115], in which the drug 
is administered at a lower dose, but at regular, and more frequent intervals than 
traditional maximum-tolerated dose cancer chemotherapy [116].  
Our previous studies showed that administration of CPA on an intermittent, every 
6-day metronomic schedule activates a robust innate anti-tumor immune response in 
several glioma models, as seen in both scid immunodeficient mice and in immune 
competent C57BL/6 (B6) mice [55, 56, 70]. The dependence of tumor regression on NK 
cells was established by NK cell immunodepletion and by using mouse models deficient 
in NK cells or in the NK cell effector perforin 1 [55]. Furthermore, in studies using brain 
tumor xenografts implanted in scid mice, tumor recruitment of NK cells was not observed 
and tumor regression was not achieved when CPA was given every 3-days, or on a daily 
basis [56]. In addition, NK cell activation was not sustained when drug-free breaks were 
extended beyond 6 days [57] Thus, the ability of CPA to activate a strong, sustained 
innate anti-tumor immune response is highly dependent on the metronomic schedule. It is 
unclear, however, whether the 6 day-repeating metronomic schedule can activate a robust 
adaptive immune response, and whether it can ablate large implanted gliomas and 
activate long-term adaptive immunity. Here, we investigate these questions using a fully 
immune competent, syngeneic GL261 glioma mouse model. Immune cell recruitment and 
activation were monitored in the metronomic CPA-treated tumors by the time-dependent 
changes in immune cell marker genes. The contribution of CD8
+ 
T cells to CPA-induced 
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tumor regression was investigated by immunodepletion, and the activation of specific, 
long-term anti-tumor immune memory was examined by re-challenging CPA-cured mice 
with GL261 glioma cells and by cross-challenging with B16-F10 melanoma and Lewis 
lung carcinoma (LLC) cells. Our findings are discussed in terms of the impact of 
metronomic CPA dose and schedule on tumor regression, immune responses and memory 
formation, and the induction of effector pathways associated with CTLs and NK cells. 
3.3 Materials and Methods 
Tumor cell lines, mouse tumors, and treatments  
Mouse GL261 glioma cells were authenticated by and obtained from the 
Developmental Therapeutics Program Tumor Repository (National Cancer Institute, 
Frederick, MD). Mouse B16-F10 melanoma (ATCC® CRL-6475™) and LLC Lewis 
lung carcinoma (ATCC® CRL-1642™) cell lines were purchased from ATCC 
(Manassas, VA). All three cell lines were grown at 37C in a humidified 5% CO2 
atmosphere in RPMI-1640 culture medium containing 10% fetal bovine serum, 100 
units/ml penicillin and 100 g/ml streptomycin. Six-week-old (20-23 g) male C57BL/6 
(B6) mice (Taconic Farms, Germantown, NY) were housed and treated under protocols 
approved by the Boston University Institutional Animal Care and Use Committee. GL261 
glioma cells (4 x 10
6
), B16-F10 melanoma cells (1 x 10
6
), or LLC Lewis lung carcinoma 
cells (2 x 10
6
)
 
were implanted by s.c. injection on the posterior flanks in 0.2 ml serum-
free RPMI per site using a U-100 insulin syringe and 28.5 gauge needle (BD Biosciences, 
Cat.# 329461). Tumor areas (length x width) were measured twice weekly using Vernier 
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calipers (VWR International, Cat.# 62379-531) and tumor volumes were calculated: Vol 
= (/6)*(L*W)3/2. Tumors were monitored and drug treatment was initiated at mean 
tumor volumes specified in each study. Tumor volumes were normalized to a value of 
100% at the drug treatment starting point (t = 0 days) for each treatment group to 
normalize the size differences between individual tumors at the time of first treatment, 
which in some cases can be substantial (e.g., Fig. 3-5A). This approach controls for 
differences in initial tumor size at the onset of drug treatment and enabled us to reach 
statistical significance with fewer mice, in accordance with Institutional Animal Care and 
Use Committee guidelines. We have established that the raw tumor volume trends are 
very similar to those of the normalized tumor volume data, confirming that normalized 
tumor volume is an appropriate way to present the data. Mouse body weights were 
measured at least twice a week and normalized in the same manner. Mice whose 
implanted GL261 gliomas were cured by metronomic CPA treatment (‘cured mice’) were 
rested for ~ 4 weeks then reinjected with GL261 cells (‘re-challenge’), B16-F10 cells or 
LLC cells (‘cross-challenge’), as indicated, to evaluate the acquisition of immune 
memory. Re-challenged Gl261 tumors that initially grew and then regressed (in the 
absence of any drug treatment) (‘rejected tumors’) were sampled for FACS and immune 
cell marker analysis, as described below.  
Mice were treated with CPA monohydrate (Cat. # C0768, Sigma-Aldrich, St. 
Louis, MO) every 6 days at 140 mg/kg-body weight per injection (CPA/6d) or at 90 
mg/kg-body weight per injection (CPA(90)/6d), as specified. The CPA doses reported are 
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based on the non-hydrated molecular weight of 261. NK cell-depleting antibody anti-
asialoGM1 (‘anti-GM1’) (Cat.# 986-10001, Wako Chemicals USA, VA) was 
administered as described [55]. Briefly, anti-GM1 (50 µl) was given once every 6 days 
beginning 3 days prior to the first CPA injection by i.p. injection after dilution with 2 
volume of sterile PBS on the day of injection (final volume,150 µl/mouse). CD8+ T cells 
were depleted using monoclonal antibody anti-CD8a (clone 53-6.72, Cat.# B30004-1, 
Bio-XCell, West Lebanon, NH) by i.p. injection at 0.28 mg antibody/mouse. Anti-CD8a 
was injected once every 6 days, except as follows: 1) when combined with CPA/6d 
treatment, the first three anti-CD8a injections were given on days -3, -1, and +3 relative 
to the first CPA treatment on day 0, and every 6 days thereafter; and 2) when combined 
with CPA(90)/6d treatment, the first two anti-CD8a injections were given on day -17 and 
on day -15 relative to CPA(90)/6d treatment beginning on day 0, and every 6 days 
thereafter, as marked in each figure using vertical arrows. Anti-CD8a (6.88 mg/ml) was 
diluted with 3 volumes of PBS and then injected at 162.8 µl/injection/mouse. Fisher’s 
exact test was used to assess the significance of differences in tumor take rate between 
groups (tumor rejection vs tumor growth), and Student’s t-test was used to establish the 
significance of differences in tumor growth rate for CPA treatment in combination with 
different antibodies. Significance is noted by *, p < 0.05; **, p < 0.01; and ***, p < 
0.001. 
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qPCR analysis of marker genes 
Changes in tumor-infiltrating immune cells were monitored by changes in the 
expression of immune cell marker genes, as determined by qPCR analysis of total tumor 
RNA. Changes in the marker genes reported here are indicative of changes in the 
corresponding marker protein levels and immune cell numbers, as established previously 
by immunohistochemistry and/or FACS analysis of metronomic CPA-treated GL261, 9L 
and U251 gliomas implanted in the scid or B6 mouse models [55, 56, 117]. and further 
confirmed here in select cases by FACS analysis. NK cell marker gene expression levels 
showed a close association with the extent of tumor regression induced by metronomic 
CPA treatment [56]. However, we cannot exclude the possibility that expression of some 
of the other genes examined might come from mixed cell types. Isolation of total tumor 
RNA, reverse transcription, and qPCR were carried out as described [55]. Primers 
designed using Primer Express software (Applied Biosystems, Carlsbad, CA, USA) are 
described in [55, 56]. or are presented in Table 3-1. qPCR data were analyzed using the 
comparative CT method and are presented as relative levels of each RNA compared to the 
RNA level in untreated tumors after normalization to the 18S RNA content of each 
sample. qPCR data are expressed as mean values  S.E. for n=6 tumors per time point for 
each treatment group, unless indicated otherwise. Statistically significant differences 
between mean values of different treatment groups were determined by one-way 
ANOVA (for three of more comparisons) or two-tailed Student’s t-test (for two group 
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comparisons). Significance is indicated in each figure by: *, p < 0.05; **, p < 0.01; and 
***, p < 0.001. 
FACS sample preparation and data analysis 
A FACSCalibur™ instrument (Cat.# 342975; BD Biosciences) was used for 
FACS analysis of tumor infiltrating immune cells in the following five step protocol. Step 
1, Preparation of single-cell suspension using a gentleMACS Dissociator (Miltenyi 
Biotec, Auburn, CA): 1 ml of complete medium (RPMI-1640 culture medium containing 
10% fetal bovine serum, 100 Units/ml penicillin and 100 g/ml streptomycin) was added 
to a C-tube (Cat.# 130-093-237, Miltenyi Biotec) on ice. A piece of freshly excised tumor 
tissue (~ half to one pea size) was placed in the C-tube and cut into pieces < 0.5 mm in 
size using scissors. Collagenase I (Cat.# 4196, Worthington; 400 unit (40 µl), using stock 
adjusted to 10 unit/µl using PBS, with frozen aliquots stored at -80C) and DNase I 
(Cat.# 260913, Calbiochem; 5 x 10
4
 Dornase Unit (10 µl), using stock adjusted to 5 x 10
3
 
Dornase Unit/µl using sterile ddH2O, with frozen aliquots kept at -80C) were added 
followed by gentle shaking in a 37C water bath for 30 min. Complete medium (4 ml) 
was then added to bring the volume to 5 ml. The C-tube was mounted on a gentleMACS 
Dissociator and processed once using program 4.1 (Mouse-Implanted-Tumor program). 
The C-tube was briefly spun and the cells were passed through a 70 µm filter (Cat.# 
22363548, Fisher Scientific) into a 50 ml conical tube pre-rinsed with 1 ml complete 
medium, followed by a wash of the C-tube and filter with an additional 10 ml complete 
medium; 2) Red blood cell lysis: The filtered cells were spun down at 400 g for 5 min, re-
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suspended in ~1 ml of RBC lysis buffer (Cat.# 00-4333-57, eBioscience, San Diego), and 
gently mixed for 10 min at 20-22C. PBS (2 ml) was added and the cells were pelleted at 
400 g, washed once using 15 ml PEB (PBS, pH 7.2, 0.5% BSA, 2 mM EDTA) and re-
suspended in 0.5 to 1 ml PEB to give a final concentration of 10
6
 to 10
9
 cells/ml; 3) 
Antibody staining: 100 µl cells were stained with 2 µl anti-CD16/32 in a 5 ml test tube at 
4C for 20 min, to block non-specific mouse IgG Fc binding to Fc receptor-expressing 
cells. Fluorescence-conjugated antibody was then added in amounts specified below, 
followed by 10 min incubation at 4C. The cells were washed once with 3 ml PEB and 
re-suspended in 200 µl PEB; 4) FACS analysis: Propidium iodide was added to the cells 
(20 ng/ml, final concentration) immediately before events were collected using BD 
CellQuest Pro software (BD Biosciences). Antibody sources and amounts used per FACS 
reaction: anti-CD16/32 (Cat.# 14-0161-85, clone 93, 2 µl), anti-mouse NK1.1-PE 
(Cat.#12-5941, clone PK136, 1 µl), anti-mouse CD11b-PE (Cat.# 12-0112, clone M1/70, 
0.2 µl), rat IgG2a k-isotype-PE (clone eBR2a, Cat.#12-4321-80, 1 µl), and mouse IgG 2a 
k isotype-PE (clone eBM2a, Cat.#12-4724-81, 1 µl) were all purchased from 
eBioscience, Inc. (San Diego, CA); rat IgG2a k-isotype (Cat.# 553929, 1 µl) from BD 
Biosciences; anti-mouse NK1.1-APC (Cat.# 130-102-350, clone PK136, 5 µl) from 
Miltenyi Biotech (San Diego, CA); anti-mouse CD8a-APC (Cat.# 20-1886, Rat IgG 2b, 
clone 2.43, 0.7 µl), anti-mouse CD8a-PE-Cy7 (Cat.# 60-1886, Rat IgG 2b, clone 2.43, 
0.7 µl), anti-mouse CD3e-FITC (Cat.# 35-0031, Armenian Hamster IgG, clone 145-2c11, 
1 µl), anti-Gr-1-FITC (Cat.# 35-5931, clone RB6-8C5, 1 µl), anti-mouse Emr1-APC 
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(Cat.# 20-4801, clone BM8.1, 2.5 µl), and anti-mouse CD45-PE (Cat.# 50-0451, clone 
30-F11, 0.2 µl) all from Tonbo Biosciences (San Diego, CA). 
For FACS analysis of blood, ~0.5 ml whole blood was sampled via the cheek 
pouch prior to euthanasia. Alternatively, ~20 µl whole blood was collected from the tail 
vein for analysis. Blood was stored in a 1.5 ml Eppendorf tube with Heparin sodium 
(1000 unit/ml in 0.9% NaCl, Cat. # 3149, Sigma-Aldrich, St. Louis, MO). For each 
FACS reaction, 1 ml of RBC lysis buffer was added to ~20 µl fresh whole blood with 
gentle shaking for 20 min at 20-22C. PBS (2 ml) was added to terminate the lysis 
reaction followed by one spin and wash using 3 ml PEB. The cells were re-suspended in 
200 µl PEB and then stained with antibody, as described above for the tumor-infiltrated 
immune cell FACS analysis protocol. FlowJo data analysis software (Ashland, OR) was 
used to analyze the data. Propidium iodide-positive cells were routinely excluded.  
3.4 Results 
Metronomic CPA treatment activates significant CD8
+ 
T cell responses  
GL261 tumors were implanted in B6 mice and given two cycles of metronomic 
CPA treatment. A prolonged period of tumor regression, lasting at least 15 days, was 
induced beginning shortly after the second CPA injection (Fig. 3-1A). Analysis of 
changes of expressed immune cell marker genes in the tumor compartment indicated that 
NK cell (Nkp46) and CD8a
+
 T cell responses were already induced by the first CPA 
cycle (Fig. 3-1B). No changes in Nkp46 expression were seen when comparing day 6 
after the first CPA treatment to day 7 (i.e., day 1 after the second CPA treatment), 
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consistent with our findings in scid mice, where CPA ablation of the tumor-associated 
NK cell population was not apparent until after the second CPA injection [70]. The CTL 
marker CD8a and the immune suppressive Treg cell marker Foxp3 were significantly 
decreased 3 days after the first CPA injection and rebounded on day 6. CD8a increases 
seen on day 6 returned to baseline one day after the second CPA treatment (day 7, Fig. 3-
1B).  
The 2-4-fold increases in tumor-associated CTLs, NK cells, and their shared 
cytotoxic effectors Prf1 and Gzmb [118-120], seen 6 days after the first CPA injection 
(Fig. 3-1B), were further increased to 15-20-fold overall, 6 days after the second CPA 
injection (Fig. 3-1C, Fig. 3-1D). Large increases were also seen for tumor-associated 
macrophage (CD68 and Emr1) and dendritic cell (CD74) markers (Fig. 3-1D). These 
immune cell increases were largely sustained through day 15. In contrast, the cytotoxic 
effectors Prf1 and Gzmb peaked on day 6 then decreased significantly, as seen on days 9, 
12, and 15 after the second CPA treatment (Fig. 3-1C-D). Prf1 levels correlated 
negatively with Foxp3 levels on days 6 and 9 after the second CPA treatment (Fig. 3-
1C,E), suggesting that Treg cell-mediated suppression [121, 122] contributes to the 
decline in Prf1 and Gzmb seen after the second CPA injection. 
Role of CD8
+ 
T cells in metronomic CPA-induced tumor regression  
The metronomic CPA-treated tumors were depleted of CD8+ T cells, either alone 
(anti-CD8a antibody) or in combination with NK cell depletion (anti-CD8a + anti-GM1 
antibodies) to discern the contribution of each immune cell type to tumor regression. 
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FACS analysis verified the effectiveness of immune cell depletion, both in blood and in 
the tumors (Fig. 3-2A, E-H), and the extent of depletion in tumors was confirmed by 
monitoring CD8a and Nkp46 marker genes (Fig. 3-2B). Neither antibody altered CD68-
marked macrophage levels, consistent with the established immune cell specificity of 
each antibody (Fig. 3-2B). However, CD8
+
 T cell immunodepletion slowed tumor 
regression significantly (Fig. 3-2C), and to a greater extent than NK cell 
immunodepletion (Fig. 3-2I), indicating that the CD8
+
 T cells make a more significant 
contribution to CPA-induced tumor regression. The CPA-treated (CD8
+
 T cell + NK 
cell)-co-depleted tumors regressed significantly more slowly than NK cell-depleted 
tumors, however, the rate of regression was indistinguishable from that of CPA-treated 
tumors depleted of CD8
+
 T cells alone (Fig. 3-2C,I). These findings support the 
hypothesis that the tumor regressing activity associated with NK cells is dependent on, 
and may be mediated by CD8
+
 T cells (model, Fig. 3-2D).  
Next, we assayed the impact of NK cell and CD8
+
 T cell depletion on five 
cytotoxic immune cell effectors [123] induced by metronomic CPA treatment: Prf1, 
Gzmb, Tnfa, Ifng, and Fasl (Fig. 3-2B). Prf1 and Gzmb levels in the CPA-treated tumors 
were unaffected by CD8
+
 T cell depletion but were substantially reduced by CD8
+
 T cell 
and NK cell co-depletion (Fig. 3-2B), suggesting NK cells are the primary source of Prf1 
and Gzmb. Fasl was significantly (albeit partially) down regulated by CD8
+
 T cell 
depletion, with a trend toward a further decrease seen upon co-depletion of NK cells (Fig. 
3-2B). Tnfa and Ifng were significantly reduced by CD8
+
 T cell depletion, however, this 
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inhibition was reversed upon co-depletion of NK cells. Metronomic CPA induction of 
Tgfb, an immune suppressive and protumor growth factor [124], was largely independent 
of CD8
+
 T cells and NK cells (Fig. 3-2B). Finally, CPA treatment significantly increased 
the lymphocyte-activating cytokines IL15 and IL18, consistent with systematic immune 
activation [125], but the expression of these cytokines was only partially reduced upon 
CD8
+
 T cell depletion, either with or without NK cell depletion (Fig. 3-2B).model for the 
contributions of CD8
+
 T cells and NK cells to CPA-induced production of these cytotoxic 
mediators is shown in Fig. 3-2D. 
Impact of CPA dose on CD8
+ 
T cell-dependence of GL261 regression  
The partial inhibition of tumor regression following CD8
+ 
T cell depletion (Fig. 3-
2C) suggests that regression is dependent partially on CD8
+
 T cells and partially on the 
direct tumor cytotoxic action of CPA. To test this hypothesis, we examined the impact of 
reducing the every 6 day metronomic CPA dose from 140 mg CPA/kg (CPA/6d) to 90 
mg CPA/kg (CPA(90)/6d). CPA doses below 140 mg/kg are associated with a significant 
decrease in circulating 4-hydroxy-CPA, the active, cytotoxic metabolite [56]. 
CPA(90)/6d induced major tumor regression (Fig. 3-3A), as was also seen with CPA/6d 
treatment (Fig. 3-2C); however, in contrast to CPA/6d treatment, a significant subset (5 
out of 14) of the CPA(90)/6d-treated tumors did not undergo sustained regression (Fig. 3-
3B), which could be explained by the lower circulating 4-hydroxy-CPA levels at the 
lower CPA dose. Further, CPA(90)/6d treatment significantly increased tumor 
recruitment of NK cells and CD8
+
 T cells in the regressing tumors, as well as expression 
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of the NK cell and T cell cytotoxic markers Prf1 and Gzmb (Fig. 3-3C). CPA(90)/6d also 
increased expression of the dendritic cell co-stimulatory molecule CD86 and several 
other genes important for NK cell and T cell proliferation and activation (IL15, IL18, 
Nkg2d, Fasl; Fig. 3-4A-B) [123]. The macrophage marker Emr1 was also up regulated, 
as was the cytokine Csf1 (Fig. 3-4A-B), which is critical for macrophage development 
and proliferation [126]. Notably, CPA(90)/6d induced a much stronger increase in the M1 
(anti-tumor) macrophage marker iNos than the M2 (pro-tumor) macrophage marker 
Arg1, suggesting anti-tumor macrophage polarization by CPA(90)/6d treatment (Fig. 3-
4A-B). Several other factors associated with an immune suppressive microenvironment 
were only moderately changed or were down regulated by CPA(90)/6d treatment (Foxp3, 
marking Treg cells; Vegfa, which stimulates angiogenesis and is a chronic inflammation 
marker; and Hif1a, a hypoxia marker). CPA/6d-treated tumors showed very similar 
expression profiles for each of these factors (Fig. 3-4A-B).  
The dependence of tumor regression on CTLs was much more apparent in the 
CPA(90)/6d-treated mice than in the CPA/6d-treated mice. Thus, CD8
+
 T cell 
immunodepletion resulted in 9 of 10 tumors escaping CPA(90)/6d-induced regression, as 
compared to 5 out of 14 escaping tumors with CPA(90)/6d treatment alone (Fig. 3-3A, 
3B) (p=0.013, Fisher’s exact test). In contrast, 0 out of 10 tumors escaped CPA/6d-
induced regression upon depletion of CD8
+
 T cells, either alone or in combination with 
NK cell depletion (Fig. 3-2C). Immunodepletion of CD8
+ 
T cells, verified by FACS 
analysis of peripheral blood (Fig. 3-3D), had at most a small stimulatory effect on tumor 
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growth in the absence of CPA treatment in some, but not all, experiments (data not 
shown). While this could contribute to the slower regression seen upon immune cell 
depletion with CPA/6d treatment (Fig. 3-2C), it is far too small an effect to account for 
the dramatic escape from regression seen in the CPA(90)/6d-treated tumors (Fig. 3-3A). 
Thus, at the CPA(90)/6d dose, where direct 4-hydroxy-CPA tumor cell cytotoxicity is 
expected to be less extensive than at CPA/6d, we observed major GL261 glioma 
regression that is highly dependent on CD8
+ 
T cells. In the tumors unresponsive to 
CPA(90)/6d treatment, CD8a and Gzmb marker levels were not elevated compared to 
CPA-free control tumors (Fig. 3-4C), confirming that CD8
+
 T cells are a critical 
component of CPA-induced tumor regression.  
Metronomic CPA activates tumor-specific immune memory  
Next, we investigated whether metronomic CPA treatment induces long-term 
anti-tumor immunity in the glioma-bearing B6 mice. GL261 glioma-bearing mice were 
treated with metronomic CPA/6d for 10-11 cycles, resulting in tumor ablation (Fig. 3-
5A). Mouse body weights were relatively stable (Fig. 3-6), indicating that host toxicity 
was manageable. The mice were maintained drug-free for ~4 weeks then re-challenged 
with fresh GL261 tumor cells injected at a contralateral site (Fig. 3-5B). Whereas 25 of 
25 GL261 tumors implanted in tumor-naive mice grew by day 23 after inoculation, only 
6 of 18 tumors re-implanted in the CPA/6d-cured mice grew after 60 days (Fig. 3-5B, 
Table 3-2). This high rate of tumor rejection (67%, vs. 0% rejection by naive mice, Table 
3-2) indicates that the cured mice acquired anti-tumor immune memory to GL261 
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tumors. The subset of CPA(90)/6d-treated mice that were cured of the GL261 tumors also 
showed significant rejection of re-implanted GL261 tumor cells (tumor rejection in 5 of 6 
mice; 83%, vs. 0% rejection by naive mice, Table 3-2), indicating that CPA(90)/6d 
treatment is sufficient for induction of long-term immune memory. 
To further examine the specificity of the anti-tumor memory, metronomic CPA-
cured GL261-bearing B6 mice were implanted with two other B6 mouse syngeneic tumor 
cell lines, B16-F10 and LLC, in a cross-challenge assay (n=10 tumors per line). All 20 
cross-challenged sites grew tumors by day 13 (Fig. 3-5C-D), i.e., no tumor rejection. 
Further, metronomic CPA treatment had no substantial effect on B16-F10 or LLC tumor 
growth (Fig. 3-5C-D). Thus, the anti-tumor memory induced by metronomic CPA is 
specific to GL261 tumors.  
Molecular characteristics of CPA-induced anti-tumor immune memory  
To obtain mechanistic insight into whether T cells contribute to GL261 tumor 
rejection, we analyzed immune cell levels in mice that rejected the re-implanted GL261 
tumors compared to mice with GL261 tumors that grew. FACS analysis revealed a 
significant increase in CTLs in both the tumor fraction and in peripheral blood of the 
metronomic CPA-cured mice that rejected the GL261 tumor re-challenge as compared to 
mice with growing tumors (Fig. 3-7). Further, mice rejecting the GL261 tumors showed 
lower levels of circulating CD11b
+
Emr1
+
 macrophages and CD11b
+
Gr1
+
 myeloid-
derived suppressive cells (MDSCs), but no differences in NK cells (Fig. 3-7C), 
suggesting that circulating CTLs, and perhaps also macrophages and MDSCs, serve as 
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diagnostic markers for monitoring immune surveillance or tumor regrowth status 
following metronomic CPA treatment. These findings are consistent with the significant 
increase in CD8a expression seen in the rejected tumors compared to growing GL261 
tumors (Fig. 3-7AB). Moreover, in a preliminary study, we found that partial (59%) 
depletion of CD8
+ 
T cells from the metronomic CPA-cured mice (Fig. 3-8A) increased 
the tumor take rate substantially, from 0% (0 out of 6 memory mice without anit-CD8a 
treatment) to 33% (2 out of 6 memory mice treated with anti-CD8a) when the mice were 
re-challenged with GL261 tumors (Fig. 3-8B). 
3.5 Discussion 
Metronomic scheduling, which involves frequent, often daily, anticancer drug 
administration at low doses, offers several advantages over traditional MTD 
chemotherapy, including its ability to activate anti-tumor immune responses [55, 78, 
127]. However, it is not clear what doses and schedules are most effective at eliciting a 
potent adaptive anti-tumor immune response, or whether the immune responses obtained 
evoke long-term immune memory [50, 128-130]. Further, although several cancer 
chemotherapeutic agents, including drugs shown to be effective using metronomic 
scheduling, such as CPA, have well known immune modulatory activity [50, 78], 
including the potential to activate immunogenic cell death [35], it has not been 
established whether single agent chemotherapy can activate an immune response that is 
sufficiently potent to induce tumor ablation linked to the acquisition of long-term, tumor-
specific immunity. Indeed, some studies report that the cytotoxicity of CPA is deleterious 
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to maintenance of long-term anti-tumor immune memory [68]. Previously, we found that 
metronomic scheduling of CPA can activate robust innate anti-tumor immunity and 
induce NK cell-dependent regression of large gliomas implanted in scid adaptive 
immunity-deficient mice when given on a 6 day-repeating schedule [55, 56, 70]. More 
frequent metronomic schedules (daily or every 3 day drug treatment) delivering the same 
total drug dose were much less effective, apparently due to the frequent ablation of tumor 
recruited NK cells [56], while less frequent metronomic scheduling (drug treatment every 
9 or 12 days) was initially effective at immune stimulation, but ultimately led to tumor 
escape after several treatment cycles [70]. Here we show that a strong, sustained CD8
+
 T 
cell-dependent adaptive immune response can be activated by the same 6 day-repeating 
metronomic CPA schedule in an immune competent syngeneic B6 mouse model, 
resulting in complete tumor ablation associated with acquisition of long-term, tumor-
specific anti-tumor immune memory characterized by rejection of syngeneic glioma re-
challenge.  
Our investigation of the time course of metronomic CPA-induced changes in 
immune marker levels in GL261-bearing B6 mice showed that a single injection of CPA 
at 140 mg/kg induced only modest immune responses, whereas a second CPA injection 
resulted in strong up regulation of immune cell markers for CTLs and several innate 
immune cells 6 days later, including NK cells, dendritic cells, and macrophages. These 
findings highlight the importance of repeated CPA-induced tumor cell damage, and are 
consistent with our earlier findings in the scid mouse model [55, 56, 70, 117]. We also 
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observed a significant down regulation of Treg cell (Foxp3) and CTL (CD8a) marker 
genes 3 days after the first CPA injection, followed by a rebound by day 6. Moreover, 
CD8a expression was significantly reduced one day after the second CPA treatment. This 
ability of CPA to deplete CTLs, as well as Tregs, is consistent with earlier reports that 
CPA at a dose of 50 mg/kg given every 4 days is toxic to CTLs in draining lymph nodes 
[65]. and that daily CPA treatment at 10 or 20 mg/kg is associated with decreases in 
tumor-specific T cells [66]. Together, these findings support the proposal that a drug-free 
interval longer than 3 days is required to avoid frequent ablation of CTL responses.  
When CPA treatment was halted after two 6-day CPA cycles, Foxp3-marked Treg 
cells were significantly increased in the tumor compartment 9 days later, and this increase 
correlated with the decreased expression of the CTL and NK cell cytotoxic mediator Prf1. 
Another CTL and NK cell effector marker, Gzmb, showed a similar pattern. The increase 
in Foxp3 and the associated decreases in Prf1 and Gzmb seen 9-15 days after CPA 
treatment are characteristic of Treg-mediated immune suppression [121, 122], and may 
explain why CPA given on a 14-day repeating schedule inhibits the tumor regression and 
long-term immune response that the TLR7/TLR8 agonist resiquimod (R488) activates in 
a syngeneic rat CNS-1 glioma model [68]. These findings highlight the critical 
importance of metronomic interval on the success of chemo-immunomodulation and the 
need to avoid immune suppression by Treg cells activated by CPA or other cytotoxic 
drugs [64, 66].  
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Immunodepletion studies indicated that CD8
+ 
T cells make a greater contribution 
than NK cells to metronomic CPA-induced tumor regression, and suggested that the 
tumor regression activity associated with NK cells in this model is dependent on CD8
+
 T 
cells (see model in Fig. 3-2D). This is reminiscent of the priming role of NK cells in 
adaptive T cell responses described in the context of infectious disease [131]. We found 
that NK cell depletion, but not CD8
+
 T cell depletion, decreased tumor-associated Prf1 
and Gzmb, suggesting these cytotoxic effectors are primarily expressed by NK cells in 
our model. Alternatively, this finding could result from competitive interactions between 
NK cells and T cells, which can lead to compensatory increases in Prf1 and Gzmb 
production by NK cells when CD8
+
 T cells are absent [132, 133]. Indeed, the immune 
stimulatory cytokines IL15 and IL18, which we found to be induced six days after the 
second CPA treatment, can increase competition between NK cells and T cells for 
cytokines [134]. We also found that Tnfa and Ifng expression increased when the CPA-
treated tumors were depleted of both CD8
+
 T cells and NK cells as compared CD8
+
 T cell 
depletion alone. Conceivably, in the absence of CD8
+ 
T cells, the CPA-induced NK cells 
may suppress Tnfa and Ifng expressing cells, such as macrophages [28, 135], thereby 
making the tumor microenvironment more favorable for tumor growth and offsetting the 
beneficial anti-tumor effects of Prf1 and Gzmb production. However, we cannot rule out 
the possibility that the CPA-treated tumor cells contribute to some of the observed 
changes in immune factor gene expression, in particular Fasl, Tnfa and Ifng. Other 
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immune cells, such as CD4
+
 T cells, may also contribute to CPA-mediated tumor 
regression [136].  
Long-term specific anti-tumor immunity and immune memory developed in a 
majority of the GL261-bearing mice treated on the 6 day-repeating metronomic CPA 
schedule, as evidenced by the absence of tumor growth upon re-challenge with fresh 
GL261 tumor cells but not when cross-challenged with B16-F10 or LLC tumor cells. The 
absence of detectable tumor regrowth after discontinuation of CPA treatment for as long 
as 33 days (data not shown) supports this conclusion. An increase in circulating CD8
+
 T 
cells was seen in mice that rejected the GL261 tumor re-challenge, consistent with the 
expansion of tumor-reactive CTLs that contribute to the rejection, while circulating 
macrophage and MDSC populations were decreased. Accordingly, changes in blood 
levels of CTLs, macrophages, and MDSCs may serve as useful diagnostic markers for 
predicting systematic anti-tumor responses. 
Strong increases in intratumoral levels of Nkp46, CD8a, Prf1, Gzmb and several 
other immune stimulatory genes, including the M1 (anti-tumor) macrophage marker 
iNos, were seen in mice given CPA at either 90 mg/kg (CPA(90)/6d) or 140 mg/kg 
(CPA/6d) every 6 days. By contrast, pro-tumor M2 macrophages and immune 
suppressive factor marker genes showed only modest increases or were down regulated 
(VEGFA) at both CPA doses (Fig. 3-4A-B). The strong Prf1 and Gzmb responses 
suggest that immunosuppressive factors, such as MDSCs, which inhibit NK cell and T 
cell proliferation and activation [137, 138], are not significantly increased at either CPA 
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dose, although it remains possible that immunosuppressive factors not examined here 
could be produced by surviving tumor cells and therefore be more abundant at the lower 
CPA dose. Nevertheless, complete regression was achieved in a substantial subset of the 
mice treated at the lower CPA dose. Further, our finding that the complete regression 
response was extended to include all of the mice treated at the higher CPA dose suggests 
that CPA dose-dependent tumor cell cytotoxicity is an essential factor that works in 
cooperation with CPA activation of immune-based regression to drive tumor regression 
in our models. 
Our findings suggest that at high CPA doses (e.g., CPA/6d), the cytotoxic action 
of CPA may dominate the overall therapeutic response. Supporting this view, 
immunodepletion of CD8
+ 
T cells caused 9 out of 10 of the CPA(90)/6d-treated tumors to 
escape, evidencing a major role of T cell-mediated tumor cell cytotoxicity in tumor 
regression, whereas at the CPA/6d dose CD8
+ 
T cell depletion had a more modest impact 
on tumor regression. Individual CPA(90)/6d-treated tumors that did not regress were 
apparently deficient in CD8
+
 T cells, suggesting these tumors can mount mechanisms that 
suppress the anti-tumor immune response at a late stage of therapy. Alternatively, 
CPA(90)/6d treatment may fail to elicit a sufficiently strong anti-tumor immune response 
in the unresponsive tumors, which ultimately leads to tumor escape. Nevertheless, those 
mice that were cured by CPA(90)/6d treatment developed long-term immunity against 
GL261 tumor cell re-challenge at a frequency at least as high as CPA/6d cured mice 
(Table 3-2). These findings are consistent with the report that both 83 mg/kg and 150 
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mg/kg CPA treatment can induce spleen production of type I interferon, which favors 
memory T cell proliferation [114].  
Based on our findings, we propose that metronomic CPA-treated GL261 tumors 
release GL261 tumor-unique antigens that are presented, interact with, and activate 
specific T cell receptor-harboring T cell clones, which are subsequently transformed to 
long-lived memory T cells. Several of the cytokines and chemokines induced by 
metronomic CPA treatment [47, 55, 70, 114] can recruit and activate T cells, and might 
be a prerequisite for CTL infiltration and a sustained anti-tumor immune response [21]. 
CPA induction of IL15 (Fig. 3-2B, Fig. 3-4A-B) may stimulate homeostatic proliferation 
of memory T cells[139]. Supporting this proposal, partial depletion of CD8
+ 
T cells from 
the metronomic CPA-cured mice increased the tumor take rate substantially when the 
mice were re-challenged with GL261 tumors (Fig. 3-8). 
While CPA and other cytotoxic drugs have well-established immunomodulatory 
functions [50, 51, 78, 140, 141], to our knowledge, this study is the first report showing 
that systematic treatment with CPA – or any other cytotoxic monotherapy – can induce 
complete regression of large established tumors and confer long-lived immune memory. 
We hypothesize that to achieve this remarkable response, both the dose and the schedule 
of chemotherapy must be optimized with respect to each of the following: 1) destruction 
of a large fraction of the tumor cells without inducing drug resistance; 2) elimination of 
Tregs and other immunosuppressive factors to allow anti-tumor immune response to 
develop; 3) induction of immunogenic cell death leading to a strong anti-tumor response 
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in a manner that precludes tumors relapse and metastasis; and 4) effective transition from 
primary T cell response to long-lived memory T cell production. Tumor cells can be 
killed indirectly by taking advantage of the intrinsic anti-angiogenic activity of daily, 
low-dose metronomic chemotherapy [142], however, this approach does not kill a large 
fraction of tumor cells unless combined with immunotherapy or anti-angiogenesis agents 
[66, 143, 144]. Further, frequent dosing of CPA, which is required to maximize anti-
angiogenesis, limits the effectiveness of immunotherapy at inducing tumor-specific T 
cells, even though it may be efficacious at blocking Treg cell-mediated immune 
suppression [65, 66]. CPA at a dose of 50 mg/kg given every 7 days is not sufficient to 
suppress tumor growth [66], and in the present study, metronomic CPA given at 90 
mg/kg every 6 days did not cure all of the GL261 tumors. These findings indicate the 
importance of the intrinsic tumor cell cytotoxicity of the cancer chemotherapeutic agent.  
The effective daily dose of CPA in our 6-day metronomic regimen is similar to 
that used in MTD CPA schedules in mouse models [55, 95], except that the length of the 
drug-free break is much shorter. Whereas MTD schedules necessitate a prolonged drug-
free break, during which neo-vasculature development and chemotherapy resistance often 
occur, the 6 day-repeating CPA schedule employed in our studies provides a good 
balance between maximizing tumor cell toxicity while minimizing the frequency of 
immune cell ablation. Thus, the 6-day metronomic schedule induces major GL261 
glioma regression without major rebound of immune suppressive Tregs or loss of anti-
tumor CD8
+
 T cell responses. Further, the transient lymphopenic effects of the 6 day-
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repeating CPA schedule may help reduce the tumor-tolerance of CD8
+
 T cells and 
thereby increase homeostatic proliferation of tumor-reactive CD8
+
 T cells [145]. The 
relationship of CPA dose and dosing interval might also have important implications for 
chemotherapy combined with other therapeutic modalities, such as oncolytic viral 
therapy. Specifically, a short immune suppressive window may reduce the host anti-viral 
immune response and thereby facilitate tumor cell exposure to a replicating oncolytic 
virus, leading to a rebound in anti-tumor immunity upon danger signal release following 
oncolytic virus-mediated tumor cell lysis [77]. In contrast to our findings, the 6-day 
metronomic CPA schedule used by Browder et al., apparently did not to lead to long-
lived immunity [95], perhaps because the tumor models employed did not respond to 
CPA by immunogenic cell death, whose activation may vary between tumor models [50, 
51, 59]. Alternatively, the CPA dose used by Browder et al. (170 mg/kg) may be too high 
for CTLs to recover sufficiently between treatments. While supportive care measures 
were required to maintain the health of CPA-treated mice in that study [95], the GL261-
bearing B6 mice treated with CPA at 140 mg/kg in the present study were largely free of 
drug toxicity, as indicated by body weight measurements (Fig. 3-6), and did not require 
any special supportive care.  
Intermittent metronomic CPA scheduling, shown here to be strikingly effective 
for treatment of glioma in B6 mice, may have translational potential for clinical 
development of more effective drug schedules for human glioma treatment. The current 
clinical standard of care chemotherapy regimen for glioma is based on temozolomide, 
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which has a median survival of 14 months and a 5-year survival rate < 3% for 
glioblastoma multiforme patients [102, 146, 147]. While early clinical trials showed that 
CPA was not effective for treatment of human brain tumors [148-150], those studies 
employed MTD schedules, and not the intermittent, 6-day scheduling that our mouse 
model studies show is far superior to MTD CPA treatment with regards to immune cell 
recruitment and glioma regression [55, 56]. Further, while a metronomic regimen of low-
dose temozolomide (0.5 mg/kg per day) depletes Treg cells in RG2 gliomas grown in 
Fischer 344 rats, the dosage used was too low to suppress glioma cell growth [81]. 
Conceivably, a high dose, intermittent metronomic schedule of temozolomide, or of 
CPA, may show better efficacy in human glioma treatment. While immune escape 
mechanisms remain a barrier to the application of immunotherapy [10, 101, 105], the 
present findings suggest that CPA and perhaps other immunogenic chemotherapeutic 
drugs may have much translational promise when optimized drug doses and schedules are 
developed using reliable clinical markers for immunogenic cell death and downstream 
immune responses. 
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Table 3-1. Primer sets used for qPCR analysis of the indicated gene transcripts. 
 Gene names are shown in parentheses. Sequences for the following primer sets were reported 
previously [55]: natural cytotoxicity triggering receptor 1 (Nkp46), perforin 1 (Prf1), granzyme B 
(Gzmb), CD68 antigen (CD68), CD74 antigen (CD74), EGF-like module containing, mucin-like, 
hormone receptor-like sequence 1 (Emr1), forkhead box P3 (Foxp3), killer cell lectin-like 
receptor subfamily K, member 1 (Nkg2d, or Klrk1), nitric oxide synthase 2 (iNos or Nos2), and 
arginase (Arg1). Primers for Fas ligand (Fasl) were reported previously [56], as were those for 
colony stimulating factor 1 (Csf1), vascular endothelial growth factor(VEGFA), Interleukin 15 
(IL15) and interleukin 18 (IL18) in [57]. 
Gene Primer # Primer Sequence (5’ to 3’) 
Tumor necrosis factor, 
alpha (Tnfa) 
5186 Forward: GGTCCCCAAAGGGATGAGAA 
5189 Reverse: CAGCTGCTCCTCCACTTGGT 
Interferon-gamma (Ifng) 
6365 Forward: GCAACAGCAAGGCGAAAAAG 
6366 Reverse: GCTGGATTCCGGCAACAG 
Transforming growth 
factor, beta 1 (Tgfb1) 
6066 Forward: CCCGAAGCGGACTACTATGCT 
6067 
Reverse: 
GAGATGTCTTTGGTTTTCTCATAGATG 
CD86 antigen (CD86) 
5135 
Forward: 
TCCTGTAGACGTGTTCCAGAACTTA 
5136 
Reverse: 
GAGATCAGCAAGACTGTCACAAAGAT 
Hypoxia inducible factor 
1, alpha subunit (Hif1a) 
4196 
Forward: 
GGAGCTTTTTTCTCAGAATGAAGTGC 
4197 Reverse: TGGTTACTGTTGGTATCATAG 
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Table 3-2. Comparison of GL261 tumor take rates between primary tumor 
implantation and re-challenge in CPA-cured mice.  
Primary implantation was done as in Fig. 3-5A. Re-challenge was to implant same 4 x 10
6
 tumor 
cells in a contralateral site in CPA-cured mice ~ 4 weeks after the primary tumors were ablated. 
The primary GL261 tumor rejection rate, determined 25 days after implantation, was compared 
with that of re-challenged GL261 tumor cells 60 days after re-challenge. Fisher’s exact test (2-
tailed) was used to evaluate the significance of the differences in tumor rejection rates between 
primary and re-challenge tumor implantations. 
 
Primary tumor 
implantation 
GL261 Tumor re-challenge 
CPA/6d cured mice 
CPA(90)/6d cured 
mice 
 
Number of mice 
Mice with growing tumors 25 6 1 
Mice rejecting tumors 0 12 5 
Tumor rejection rate 0% 67% 83% 
Significance 
(Fisher's exact test) 
 
p<0.0001 p<0.0001 
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Fig. 3-1. GL261 tumor regression and NK cell and T cell recruitment are induced by 
two cycles of metronomic CPA treatment. 
(A) Growth curves of GL261 tumors that were untreated or treated with two cycles of 
metronomic CPA/6d. Data shown are normalized tumor volumes, mean ± SEM, for untreated 
tumors (n = 13 (days 0-6) and n = 7 (days 7-9)) and n = 6 CPA-treated tumors. Mean tumor 
volumes on the day of first CPA treatment (day 0) = 395 ± 135 
mm3
 (untreated tumors) and 762 ± 
92 
mm3
 (CPA-treated tumors). (B, C) Time course of changes in marker genes for NK cells 
(NKp46), CD8
+
 T cells (CD8a), their shared cytotoxic effectors (Prf1, Gzmb), Treg (Foxp3), and 
macrophages (Emr1), assayed by qPCR in GL261 tumors treated with one or two injections of 
metronomic CPA, as in A. Tumors were sampled 1, 3, 6 days after the first CPA injection and 1 
day after the second CPA, as diagrammed in B1 (B), or on days 6, 9, 12, and 15 after the second 
CPA injection (corresponding to 12, 15, 18, 21 days after the first CPA treatment), as 
diagrammed in C1 (C). Data shown are relative gene expression levels compared to the mean 
values for untreated tumors after normalization to the 18S rRNA content of each sample, mean ± 
SEM: n = 7 untreated tumors, n = 5 to 8 CPA-treated tumors per time point. One-way ANOVA 
analysis for the indicated comparisons in B and C: *p<0.05, **p<0.01, ***p<0.001. (D) Time 
courses of changes in expression of macrophage markers Emr1 and CD68, NK cell and T cell 
common effector marker Gzmb, and dendritic cell marker CD74. Tumor samples were analyzed 
by qPCR as in Fig. 1C, except that pooled cDNA from individual tumors were assayed. Error 
bar: mean ± SD. (E) Pearson correlation analysis between the relative expression levels of Prf1 
and Foxp3 for day 6 and day 9 tumor samples shown in Fig. 3-1C. Pearson r = -0.524; One-tailed 
p = 0.040; n = 12 pairs. 
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Fig. 3-1 
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Fig. 3-2. Contribution of CPA/6d induced NK cells and T cells to tumor regression.  
(A) FACS analysis of CTLs and NK cells in blood and tumors from untreated (‘UT’) mice and 
from mice treated with CPA/6d (‘CPA’), alone or in combination with anti-CD8a (‘+aCD8’), or 
with anti-CD8a and anti-GM1 antibody (‘+aCD8 +aGM1’). Error bar: mean ± SEM. Blood 
(cheek pouch sampling) and tumors were sampled 6 days after the second metronomic CPA 
injection. FACS analysis of blood CTLs and NK cells, n = 5 per group; and for tumor CTL and 
NK cell analysis, n = 8-13 untreated tumors, 6-12 CPA-treated tumors, 6 tumors treated with 
CPA + anti-CD8a, and 6 tumors treated with CPA + anti-CD8a + anti-GM1. CD8
+
 T cell 
depletion by anti-CD8a was 99% effective in blood and 97% effective in tumors. NK cell 
depletion by anti-GM1 antibody against NK cells was 84% in blood and 69% in tumors. (B) 
Relative expression level of the indicated immune cell and cytotoxic effector markers and Tgfb in 
untreated tumors (first bar), or in tumors treated with CPA/6d, alone (second bar), or in 
combination with anti-CD8a (third bar), or anti-CD8a + anti-GM1 (fourth bar). Tumors were 
sampled 6 days after the second CPA injection. Mean ± SEM: n = 6 to 9 tumors in each group. 
(C) Normalized growth curves for GL261 tumors treated with CPA/6d, CPA/6d + anti-CD8a, or 
CPA/6d + anti-CD8a + anti-GM1. Tumor volumes on the day of first CPA treatment (day 0) were 
as follows (mean volume ± SEM): 1517 ± 469 
mm3
 (6 untreated tumors), 1490 ± 216 
mm3
 (11 
tumors treated with CPA/6d), 1496 ± 277 
mm3
 (12 tumors treated with CPA/6d + anti-GM1; see 
data in Fig. 3-2I), 1506 ± 402 
mm3
 (10 tumors treated with CPA/6d + anti-CD8a), 1668 ± 531 
mm3
 
(8 tumors treated with CPA/6d + anti-CD8a + anti-GM1). One-tailed t-test analysis on 12, 18, 24, 
30, 36 days after treatment: *p<0.05, **p<0.01, ***p<0.001, when comparing CPA vs CPA + 
anti-CD8; ++p<0.01, +++p<0.001, when comparing CPA vs. CPA + anti-CD8 + anti-GM1. After 
day 51 (#), volume measurements shown reflect flat scar tissue that remained at the tumor site; no 
primary tumor regrowth was seen after discontinuation of CPA treatment. (D) Scheme for roles 
of CPA-activated NK cell and T cells in tumor regression (see text). One way ANOVA analysis 
for A and B: *p<0.05, **p<0.01, ***p<0.001; two-tailed t-test for select comparisons in B: +p< 
0.05. (E-H) Representative FACS plots for Fig. 3-2A, analyzing levels of CTLs and NK cells in 
blood (E and F, respectively) and in GL261 tumors (G and H, respectively). Pseudo dot plots or 
contour plot were used to highlight the separation of cells positive for staining from cells showing 
background staining. Corresponding isotype antibody controls and no antibody controls showed 
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minimal background staining are not shown. (I) Comparison of GL261 regression kinetics in 
mice treated with CPA/6d, CPA/6d + anti-GM1, CPA/6d + anti-CD8a or CPA/6d + anti-CD8a + 
anti-GM1. Shown is the time course for changes in tumor volumes in each of the treatment 
groups from day 0 to day 30 after beginning CPA treatment, as in Fig. 3-2C, and for CPA/6d + 
anti-GM1, as Fig. 6A in [55]. One-tailed t-test: ^p<0.05, ^^p<0.01, ^^^p<0.001 for CPA + anti-
GM1 vs. CPA alone; +p<0.05 for CPA + anti-GM1 vs. CPA + anti-CD8; **p<0.01 for CPA + 
anti-CD8 + anti-GM1 vs. CPA + anti-GM1. No significance was found for CPA + anti-CD8 + 
anti-GM1 vs. CPA+anti-CD8. CD8
+
 T cell immunodepletion is seen to slow tumor regression to a 
greater extent than NK cell immunodepletion, as seen from the day 24 and day 30 data. 
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Fig. 3-3. CD8
+
 T cell depletion abolishes CPA(90)/6d induced GL261 tumor 
regression.  
(A) Normalized growth curves for GL261 tumors treated with CPA(90)/6d alone (n = 5 
unresponsive tumors; 9 responsive tumors) or CPA(90)/6d + anti-CD8a antibody (n = 10) on days 
marked beneath the X-axis (arrows). Data shown are mean ± SEM. Mean tumor volume on the 
day of first CPA treatment (day 0) was 897 ± 336 
mm3
 for CPA(90)/6d unresponsive tumors, 702 
± 133 
mm3
 for CPA(90)/6d responsive tumors and 847 ± 265 
mm3
 for CPA(90)/6d + anti-CD8 
group. The CPA(90)/6d unresponsive tumors grew significantly slower than tumors in the 
CPA(90)/6d + anit-CD8 group starting from day 18 after CPA treatment (+p<0.05, one-tailed t-
test). (B) Growth curves for individual tumors treated with CPA(90)/6d alone (left) or 
CPA(90)/6d + anti-CD8a (right), with n=5 unresponsive tumors and n=9 regressing tumors 30 
days after beginning CPA(90)/6d treatment, which was significantly different from CPA(90)/6d + 
anti-CD8a co-treatment group (n=9 unresponsive and n=1 regressing tumors) by Fisher’s exact 
test, p value = 0.013. (C) Relative gene expression of NK cell marker Nkp46, CTL marker CD8a, 
and their common effectors Prf1 and Gzmb assayed by qPCR in GL261 tumors treated with three 
CPA(90)/6d cycles, as in (A). Tumors were sampled 6 days after the third CPA injection. Mean ± 
SEM: n = 7 untreated tumors, n = 4 CPA(90)/6d treated tumors. Two-tailed t-test: *p<0.05, 
**p<0.01, ***p<0.001. (D) FACS analysis of CD3e+CD8a+ T cell levels in peripheral blood 
from GL261-bearing untreated mice or mice treated with anit-CD8a antibody. Blood samples 
were collected from mouse tail tip 6 days after the second antibody injection, as shown in (A). 
Shown are representative plots from each group, with quantification of the FACS data shown on 
the right: mean ± SEM: n = 4 per group. CD8+ T cell depletion was >99% complete. 
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Fig. 3-4. Expression levels of the immune marker genes in GL261 tumors treated 
with CPA(90)/6d or CPA/6d.  
(A) Data are shown for the dendritic cell co-stimulatory molecule CD86, genes important for NK 
cell and T cell proliferation and activation (IL15, IL18, Nkg2d, Fasl), macrophage marker Emr1, 
cytokine Csf1, M1 (anti-tumor) macrophage marker iNos, M2 (pro-tumor) macrophage marker 
Arg1, Treg cell marker Foxp3, angiogenesis and chronic inflammation marker Vegfa, and the 
hypoxia marker Hif1a. Gene expression was assayed by qPCR in GL261 tumors treated with 
three CPA(90)/6d cycles, as in Fig. 3-3C. Tumor RNAs pooled from n=7 untreated tumors and 
from n=4 CPA-induced regressing tumors were analyzed 6 days after the third CPA injection. 
Error bar: mean ± SD. (B) Relative gene expression, as in A, for GL261 tumors sampled 6 days 
after the second CPA/6d injection, as in Fig. 3-1C, based on n=6 pooled tumor RNAs per group. 
The untreated tumor pool was same as in A. Error bar: mean ± SD. Comparable results based on 
analysis of individual tumors given the same CPA treatments can be seen in Fig. 3-1C for Foxp3, 
Fig. 3-2B for Fasl, IL15 and IL18. (C) Relative GL261 tumor expression levels of CTL marker 
CD8a and effector marker Gzmb were assayed by qPCR in untreated GL261 tumors or in tumors 
unresponsive to CPA(90)/6d (Fig. 3-3A, 3B) 6 days after the 7th metronomic CPA(90)/6d 
treatment. Mean ± SEM: n = 16 untreated tumors, n = 5 CPA(90)/6d treated tumors. 
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Fig. 3-5. Metronomic CPA induces long-term tumor-specific immunity.  
(A) Growth curves for individual GL261 tumors implanted on one or two posterior flanks in 
tumor-naïve B6 mice (primary tumors). CPA/6d treatment days are marked by arrows. After day 
51~60 (#), volume measurements shown reflect flat scar tissue that remained at the tumor site; no 
primary tumor regrowth was seen after discontinuation of CPA treatment. (B) Growth curves for 
re-challenged GL261 tumors implanted on the contralateral side of the primary implantation site 
in mice cured by CPA/6d treatment, as in A. Mice were rested for 33 days between last CPA 
injection and re-challenging. Six re-challenged tumors grow by 60 days after re-challenge and 12 
tumors were rejected. (C, D) Individual growth curves for cross-challenged B16-F10 melanoma 
(C) and LLC Lewis lung carcinoma (D) tumor cells implanted bilaterally in CPA/6d cured mice 
~4 weeks after GL261 tumors were cured by CPA/6d treatment. All 20 cross-challenge sites 
showed aggressive tumor growth within 13 days of implantation. CPA/6d treatment initiated 
(arrows) did not impact tumor growth.  
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Fig. 3-6. Relatively stable body weight of GL261-bearing mice treated with CPA/6d 
indicates manageable toxicity.  
Normalized body weight of GL261-bearing mice that were untreated (n = 5 mice) or were treated 
with CPA/6d (arrows) (n=28 mice). Values shown are mean normalized body weights ± SE. The 
rapid increase in body weight of the mice bearing untreated tumors reflects the increase in tumor 
volume. 
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Fig. 3-7. Elevated CTLs in blood and increased CTL infiltration in tumors were 
associated with tumor rejection.  
(A) FACS analysis of CTLs and (B) qPCR analysis of gene expression of CD8 and Nkp46 in 
growing GL261 tumors from primary inoculation in fresh mice compared to GL261 tumors re-
implanted (re-challenged) that either were rejected or that grew in the CPA/6d cured mice. The 
re-challenged tumors were sampled 22 or 32 days after implantation. Mean ± SEM: n=12 
growing tumors from primary inoculation, 5 rejected re-implanted tumors, 5 growing re-
implanted tumors. One way Anova analysis: *p<0.05; **p<0.01. (C) FACS analysis of immune 
cells in peripheral blood of CPA/6d cured mice that rejected (n=3) or grew (n=5) re-implanted 
GL261 tumors. Blood sampling (cheek pouch): 22 days after tumor re-challenge. Shown are 
mean ± SEM. Two-tailed t-test: *p < 0.05. Representative FACS plots are shown on right.  
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Fig. 3-8. Partial depletion of CD8 T cells increased tumor take rate of CPA-cured 
mice.  
(A) FACS analysis of CTLs (CD3
+
CD8
+
) in peripheral blood of CPA(90)/6d-cured mice that 
were re-challenged by GL261 tumors and that were treated without or with anti-CD8, as shown in 
black arrows in diagram starting day -1 after re-challenging. Blood samples from mouse tail were 
taken 18 or 49 days after tumor re-challenge. Data shown are mean ± SEM values for n = 6 mice 
in each group. One way Anova analysis: **p<0.01, ***p<0.001. (B) Growth curves for the 
second re-challenged GL261 tumors implanted on the posterior flanks of the mice that were cured 
by CPA(90)/6d treatment and rejected the first GL261 tumor re-challenge. Mice were rested for 
about four weeks between last CPA injection and the first re-challenge and about eight weeks 
between the first re-challenge and the second re-challenge. Three tumors on two anti-CD8 treated 
mice grew substantially 60 and 80 days after the second re-challenge 
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CHAPTER FOUR: MOLECULAR MECHANISMS UNDERLYING 
METRONOMIC CYCLOPHOSPHAMIDE TUMOR MODEL, MOUSE HOST, 
AND DRUG SCHEDULE DEPENDENCE ON IMMUNE RESPONSES 
4.1 Abstract 
Cyclophosphamide (CPA) and certain other cancer chemotherapeutic drugs can 
activate immunogenic tumor cell death with induction of a strong anti-tumor immune 
response and major tumor regression, as seen in several glioma models when CPA is 
given on an intermittent, 6-day repeating metronomic schedule (CPA/6d). However, not 
all tumors intrinsically sensitive to CPA cytotoxicity exhibit such drug-induced immune 
responses. Here, we investigated genes and molecular responses associated with the 
striking differential CPA/6d responsiveness of GL261 tumors (immune responsive) 
compared to LLC and B16F10 tumors (immune unresponsive) in a syngeneic B6 mouse 
model. Transcriptomic profiling by RNA-seq revealed that CPA/6d activation of immune 
stimulatory KEGG pathways and upstream regulators was minor, moderate and strong in 
LLC, B16F10, and GL261 tumors, respectively. Untreated GL261 tumors showed a 
higher level of immune activity than untreated LLC and B16F10 tumors. CPA-treatment 
activated more negative regulators of immune responses in GL261tumors than LLC and 
B16F10 tumors, suggesting that the lack of robust immune responses in CPA-treated 
LLC and B16F10 tumors is not due to more immune suppressive tumor 
microenvironment. CPA/6d treatment of LLC tumors uniquely inhibited VEGFA-
targeted genes and down regulated cell adhesion and transendothelial migration genes 
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while up regulating drug metabolism pathways. In B16F10 tumors, CPA uniquely 
activated KDM5B, RBL2, and SPARC, and inhibited CSF2, FOXM1, and CD24. In 
adaptive immune-deficient scid mice, where CPA/6d-induced GL261 regression is 
incomplete and often is followed by late tumor growth rebound, a subset of cytokine-
cytokine receptor interaction gene responses to CPA/6d were deficient as was T cell 
receptor signaling and several other immune-related responses seen in the fully immune 
competent B6 mouse model. Finally, lengthening the treatment interval from 6 to 9 days 
(CPA/9d), which impairs the sustainability of early natural killer cell responses and 
results in early tumor growth rebound in the GL261(scid) model, resulted in fewer 
cytokine and higher drug metabolism gene expression changes. These studies elucidate 
the tumor model, drug schedule, and adaptive immune-dependence of CPA-induced 
immune responses and provide new insights for molecular signaling events underlying 
the deficiencies in immune responses in intermittent metronomic CPA unresponsive 
tumor models.  
4.2 Introduction 
The efficacy of chemotherapy depends on its ability to stimulate anti-tumor 
immune responses [32, 151], in addition to its intrinsic cytotoxic effects on tumor cells. 
However, new drug screening and drug development pipelines are primarily based on in 
vitro tumor cell cytotoxicity assays and anti-tumor activity in vivo, which is often 
determined by using immune deficient xenograft mouse models. Without examining the 
capacity of chemotherapeutical agents to induce immune response, chemotherapy 
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efficacy in the clinic is less effective than expected, often showing large discrepancy with 
preclinical results [50]. In contrast, some chemotherapeutic agents are active via immune-
dependent mechanisms on tumor cells that are not necessarily sensitive to drugs in in 
vitro cytotoxicity assays [50, 151]. This highlights the need to identify molecular 
mechanisms underlying chemotherapy-activated anti-tumor immune responses. 
Immunogenic tumor cell death induced by chemotherapy leads to anti-tumor 
immune responses. Several hallmarks of immunogenic cell death have been characterized 
[32]. For example, calreticulin on the tumor cell surface serves as an “eat-me” signal for 
dendritic cells [34], while HSP90 expressed on the tumor cell surface assists dendritic 
cell-tumor cell adhesion and stimulates dendritic cell maturation [37]. The Alarmin 
molecule HMGB1 is released into the extracellular matrix and stimulates dendritic cell 
antigen presentation and production of IL-1beta to activate CD8 T cells [32, 38]. ATP 
released from apoptotic tumor cells can also activate dendritic cells [32, 39]. However, it 
is not clear what molecular signatures are associated with differential tumor responses to 
chemotherapy, i.e., immunogenic vs. non-immunogenic tumor cell death. Important 
questions include the identification of upstream regulators and gene pathways that 
constitute an anti-tumor immune response, whether tumor responsiveness to 
chemotherapy can be predicted based on tumor gene profiles, the impact of host 
immunity on tumor responsiveness to chemotherapy, and the impact of drug scheduling 
on tumor responsiveness.   
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Cyclophosphamide (CPA) is a bifunctional alkylating agent widely used in 
treating cancer and autoimmune diseases [8]. CPA can induce immunogenic tumor cell 
death and activate robust immune responses in several tumor models, including AB1 
mesothelioma [45], immortalized murine embryonic fibroblasts [152], and EL-4 and 
RBL-5 lymphoma cells [35]. We previously reported that CPA given on an intermittent, 
every 6-day repeating schedule at 140 mg/kg/injection (CPA/6d) induces major tumor 
regression and activates robust anti-tumor immune responses in several glioma models, 
as seen in both scid (adaptive immune-deficient) mice and in fully immune competent 
C57BL/6 (B6) mice [55-58]. We have also studied tumor-associated gene responses in 
CPA-treated U251 and 9L xenografts grown in scid mice (Doloff and Waxman, in 
review). Many CPA/6d-induced factors were identified in CPA/6d-treated gliomas 
implanted in scid mice, including cytokines, chemokines, and immune regulatory genes 
related to innate immune cell recruitment, tumor regression or tumor escape. Further, 
interferon signaling was identified as a major upstream regulator of the observed immune 
responses (Doloff and Waxman, in review). However, it is unknown whether CPA/6d 
activation of immune responses in B6 mice proceeds by the same mechanism as in scid 
mice, or whether this regimen is effective in other tumor models with different histology. 
To this end, we examined the effects of CPA/6d treatment in LLC (Lewis lung 
carcinoma) and B16F10 (melanoma) tumors implanted in B6 mice. This treatment 
induces only minor growth delay for LLC tumors and moderate growth delay for B16F10 
tumors (CS Chen and M Jordan, unpublished experiments). We thus performed RNA-seq 
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analysis and compared gene responses induced by CPA/6d treatment in the immune 
responsive GL261 tumors to the immune unresponsive LLC and B16F10 tumors. The 
upstream regulator (UPR) analysis module from Ingenuity Pathway Analysis (IPA) was 
used in combination with KEGG pathway analysis, and DAVID Cluster enrichment to 
identify significant molecular signaling pathways associated with tumor responsiveness 
to CPA.  
CPA/6d treatment induces complete regression of GL261 tumors implanted in B6 
mice with activation of long-term tumor-specific immunity [69], however, in scid mice 
the same drug treatment induces major tumor regression followed by growth rebound 
[57]. We thus compared gene responses induced by CPA in GL261 tumors in B6 mice 
(GL261(B6)) with GL261 tumors in scid mice (GL261(scid)). We also compared gene 
responses to CPA/6d treatment versus CPA/9d treatment (i.e., on every 9-day repeating 
schedule), when the tumor-infiltrating natural killer cell responses are initially very 
strong but are not sustained, leading to earlier resumption of tumor growth, despite 
ongoing metronomic CPA treatment [57].  
Different gene sets derived from above comparisons were discussed in the context 
of immune activation. Thus, our study provided new insights for immune activation 
deficiency related to tumor model, mouse host immune competency, and metronomic 
chemotherapy drug scheduling.  
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4.3 Materials and Methods 
Tumor cell lines, mouse tumors, and treatments 
 Mouse tumor cell lines syngeneic in C57BL/6 mice were authenticated by and 
obtained from Developmental Therapeutics Program Tumor Repository (National Cancer 
Institute, Frederick, MD) (GL261 glioma) and ATCC (Manassas, VA) (B16F10 
melanoma (ATCC® CRL-6475™) and LLC Lewis lung carcinoma (ATCC® CRL-
1642™)). All three cell lines were grown at 37C in a humidified 5% CO2 atmosphere in 
RPMI-1640 culture medium containing 10% fetal bovine serum, 100 units/ml penicillin 
and 100 g/ml streptomycin. Six-week-old (26-28 g) male ICR/Fox Chase immune 
deficient scid mice (Taconic Farms, Germantown, NY) and six-week-old (20-23 g) male 
C57BL/6 (B6) mice (Taconic Farms, Germantown, NY) were housed and treated under 
protocols approved by the Boston University Institutional Animal Care and Use 
Committee. GL261 glioma cells (4 x 10
6
) were implanted by s.c. injection on the 
posterior flanks of B6 mice (GL261(B6)) or scid mice (GL261(scid)) in 0.2 ml serum-
free RPMI per site using a U-100 insulin syringe and a 28.5 gauge needle (BD 
Biosciences, Cat.# 329461). B16F10 melanoma cells (1 x 10
6
) or LLC Lewis lung 
carcinoma cells (2 x 10
6
)
 
were implanted by s.c. injection on the posterior flanks of B6 
mice as described above for GL261 tumors in experiments. Tumor areas (length x width) 
were measured twice weekly using Vernier calipers (VWR International, Cat.# 62379-
531) and tumor volumes were calculated: Vol = (/6)*(L*W)3/2. Tumors were monitored 
and drug treatment was initiated at mean tumor volumes specified in each study. Tumor 
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volumes were normalized to a value of 100% at the drug treatment starting point (t = 0 
days) for each treatment group to control for differences in initial tumor size at the onset 
of drug treatment, which enabled us to reach statistical significance with fewer mice, as 
described [69] and in accordance with Institutional Animal Care and Use Committee 
guidelines. Mouse body weights were measured at least twice a week and normalized in 
the same manner. Mice that were implanted with GL261 tumors were treated with CPA 
monohydrate (Cat. # C0768, Sigma-Aldrich, St. Louis, MO) at 140 mg/kg-body weight 
per injection every 6 days (CPA/6d). Some of the GL261(scid) tumors were treated with 
same 140 mg/kg-body weight per injection CPA dose but on an every 9 day repeating 
schedule (CPA/9d), as noted. Mice bearing LLC or B16F10 tumors were treated with 
same CPA monohydrate at 150 mg/kg-body weight per injection (CPA/6d). The CPA 
dose was based on the non-hydrated molecular weight of 261. All mouse studies using 
the LLC and B16F10 tumor model, including tumor cell implantation, tumor monitoring 
and sampling, were carried out by CS Chen of this laboratory. 
RNA-seq analysis  
Tumor total RNAs were extracted using Trizol reagent as in [55]. For half of the 
RNA samples from LLC and B16F10 tumors, RNA was extracted by CS Chen of this 
laboratory; the other half RNA samples for LLC and B16F10 tumors and all further 
laboratory work and data analysis described below were carried out by J. Wu. Individual 
tumor RNA samples that failed to show clear 28S and 18S rRNA bands upon agarose gel 
electrophoresis or having Agilent Bioanalyzer RIN values lower than 7 were excluded. 
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Individual tumor RNAs were pooled and 1 g of pooled total RNA was used for RNA-
seq library preparation. Two independent pools of tumor RNA were sequenced for each 
sample, as specified in the legend to Table 4-1. For GL261 tumors grown in scid mice, 
RNA-seq libraries were prepared using the Illumina TruSeq® mRNA library Prep kit 
(Cat# RS-122-2101) and sequenced on an Illumina HiSeq2500 instrument in the Boston 
University Department of Computational Biomedicine (Boston, MA), generating 68 nt 
single-end reads. For all other tumor RNA samples, including GL261, LLC, and B16F10 
tumors grown in B6 mice, RNA-seq libraries were prepared using NebNext® Ultra 
Directional RNA Library Prep kit for Illumina® (NEB, Cat# E7420). NEBNext® 
Multiplex Oligos for Illumina® (NEB, Cat# E7335s) were used for multiplexing. The 
Agencourt AMPure XP system (Beckman Coulter, Cat# A63880) was used for size 
selection and purification. Library quality and size distribution were assessed using the 
Agilent Bioanalyzer DNA high sensitivity chip kit (Agilent Technologies, Cat# 5067-
4627). Samples were sequenced on an Illumina HiSeq2000 instrument at the BioMicro 
Center at the Massachusetts Institute of Technology (Cambridge, MA), generating 50 nt 
single-end reads. 
Data analysis  
Sequence reads were aligned to the mouse genome build mm9 (NCBI 37) using 
Tophat (version 2.0.13) [153-155]. Differential expression analysis for RefSeq genes was 
conducted using the Bioconductor package DESeq (version 1.18.0) [156].  
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CPA-induced significant gene responses meeting the cutoff values of |fold-
change| (FC) > 2 and p < 0.001 are shown in App. 4-1A for GL261(B6) tumors, App. 4-
1B for LLC tumors, App. 4-1C for B16F10 tumors, App. 4-1D for GL261(scid) tumors 
treated with CPA/6d, App. 4-1E for GL261(scid) tumors treated with CPA/9d, and App. 
4-1F for GL261(scid) tumors that responded commonly to the CPA/6d and CPA/9d 
schedules, respectively. See Fig. 4-3 for analysis diagram and Fig. 4-4 for Venn diagram 
showing the number of gene responding to CPA in each tumor model. 
Upstream regulator analysis  
Genes that were either up regulated or down regulated by CPA treatment at |FC|  
> 2 and p < 0.001 were uploaded with the corresponding gene expression FC values to 
https://analysis.ingenuity.com/pa/launch.jsp for Ingenuity Pathway Analysis (IPA). The 
Upstream Analysis module of IPA was then used to identify enriched upstream regulators 
(UPRs), the corresponding predicted activation Z-score and bias-corrected Z-score, 
targeted molecules in each dataset, p-values of overlap between targeted genes and UPR-
regulated genes in the IPA database, and the associated mechanistic networks. Individual 
UPRs were then identified as being “Activated” or being “Inhibited” as predicted by IPA. 
Since our goal is to study endogenous master UPRs induced by metronomic CPA 
treatment, we excluded all UPRs that are classified by IPA as chemicals, except 
endogenous mammalian chemicals. In addition, we excluded from the listing any “group 
UPR” identified by IPA which duplicate their individual constituent UPRs. In cases when 
two UPRs with same name were identified, e.g., one from human another from mouse, 
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the UPR with higher activation score was kept. The resultant UPR lists identified by IPA 
are provided in App. 4-2A for GL261(B6) tumors, App. 4-2B for LLC tumors, App. 4-2C 
for B16F10 tumors, App. 4-2D for GL261(scid) tumors treated with CPA/6d, and App. 4-
2E for GL261(scid) tumors treated with CPA/9d, respectively. See Fig. 4-3 for a diagram 
summarizing results of UPR analysis. 
To increase the stringency of UPR identification, UPRs identified by IPA 
underdefault conditions were further filtered by applying the following more stringent 
conditions: p-value of overlap < 0.0001, number of targeted genes > 10, and absolute 
value of the predicted activation Z-score and the bias-corrected activation Z-score were 
both > 2 (Stringent UPRs) (Fig. 4-1). Next, we applied the following criteria to assess the 
uniqueness of each significant UPR identified in one tumor model (e.g., GL261(B6) 
tumors) when compared to a second tumor model (e.g., LLC tumors). Stringent UPRs 
identified in one tumor model (model A) absent from the listing of UPRs generated by 
IPA under default conditions for a second tumor model (model B) were designated 
unique UPRs for tumor model A. In addition, candidate unique UPRs for the first tumor 
model (model A) were identified as those that met either of the following two conditions 
(see Fig. 4-2): (1) |activation Z-score| and |bias-corrected Z-score| for the UPR are both < 
2 in the second tumor model; or (2) |activation Z-score| and |bias-corrected Z-score| for 
the UPR are both > 2 in the second tumor model, but show the opposite activation state, 
i.e., Activated in one model vs. Inhibited in the other model. The p-value of overlap was 
then used to determine the uniqueness of each candidate unique UPR, as follows. If the 
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p-value of overlap for a given candidate UPR was > 0.001 in the second tumor model, 
the UPR was considered unique to the first model. Alternatively, if the p-value of overlap 
of the candidate UPR in the second tumor model was < 0.001 but > 0.0001, and if it was 
> 100-fold higher than the p-value for overlap of that UPR in the first tumor model, then 
the UPR was considered unique to the first model. However, if the p-value of overlap of a 
given candidate UPR was < 0.0001 in the second tumor model, the UPR was not 
considered unique to the first model, despite having an |activation Z-score| or a |bias-
corrected Z-score| < 2 in the second tumor model, and even if its p-value of overlap was 
> 100-fold higher than that of the UPR in the first tumor model (Fig. 4-2).  
Stringent UPRs are shown in App. 4-3A for GL261(B6) tumors, App. 4-3B for 
LLC tumors, App. 4-3C for B16F10 tumors, App. 4-3D for GL261(scid) tumors treated 
with CPA/6d, App. 4-3E for GL261(scid) tumors treated with CPA/9d, and App. 4-3F for 
GL261(scid) tumors that responded commonly to CPA/6d and CPA/9d schedules, 
respectively. See Fig. 4-3 for analysis diagram. 
When comparing UPRs in GL261(scid) and GL261(B6) tumors, we first 
identified significant UPRs for CPA/6d or CPA/9d treated GL261(scid) tumors using the 
set of genes whose expression was significantly altered by CPA/6d treatment (2,574 up 
regulated genes and 1,250 down regulated genes at |FC|>2 and p < 0.001) (App. 4-1D; 
see App. 4-2D for default UPRs) or was significantly altered by CPA/9d treatment (2,713 
up regulated genes and 1,564 down regulated genes at |FC|>2 and p < 0.001)(App. 4-1E; 
see App. 4-2E for default UPRs). Considering the high (77%) overall similarity of gene 
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responses, and the strong tumor regression phenotype shown by both CPA/6d and 
CPA/9d treated GL261(scid) tumors at the time of tumor sampling, i.e., 6 days after 2
nd
 
CPA injection, we used the set of 179 UPRs common to CPA/6d- and CPA/9d-treated 
GL261(scid) tumors (App. 4-3F) and compared them with the set of UPRs identified in 
the CPA/6d-treatd GL261(B6) tumors (2,121 UPRs; App. 4-2A). When assessing the 
uniqueness of the significant UPRs identified in the GL261(B6) model (180 UPRs; App. 
4-3A) relative to the GL261(scid) model, we considered all UPRs derived from CPA/6d-
treated GL261(scid) tumors (1,898 UPRs; App. 4-2D; see Fig. 4-3 for diagram). 
KEGG pathway analysis 
Genes that were up or down regulated significantly by CPA treatment at |(FC)| > 
2 and p < 0.001 were analyzed as separate gene lists using DAVID Bioinformatics 
Resources 6.7 with default parameters (http://david.abcc.ncifcrf.gov/tools.jsp) to identify 
KEGG pathways and DAVID functional annotation clusters (DAVID clusters) that were 
enriched in the set of CPA up regulated genes, and separately, in the set of CPA down 
regulated genes. Pathways with p-values < 0.05 and DAVID clusters with enrichment 
score > 1.3 were deemed significant. In some cases only pathways having p-values < 
0.001 are listed due to space limitation as noted. 
KEGG pathway results are shown in App. 4-4A for GL261(B6) tumors, App. 4-
4B for LLC tumors, and App. 4-4C for B16F10 tumors, respectively. See Fig. 4-5 for 
analysis diagram. 
 115 
 
 KEGG pathways specific to one tumor model or treatment condition as compared 
to another model and condition were identified as follows. First, we identified all genes 
that showed a significant change induced by CPA at |FC| > 2 and p < 0.001 in one tumor 
model but not in the second tumor model. Next, we removed all genes for which the 
difference in FC values between tumor models was ≤2. For example, for a significant 
gene change induced by CPA to be considered specific to GL261(B6) tumors compared 
to a second tumor model, e.g., B16F10 tumors, we required |(FC for GL261(B6) / FC for 
B16F10)| > 2. The resultant genes can be further compared to LLC tumors to filter out 
genes whose |(FC for GL261(B6) / FC for LLC)| ≤ 2 to identify gene responses stringent 
or unique to GL261(B6) tumors relative to B16F10 and LLC tumors. See Fig. 4-5 for 
analysis diagram. The resultant list of genes was then analyzed to identify CPA-induced 
KEGG pathways unique to GL261(B6) tumors relative to LLC and B16F10 tumors. In 
cases where a limited number of tumor model-specific genes were identified, we relaxed 
the FC difference between tumor models from >2-fold to >1.33-fold, as indicated in the 
text.  
When comparing KEGG pathways identified in GL261(scid) and GL261(B6) 
tumors, we used a similar strategy to that used in the UPR analysis. To increase the 
robustness of the analysis, i.e., for selecting genes responding significantly to CPA/6d in 
GL261(scid) tumors, we only considered those genes that responded in common between 
CPA/6d-treated (2,574 up regulated and 1,250 down regulated genes at |FC|>2 and p < 
0.001) and CPA/9d-treated GL261(scid) tumors (2,713 up regulated and 1,564 down 
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regulated genes at |FC|>2 and p < 0.001). When assessing the uniqueness of gene 
responses identified in the GL261(B6) model relative to the GL261(scid) model, we 
considered all genes derived from CPA/6d-treated GL261(scid) tumors (see diagrams in 
Fig. 4-6).  
Comparison to immunosuppressive factors  
A list of 124 immunosuppressive genes was compiled from the Gene Ontology 
term “Negative regulation of immune response” (GO:0050777), which included 196 
human and 153 mouse genes, as follows. Human gene symbol were converted to mouse 
gene symbols using the online tool MammalHom 
(http://depts.washington.edu/l2l/mammalhom.html) or by manually checking the NCBI 
Gene database (http://www.ncbi.nlm.nih.gov/gene/) in cases where no mouse genes were 
identified by the tool. Genes redundant between human and mouse and isoforms within a 
given species were removed. The resultant list of 124 negative regulators of immune 
response (App. 4-5A) was used to identify immune suppressive factors that may 
contribute to the differential CPA responsiveness seen between tumor model, as well as 
differences between mouse host and drug schedule.  
4.3 Results 
LLC and B16F10 tumors are unresponsive to metronomic CPA-induced immune cell 
recruitment  
Metronomic CPA treatment on a 6-day repeating schedule induces complete 
regression of GL261 tumors implanted in immune competent C57BL/6 (B6) mice 
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(GL261(B6) tumor model) and activates long-term tumor-specific immunity [57]. In 
contrast, two other B6 syngeneic tumor cell lines, LLC Lewis lung carcinoma and 
B16F10 melanoma, show only moderate tumor growth delay in response to metronomic 
CPA treatment (CS Chen, and ME Jordan unpublished experiments), despite their 
intrinsic sensitivity to 4-hydroxy-CPA in cell culture (ME Jordan, unpublished 
experiments). Further, initial studies indicated that the metronomic CPA-treated LLC and 
B16F10 tumors do not exhibit the strong recruitment of immune cells seen with GL261 
tumors. LLC and B16F10 tumors were therefore designated metronomic CPA immune 
unresponsive (see Table 4-1 for summary).  
RNA-seq analysis and identification of upstream regulators (UPRs) in responsive and 
unresponsive tumor models  
We used RNA-seq to characterize tumor transcriptional profiles and to identify 
gene expression changes induced by metronomic CPA treatment to better understand the 
immune-based and other responses of GL261(B6) tumors to metronomic CPA treatment 
and to elucidate the molecular mechanisms underlying the unresponsiveness of LLC and 
B16F10 tumors. Using |FC| > 2 and p < 0.001 as significance cutoff values, we identified 
2,119 up regulated genes and 809 down regulated genes in metronomic CPA-treated 
GL261(B6) tumors (Table 4-1; App. 4-1A). Many fewer genes responded to CPA in the 
unresponsive tumor models, with a total of 221 genes differentially regulated by 
metronomic CPA in LLC tumors, and 1,057 genes in B16F10 tumors (Table 4-1; App. 4-
1B-C). IPA was used to analyze the above sets of regulated genes to identify UPRs that 
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are predicted to be either activated or inhibited by metronomic CPA treatment and that 
may contribute to the gene expression changes seen in each tumor model (see full lists of 
UPRs in App. 4-2A-C). A total of 180 (145 activated and 35 inhibited), 93 (68 activated 
and 25 inhibited), and  6 (5 activated and 1 inhibited) significant UPRs were identified 
for CPA-responsive genes in GL261(B6), B16F10 and LLC, tumors, respectively (App. 
4-3A-C).  
We found that 47 out of 180 UPRs were unique to GL261(B6) tumors when 
compared to the two unresponsive tumor models (Table 4-2A; App. 4-3G; UPR 
uniqueness was determined as described in Methods and Fig. 4-2). These 47 UPRs can be 
classified into four groups based on their immune modulatory activities and their impact 
on tumor regression (Table 4-2A): 1) Factors that facilitate tumor regression by immune-
mediated mechanisms (23 activated UPRs that activate immune responses including 
HMGB1, an immunogenic cell death marker [157], and 3 inhibited UPRs that inhibit 
immune responses) or by inhibiting tumor cell survival function (6 inhibited UPRs that 
promote tumor cell survival); 2) Factors that serve as either positive or negative immune 
response modulators, depending on the cell context (10 UPRs); 3) Glioma cell lineage 
related UPRs (activated UPRs SIM1 [158] and PAX7 [159]); and 4) UPRs that may 
inhibit tumor regression by inhibiting immune responses (activated PTGS2) or by 
promoting cell survival (activated UPRs FN1 [160] and FGFR2 [161]).  
We also identified VEGFA as an inhibited UPR unique to CPA-treated LLC 
tumors as compared to VEGFA being an activated UPR in CPA-treated GL261(B6) 
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tumors (Table 4-2B). This difference may relate to the anti-angiogenic activity of 
metronomic CPA. In addition, we identified 6 UPRs that promote tumor cell survival or 
tissue repair as being unique to B16F10 compared to GL261(B6) tumors (Activated 
UPRs: KDM5B [162], RBL2 [163], SPARC [164] [165, 166]; Inhibited UPRs: FOXM1 
[167], CD24 [168, 169], CSF2 [170])  (Table 4-2C). Of note, CSF2, which is an activated 
UPR in GL261 tumors, can also stimulate intra-tumoral dendritic cell expansion and 
induce significant CD4
+
 and CD8
+
 T cell anti-tumor immune responses [171, 172], 
depending on the cell context.  
Two activated UPRs were common to all three tumor models (CHUK and 
IKBKB), three activated UPRs (JUN, in addition to CHUK and IKBKB) were common 
to GL261 and LLC tumors, and 59 UPRs were common to GL261(B6) and B16F10 
tumors (App. 4-3H). These UPRs common between GL261(B6), LLC and B16F10 tumor 
models may relate to the basal DNA damage response to CPA/6d treatment. To identify 
top UPRs among the 59 UPRs common to GL261(B6) and B16F10 tumor model, we 
used arbitrary cut-off values of p-value of overlap < E-30 and <E-10 for GL261(B6) and 
B16F10 model, respectively, since the number of GL261(B6) genes that showed 
significant responses is ~ 3-fold higher than that in B16F10 tumors (Table 4-1). These 16 
top UPRs include APP, CHUK, CSF1, IFNB1, IFNG, IKBKB, IL13, IL1B, IL6, MYC, 
STAT1, STAT3, TGFB1, TNF, TP53, and tretinoin (Column N in App. 4-3H). Of note, 
in studies of CPA/6d-treated U251 and 9L tumors in scid mice Doloff and Waxman 
identified STAT1, IFNB1 and IFNG as activated UPRs. However, based on the results in 
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B16F10 tumors, these UPRs are in-sufficient to execute CPA-activated immune 
responses. Further, we identified that nine common UPRs (Column N in App. 4-3H), 
BNIP3L, CDKN2A, cholic acid, IFNL1, IRF5, IRF7, MAVS, PAF1, TBX2, that have a 
lower p-value of overlap in B16F10 tumors as compared to GL261(B6) tumors, 
suggesting that these UPRs are associated with suppression of immune responses.  
KEGG pathways activated by metronomic CPA in responsive tumors  
Next, we identified KEGG pathways significantly enriched in the sets of genes up 
regulated or down regulated by metronomic CPA treatment. Immune response-related 
pathways dominated the set of 2,119 genes up regulated in GL261(B6) tumors. These 
pathways may be classified into four groups (Table 4-3A, p < 0.001; App. 4-4A, original 
list with complete information): 1) immune stimulatory signaling, including tumor cell 
death, danger signal sensing, tumor cell antigen processing and presentation, chemokine 
signaling promoting tumor-infiltration of immune cells, and cytokine-cytokine receptor 
interaction stimulating immune cell proliferation and activation; 2) immune effector 
activation, including NK cell-mediated cytotoxicity, T cell receptor signaling, and B cell 
receptor signaling; 3) inflammatory pathways overlapping with various immune related 
diseases; and 4) tumor cell survival and chemotherapy-resistance. The KEGG pathways 
enriched among the 809 genes significantly down regulated by metronomic CPA 
treatment in GL261(B6) tumors are primarily involved in tumor cell essential survival 
functions, mirroring CPA-induced tumor regression (Table 4-3B, p < 0.001; App. 4-4A). 
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Thus, while the GL261 KEGG pathways up regulated by CPA are dominated by immune 
activation, the down regulated KEGG pathways are mainly related to tumor cell survival. 
CPA-induced KEGG pathways in unresponsive LLC and B16F10 tumor models  
The 151 genes significantly up regulated by metronomic CPA treatment of LLC 
tumors (Table 4-1) are enriched for KEGG pathways related to focal adhesion, ECM-
receptor interaction, complement and coagulation cascades, melanoma, porphyrin and 
chlorophyll metabolism, and drug metabolism (Table 4-4A; App. 4-4B). Only two of 
these pathways (ECM-receptor interaction and complement and coagulation cascades) 
relate to immune stimulatory signaling. The 70 down regulated LLC genes are enriched 
for cell adhesion molecules and leukocyte transendothelial migration (Table 4-4B; App. 
4-4B), both of which are critical for immune cell infiltration of tumors and may 
contribute to the unusually low immune responses in the LLC model [173].  
The 663 genes up regulated in B16F10 tumors are enriched for p53 signaling, 
which may regulate tumor cell response to CPA at multiple levels, including DNA 
damage response and immune response, as well as 10 other KEGG pathways that relate 
to immune stimulatory signaling or immune-related diseases. These latter pathways 
involve lysosomes [174], complement and coagulation cascades, systemic lupus 
erythematosus, cytokine-cytokine receptor interactions, prion disease [175], JAK-STAT 
signaling, chemokine signaling, antigen processing and presentation, cell adhesion 
molecules, and ECM-receptor interaction (Table 4-5A; App. 4-4C). However, in contrast 
to GL261(B6) tumors, immune effector activation pathways were not associated with the 
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metronomic CPA responses in B16F10 tumors, suggesting that the above 10 pathways 
are necessary but not sufficient to induce significant anti-tumor immune responses in 
B16F10 tumors. The 394 down regulated B16F10 genes are enriched in tumor growth-
related pathways, such as cell cycle, DNA replication, serine and threonine metabolism, 
one carbon pool by folate, steroid biosynthesis, terpenoid backbone biosynthesis, and 
pyrimidine metabolism (Table 4-5B; App. 4-4C), consistent with the moderate tumor 
growth delay induced by CPA treatment. In addition, the down regulation of glycine, 
serine and threonine metabolism might sensitize tumor cell to the cytotoxicity of CPA 
[176].  
Differential tumor responses to metronomic CPA  
The above findings were confirmed and extended by directly comparing the 
magnitude of CPA responses in the responsive (GL261(B6)) as compared to the 
unresponsive (LLC and B16F10) tumor models. We identified 1,153 genes (App. 4-6A) 
that show significant and stringent (>2-fold) up regulation and 322 genes (App. 4-6B) 
that show significant and stringent (>2-fold) down regulation by metronomic CPA in the 
responsive as compared to both unresponsive tumor models (see Venn diagram in Fig. 4-
4 for differential gene responses before applying stringency filter). Six genes (App. 4-6C) 
showed significant and stringent (>2-fold) up regulation in both unresponsive tumor 
models compare to the responsive tumor model, and 16 genes (App. 4-6D) were 
commonly up regulated in all three models. 
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KEGG pathways enriched in the set of 1,153 genes up regulated or in the 
responsive tumor model primarily relate to immune response (App. 4-6E) and were 
similar to the pathways identified when the responsive tumor model was examined alone 
(Table 4-3A; App. 4-4A), except that the relative ranking or significance level of several 
pathways was changed (App. 4-6F). That is, the p-value-based ranking of T cell receptor 
signaling, primary immunodeficiency (inhibited), and leukocyte transendothelial 
migration increased, whereas the ranking of the lysosome pathway, JAK-STAT 
signaling, ECM-receptor interaction, focal adhesion and several other KEGG pathways 
decreased after filtering out the genes also responsive in LLC and B16F10 tumors. This 
indicates that T cell receptor signaling and leukocyte transendothelial migration are more 
specific to the responsive tumors, in contrast to the genes up regulated by CPA in the 
lysosome pathway, JAK-STAT signaling, ECM-receptor interaction, and focal adhesion, 
which are more frequently shared with the unresponsive tumor models (App. 4-6F).  
The 322 genes down regulated in the responsive tumor model are enriched in six 
KEGG pathways with tumor cell essential survival functions, such as selenoamino acid 
metabolism, cysteine and methionine metabolism, purine metabolism, pyrimidine 
metabolism and glycerophospholipid metabolism (App. 4-6G). Fc gamma R-mediated 
phagocytosis was also down regulated, which may relate to the regulation of lysosome 
antigen digestion. Further, elevation of cysteine consumption is associated with 
tamoxifen-resistance in MCF-7 cells [177]. Thus, down regulation of cysteine 
metabolism may relate to decreased resistance to CPA.  
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No KEGG pathways were enriched in the set of 16 genes (App. 4-6D) up 
regulated in all three tumor models. However, DAVID Functional Annotation Cluster 
(high stringency settings) identified endopeptidase activity (MASP1, ADAMTSL4, C1S, 
HTRA3; p=0.0056; enrichment score=1.95) and regulation of apoptosis (ADAMTSL4, 
CLU, TRP53INP1, SPP1; p=0.017; enrichment score=1.75) as being enriched among 
these 16 genes, indicating these genes may relate to basal DNA damage response (App. 
4-6H).  
Only 6 genes (App. 4-6C) were up regulated significantly and stringently by CPA 
in both unresponsive tumor models, reflecting the small number of genes responding to 
CPA in LLC tumors (Table 4-1). No enriched KEGG pathways or DAVID clusters were 
identified for these 6 genes (SEMA4G, CLCA1, CTXN1, AGT, SULF2, GPNMB) even 
at low stringency, in the case of DAVID analysis. Hypermethylation of SULF2 correlates 
with chemosensitivity [178, 179] and GPNMB may inhibit dendritic cell function and act 
as a negative regulator of T-cell activation [180].  
Gene pathways predictive of differential responsiveness to CPA in untreated tumors  
Given that GL261, LLC and B16F10 tumor cells all show similar sensitivities to 
activated CPA cytotoxicity in cell culture (Marie Jordan, unpublished experiments), we 
hypothesized that their differential responsiveness to CPA in vivo reflects the distinct 
interactions of each tumor cell line with mouse stromal cells. To identify genes and 
pathways expressed in untreated tumors that may be associated with or are predictive of 
differential tumor responsiveness to metronomic CPA treatment, we compared the 
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transcriptional profiles of untreated GL261 tumors to those of untreated LLC and B16F10 
tumors.  
We identified 1,348 genes with higher expression (App. 4-7A) and 438 genes 
with lower expression at |FC| > 2 and p < 0.001 (App. 4-7B) in untreated responsive 
tumors than in both untreated unresponsive tumors (Fig. 4-7). Surprisingly, these 1,348 
genes were enriched for immune-related signaling pathways, including immune effector 
signaling, immune stimulatory signaling, and immune disease-related signaling (App. 4-
8A). Focal adhesion may also relate to immune signaling. Only two of the enriched 
pathways (axon guidance and prion diseases) were related to the neuronal cell lineage of 
the GL261 tumors. These findings indicate that basal immune activity is higher in the 
responsive tumors; furthermore, it suggests that the increased basal immune activity of 
the GL261(B6) tumors positively impacts its responsiveness to CPA-induced immunity. 
Notably, 592 of the 1,348 genes with higher basal expression in the responsive 
tumors (43.9%) showed a change in expression following metronomic CPA treatment, 
with 296 genes up regulated and 296 genes down regulated by CPA (App. 4-7C). This 
represents a 3.5-fold enrichment when compared to all gene responses to CPA in 
GL261(B6) tumors (43.9% vs. 12.6% of all genes responding to metronomic CPA 
treatment (=2119+809)/23284) (two-tailed p < 0.0001, by Chi-square with Yates 
correction: 2,929 responded and 20,355 not responded in all probes vs. 592 responded 
and 756 not responded in 1,348 probes with higher basal expression). This enrichment 
suggests that CPA/6d treatment activates a pathway(s) that is already primed to be 
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differentially expressed in untreated GL261(B6) tumors. Immune activation-related 
pathways were significantly enriched in the set of 296 genes up regulated by CPA (App. 
4-8B), while glycine, serine and threonine metabolism and focal adhesion KEGG 
pathways were significantly enriched in the 296 genes down regulated by CPA (App. 4-
8C). In addition, genes related to glial cells and neuron establishment (DAVID clusters) 
were significantly enriched in the CPA down regulated gene set (App. 4-8D), mirroring 
the GL261(B6) tumor regression phenotype induced by CPA/6d. The down regulation of 
glycine, serine and threonine metabolism may reduce the anti-oxidative capacity of tumor 
cells and thereby sensitize tumor cell to the cytotoxicity of CPA [176].  
The 438 genes expressed at a significantly lower level in untreated responsive 
tumors compared to both unresponsive tumor models (App. 4-7B) were enriched for 
glutathione metabolism, limonene and pinene degradation, lysosome, arginine and 
proline metabolism, amino sugar and nucleotide sugar metabolism, metabolism of 
xenobiotics by cytochrome P450, valine, leucine and isoleucine degradation, glycolysis / 
gluconeogenesis, drug metabolism (App. 4-8E). Drug metabolism pathway genes include 
the glutathione S-transferases GSTM1 and GSTP1, which are associated with resistance 
to CPA [181, 182]. Glutathione can protect cells from the destructive effects of reactive 
oxygen intermediates and free radicals formed during exposure to alkylating and 
platinating agents [183, 184]. Lysosome pathway is involved in the degradation and 
recycling of macromolecules via the engagement with endocytosis, phagocytosis, and 
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autophagy. The enrichment of lysosomes and glycolysis/gluconeogenesis suggests that 
the responsive tumors have a low metabolic rate [185].  
Of the 438 genes down regulated in the responsive compared to unresponsive 
tumor models, 147 genes were up regulated in GL261(B6) tumors following CPA 
treatment and only 1 gene was down regulated (App. 4-7D). The only pathway enriched 
significantly among these 147 genes is lysosome pathway. DAVID clustering revealed 
that, in addition to lysosome pathway, blood vessel morphogenesis, pleckstrin homology-
type, glycoprotein, and endosome/cytoplasmic membrane-bounded vesicle  were 
enriched significantly (App. 4-8F). The up regulation of lysosome and 
endosome/cytoplasmic membrane-bounded vesicle clusters is consistent with the 
increased damage of macromolecules upon CPA treatment, suggesting that up regulation 
of the endosome-lysosome pathway might enhance immunogenic tumor cell death by 
increasing the digestion, processing and presentation of tumor antigens [186]. 
Alternatively, up regulation of lysosomal metabolism by CPA treatment may suppress 
some immune suppression effects mediated by steroids [174]. The up regulation of blood 
vessel morphogenesis may increase tumor uptake of active CPA metabolites and immune 
cell recruitment into tumors [187-189]. It is unclear whether the pleckstrin homology-
type cluster impacts CPA responsiveness. 
Negative regulators of immune response  
One potential mechanism that could contribute to differences in chemotherapy-
induced responses between tumor models is the suppression or depletion of immune 
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suppressive factors in the tumor environment. To determine whether CPA/6d treatment 
depletes such suppressive factors, we compared the full set of CPA-responsive genes 
(|FC| > 2, p < 0.001) in GL261(B6) tumors with a set of 124 genes that negatively 
regulate immune responses (see Methods; App. 4-5A). Surprisingly, we found that only 
one of these 124 genes was down regulated by CPA/6d treatment (gene CR2, FC = -2.1) 
while 56 genes were up regulated (App. 4-5B). Further, CPA up regulated 4 negative 
regulators of immune responses in LLC tumors and 17 in B16F10 tumors (App. 4-5C-D), 
consistent with the minor and moderate activation of immune responses, respectively, 
seen in these tumor models. One negative regulator of immune response was down 
regulated by CPA in LLC tumors (gene Hmox1, FC= -2.2) and no negative regulators of 
immune response were down regulated in B16F10 tumors. Moreover, no negative 
regulators of immune response were uniquely up regulated by CPA (|FC| > 2 between 
two models) in the two unresponsive tumor models relative to the GL261(B6) model. 
Consistently, 48 negative regulators of immune response were expressed at a higher level 
and none was expressed at a lower level in CPA-treated GL261(B6) tumors than in CPA-
treated LLC and B16F10 tumors (App. 4-5E). Thus, the lack of robust immune responses 
in the CPA-treated unresponsive tumors cannot be explained by an increase in negative 
immune responses following CPA treatment. Further, comparison of untreated responsive 
tumors vs. unresponsive tumors revealed that only one negative regulator of immune 
response was expressed at a reduced level in untreated GL261 tumors (gene Hmox1: FC 
= -2.6 vs. LLC, and FC = -3.0 vs. B16F10). In contrast, 20 negative regulators of immune 
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response were expressed at a higher basal level in untreated GL261 tumors than in LLC 
and B16F10 tumors (App. 4-5F). This suggests that 1) the lack of robust immune 
responses in CPA-treated LLC and B16F10 tumors is not likely due to a more immune 
suppressive tumor microenvironment, and 2) CPA is potent at inhibiting the immune 
suppressive tumor micro-environment, consistent with previous reports [78, 190]. The 
above comparisons with negative regulators of immune response are summarized in App. 
4-5G and in Fig. 4-8. 
Gene pathways predictive of treatment prognosis in CPA-treated tumors  
Next, we investigated whether gene pathways that can predict treatment prognosis 
can be obtained by comparing the effects of metronomic CPA treatment in responsive vs. 
unresponsive tumor models. We identified 1,907 genes with significantly higher 
expression and 429 genes with significantly lower expression in CPA-treated GL261(B6) 
tumors than in both CPA-treated unresponsive models (App. 4-9A; Fig. 4-9). KEGG 
pathway analysis showed that these 1,907 genes were enriched in immune stimulation, 
immune effector activation and immune disease-related signaling pathways (App. 4-9B), 
similar to the pathways stringently up regulated by CPA in the responsive compared to 
the unresponsive tumor models. The 429 genes showing lower expression in the CPA-
treated responsive tumors were enriched for various KEGG pathways, including 
ribosome, propanoate metabolism, pyrimidine metabolism, one carbon pool by folate, 
steroid biosynthesis, butanoate metabolism, tryptophan metabolism, lysine degradation, 
pyruvate metabolism, purine metabolism, valine, leucine and isoleucine degradation, 
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RNA polymerase, alanine, aspartate and glutamate metabolism (App. 4-9C). Most of 
these pathways are related to essential cell survival function. However, sex steroids can 
inhibit T cell development by repressing Notch ligand Dll4 expression [191]. Butanoate 
metabolism can suppress inflammation by inducing T cell apoptosis [192]. Tryptophan 
metabolism can be immune suppressive by inducing Treg cell proliferation [193].. Other 
down regulated pathways may reflect the greater number of dying tumor cells (more 
extensive tumor regression) in the responsive tumors than in the unresponsive tumors. 
Thus, in addition to up regulation of immune activation related genes, down regulated sex 
steroids, butanoate metabolism, and tryptophan metabolism KEGG pathways may predict 
CPA-induced tumor regression and immune responses. 
Molecular mechanisms associated with differential tumor responses determined by 
mouse host immune competency  
Metronomic CPA induces regression of GL261 tumors in both adaptive immune 
deficient scid mice and in immune competent B6 mice. However, whereas 45% of 
metronomic CPA-treated GL261 tumors implanted in scid mice (GL261(scid) tumors) 
eventually rebound [57], GL261 tumors implanted in B6 mice (GL261(B6) tumors) are 
fully cured at high frequency (0% tumor rebound) and develop long-lived immunity [69]. 
Given this striking difference in response, we sought to identify gene-based signatures 
and molecular mechanisms that may underlie the differential tumor responses associated 
with the scid vs. immune competent mouse host. 
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GL261 tumor RNA-seq gene expression data were compared between scid and 
B6 mice 6 days after two CPA injections. Initial analysis showed that GL261(scid) 
tumors given two CPA injections show similar (77% overlapping) gene response profiles, 
independent of whether CPA is given every 6 days or every 9 days (CPA/6d and CPA/9d 
schedules), when analyzing tumors excised 6 days after the second CPA treatment (see 
below). Therefore, to increase the robustness of the comparison to B6 mice, we removed 
the gene responses in CPA/6d-treated GL261(scid) tumors that did not respond 
significantly to the CPA/9d schedule, when considering the CPA-responsive gene set that 
was significant and stringently unique to GL261(scid) model (See Methods; see UPR and 
KEGG pathway analysis diagrams on Fig. 4-3 and Fig. 4-6, respectively).  
We identified 1,567 genes commonly up regulated (App. 4-10A) and 631 genes 
commonly down regulated (App. 4-10B) by metronomic CPA treatment at |FC| > 2 and p 
< 0.001 in GL261(B6) and GL261(scid) tumors (See differential gene responses before 
applying stringency filter in Fig. 4-4). We also identified 372 genes (App. 4-10C) that 
were up regulated significantly by CPA and 38 genes (App. 4-10D) that were down 
regulated significantly by CPA with at least a 2-fold greater response to CPA/6d 
treatment in GL261(scid) compared to GL261(B6) tumors. In addition, 130 genes (App. 
4-10E) were significantly up regulated and 24 genes (App. 4-10F) were significantly 
down regulated with at least a 2-fold greater response in the GL261(B6) tumors.  
UPR analysis identified 150 of the activated UPRs and 29 of the inhibited UPRs 
were common between CPA/6d-treated and CPA/9d treated GL261(scid) tumors (App. 4-
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3F; See details in Methods and diagram on Fig. 4-3). Among 180 significant UPRs in 
GL261(B6) tumors (145 activated and 35 inhibited UPRs; App. 4-3A), 110 UPRs (98 
activated and 12 inhibited UPRs) are in common with those identified in the GL261(scid) 
tumor model (App. 4-3I). Many of the commonly activated UPRs are associated with 
immune stimulation. Applying additional stringency filters to identify UPRs that 
uniquely respond to CPA treatment in each model (see Methods), we identified 5 unique 
UPRs: EIF2AK2, IFNL1, MAVS were activated UPRs only in GL261(B6) tumors (Table 
4-6A) and DMD and SPARC were activated UPRs only in GL261(scid) tumors (Table 4-
6B). No inhibited UPRs were unique to either model. EIF2AK2 is an intracellular 
danger-sensing molecule that is important for inflammasome activation and HMGB1 
release [157] and IFNL1 can mediate inflammatory responses in cell types different from 
those mediated by IFN-alpha/beta, such as epithelial cells [194, 195]. MAVS is required 
for the activation of NFkB and the induction of interferons in response to viral infection 
[196]. Thus, all three UPRs unique to the GL261(B6) tumor model are associated with 
immune activation. Regarding the UPRs specific to the GL261(scid) model, DMD may 
relate to glia cell differentiation [197], while SPARC can inhibit brain tumor cell growth 
but promote invasion by increased binding with a set of extracellular matrix proteins 
[164-166].  
KEGG pathway analysis showed that immune stimulatory pathways were 
enriched among the 1,567 genes up regulated by metronomic CPA treatment in both 
GL261(scid) and GL261(B6) tumors (App. 4-11A). This finding is similar to that for the 
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GL261(B6) model, except that Jak-STAT signaling, antigen processing and presentation, 
and T cell receptor signaling were at a lower ranking and B cell receptor signaling was at 
a higher ranking owing to differences in the numbers of matched genes in the 
GL261(scid) and GL261(B6) common datasets (App. 4-11B). The pathways down 
regulated in both mouse models were similar to the pathways enriched in down regulated 
genes in the B6 mouse model (App. 4-11C).  
KEGG analysis of the 372 genes (App. 4-10C) showing stringent up regulation in 
GL261(scid) but not GL261(B6) tumors, as well as the 130 genes (App. 4-10E) showing 
stringent up regulation only in GL261(B6) tumors, identified several CPA-responsive 
pathways unique to each mouse model. The top CPA-induced pathways unique to 
GL261(B6) tumors were cytokine-cytokine receptor interactions, T cell receptor 
signaling, and hematopoietic cell lineage (mostly comprised of T cell lineage markers) 
(App. 4-11D), consistent with the established adaptive immune system deficiencies in 
scid mice. Further, primary immunodeficiency (p = 0.0041) was inhibited (Fig. 4-10), 
reflecting the up regulation of Cd8, and the up regulation of Cd3and Cd3which are 
required for differentiation of pro-T cells into pre-T cells, and of Lck, which is required 
for Cd4
+
Cd8
+
 T cell differentiation into Cd8
+
 T cells, suggesting a strong Cd8
+
 T 
differentiation program [198]. Tryptophan metabolism was uniquely up regulated by 
CPA in the B6 mice (p = 0.0055). While tryptophan is an essential amino acid for 
activated T cell proliferation, tryptophan degradation by IDO (indoleamine 2,3-
dioxygenase 1) and the production of kynurenine stabilize and activate immune 
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suppressive Treg cells [193]. This suggests that immune suppression is associated with 
the activation of immune responses. Cell adhesion and antigen processing and 
presentation were also significantly up regulated in the GL261(B6) tumors, consistent 
with the activation and contribution of Cd8
+
 T cells to tumor regression in regressing 
GL261(B6) tumors [69].  
Six KEGG pathways were significantly enriched in the genes up regulated only in 
GL261(scid) tumors: calcium signaling, long-term depression, MAPK signaling, 
neuroactive ligand-receptor interaction, hypertrophic cardiomyopathy and vascular 
smooth muscle contraction (App. 4-11E). Calcium signaling may relate to the 
hyperactive innate immune system of scid mice [199], and MAPK signaling may reflect 
one of tumor cell survival/resistance mechanisms active in GL261 tumors in scid mice. 
The other pathways may relate to GL261 tumor cell glial lineage and overlapping signals 
with other immune or neuron stimulus related pathways. No enriched KEGG pathways 
were identified for the few genes uniquely down regulated in either GL261(scid) tumors 
(38 genes) or GL261(B6) tumors (24 genes). 
Gene responses associated with different metronomic CPA schedules  
The CPA treatment schedule can have a major impact on the kinetics of immune 
response and tumor regression [56, 57]. Thus, while metronomic CPA can induce 
significant NK cell responses and induce major regression of GL261 tumors implanted in 
scid mice when given on either a 6 day (CPA/6d) or a 9 day repeating schedule 
(CPA/9d), the 9 day CPA schedule results in a transient NK cell response and early tumor 
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growth rebound, whereas the 6 day schedule results in prolonged NK cell responses and 
tumor growth rebound that is substantially delayed [57]. To identify early molecular 
signaling events associated with differential NK cell responses and tumor regression 
kinetics, we compared gene changes induced by CPA/6d treatment with those induced by 
CPA/9d treatment in the GL261(scid) model. CPA-treated tumors were all sampled 6 
days after the second CPA injection. We identified 2,574 genes up regulated and 1,250 
genes down regulated at |FC| > 2 and p < 0.001 in CPA/6d-treated tumors (App. 4-1D), 
and 2,713 genes up regulated and 1,564 genes down regulated in CPA/9d-treated tumors 
(App. 4-1E); 2,352 genes were up regulated and 1,176 genes were down regulated in 
common by both CPA schedules (App. 4-1F). UPR analysis did not identify any UPRs 
uniquely associated with either model after applying a stringent uniqueness filter (see 
Methods), consistent with the very similar overall gene responses induced by CPA/9d 
and CPA/6d treatment at the time the tumors were analyzed.  
Comparing gene responses induced by each CPA schedule, we identified 361 
genes that were up regulated and 388 genes that were down regulated only in CPA/9d-
treated tumors. We also identified 222 genes that were up regulated and 74 genes that 
were down regulated only in the CPA/6d-treated tumors (App. 4-12A; see Fig. 4-11 for 
diagrams). After applying a 2-fold change stringency filter to assess the differential gene 
responsiveness of each tumor model, we identified a total of 44 up regulated genes and 3 
down regulated genes unique to the CPA/9d schedule, while 5 genes were up regulated 
and 1 gene down regulated uniquely by the CPA/6d schedule (App. 4-12B; see Fig. 4-
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11A for diagrams). No KEGG pathways were enriched in these small gene sets. DAVID 
cluster analysis indicated that the 44 up regulated genes unique to the CPA/9d schedule 
(App. 4-12B) are associated with sarcomere and actin cytoskeleton organization(App. 4-
13A). How these gene clusters relate to differential immune responses associated with 
CPA schedule will require further study. 
Next, we examined individual genes whose expression intensity (either untreated 
or CPA-treated tumors) > 50 among the gene changes unique to each CPA schedule 
(App. 4-12B) Fig. 4-11We thus identified PER2, TM7SF4, RETNLA, and other 10 genes 
that are uniquely up regulated on the CPA/9d schedule and no genes were uniquely down 
regulated by CPA/9d schedule. Further, XIST was uniquely up regulated and SMPD3 
was uniquely down regulated by the CPA/6d schedule (App. 4-12C). XIST expression 
levels correlate significantly with ovarian cancer cell sensitivity to Taxol and high XIST 
levels are associated with late relapse [200]. SMPD3, down regulated uniquely in 
CPA/6d-treated GL261(scid) tumors, can promote angiogenesis within the tumor 
microenvironment as well as metastasis by regulating exosomal microRNA secretion 
[201]. Induction of Per2 by low-dose irradiation in human breast epithelial cells can 
protect cells against subsequent exposure to high dose radiation-induced genotoxic 
effects [202]. However, while Per2 is required to induce glycolysis and suppress 
inflammatory responses during myocardial ischemia and reperfusion [203, 204], Per2 
mutant mice are more resistant to lipopolysaccharide (LPS)-induced endotoxic shock 
than control wild-type mice, potentially by down regulating the proinflammatory 
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cytokines gamma interferon IFN-gamma and IL-1beta [205].  Per2 is also a potential 
negative regulator of TLR9 and TLR9-mediated innate and adaptive immune responses 
[206]. TM7SF4 is a negative regulator of dendritic cell activity that can maintain immune 
self-tolerance [207], and RETNLA is a gene that is highly expressed in alternative 
activated macrophages [208] and can stimulate proliferation of mesenchymal stem cells 
as well as angiogenesis [209]. Thus, we identified several candidate genes that may 
contribute to the impaired NK cell response seen in CPA/9d treated tumors.  No negative 
regulators of immune response unique to either CPA schedule were identified using the 
set of 124 immune suppressive genes mentioned above. 
A larger set of genes was identified when we relaxed the stringency filter to a 
1.33-fold difference between the CPA-induced responses in CPA/6d vs. CPA/9d-treated 
tumors, while keeping the same significance filter (|FC| > 2 and p <0.001) as above (see 
Fig. 4-11B for diagrams). Under these conditions, 172 genes were up regulated and 41 
genes were down regulated by CPA only on the CPA/9d schedule, while 54 genes were 
up regulated and 8 genes were down regulated by CPA only on the CPA/6d schedule 
(App. 4-12D). Both KEGG pathway (App. 4-13B) and DAVID cluster analysis (App. 4-
13C) revealed that these 54 genes were enriched for cytokine-cytokine receptor 
interactions (INHBA, FLT3, IL12B, IL10), in addition to other immune-related KEGG 
pathways, such as systemic lupus erythematosus, suggesting that the immune response 
activated by the CPA/6d schedule is more extensive than that activated by the CPA/9d 
schedule. In contrast, the 172 genes up regulated only on the CPA/9d schedule were 
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enriched for one KEGG pathway, histidine metabolism (ASPA, HNMT, ACY3) (App. 4-
13D) and for DAVID clusters, including sarcomere, C-type lectin, and gated channel 
activity. (App. 4-13E). Of note, of the five genes in the C-type lectin cluster, three genes, 
CLEC1A [210], KLRA1 [211], and KLRA3 [212], are inhibitory lectin receptors 
expressed on myeloid and/or NK cells, KLRA10 is closely related in structure to 
inhibitory Ly49C receptors [213], and MGL2 is a marker for pro-tumor macrophages 
[214]. No KEGG pathways or DAVID clusters were enriched in the set of genes down 
regulated in either CPA/6d or CPA/9d-treated GL261(scid) tumors owing primarily to the 
small number of genes. 
Finally, applying a |FC| > 1.5 and p < 0.001 filter to directly compare CPA/9d-
treated tumors with CPA/6d-treated tumors, we identified 151 genes that are expressed at 
a higher level and 10 genes expressed at a lower level in CPA/9d-treated tumors than in 
CPA/6d-treated GL261(scid) tumors (App. 4-12E; see Fig. 4-11C for diagrams). Among 
these 151 genes, the top enriched pathways include metabolism of xenobiotics, drug 
metabolism, and glutathione metabolism (Table 4-7; App. 4-13F), which relate to 
chemotherapy resistance. A fourth enriched pathway, hematopoietic cell lineage, is 
associated with platelet, erythrocyte, neutrophil, and macrophage differentiation (Fig. 4-
12), which are potentially associated with tissue repair and resistance to chemotherapy. 
Further, glycolysis / gluconeogenesis pathway is enriched among these 151 genes, which 
might reflect increased tumor cell proliferation. Alternatively, glycolysis / 
gluconeogenesis might facilitate increased tumor cell DNA-damage repair signaling by 
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supplying NADPH and NAD
+
 [215, 216]. Among the 10 genes that are expressed at a 
lower level in CPA/9d-treated tumors, the lower level of CXCL11 suggests low anti-
tumor IFN signaling [217].  
4.4 Discussion 
Several cancer chemotherapeutic drugs, including CPA, can activate 
immunogenic tumor cell death leading to immune responses that can greatly enhance 
their therapeutic efficacy [32]. However, little is known about the molecular pathways 
that underlie the differential immune responses to CPA, or other cytotoxic drugs, seen in 
different tumor models, or the impact of host immune status and drug administration 
schedule.  
KEGG pathways associated with CPA-responsiveness of GL261(B6) tumors 
CPA given on an intermittent, every 6-day repeating metronomic schedule 
(CPA/6d) can activate potent immune responses in several implanted glioma tumors, as 
seen in both immune competent B6 mice and immune deficient scid mice [55, 56]. While 
CPA/6d treatment eradicates GL261 tumors implanted in B6 mice [69], the same 
treatment induces only minor or moderate tumor growth delay for LLC and B16F10 
tumors in the same syngeneic mouse model, even though both LLC and B16F10 tumor 
cells are intrinsically sensitive to the activated 4-hydroxy form of CPA in in vitro 
cytotoxicity assays (ME Jordan, unpublished results). While this could indicate that the 
tumor microenvironment has a major effect on tumor cell sensitivity to CPA cytotoxicity, 
our findings here identify major differences in anti-tumor immune response to 
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metronomic CPA treatment in the immune-responsive GL261(B6) tumors as compared to 
the immune-unresponsive LLC and B16F10 tumors. Thus, RNA-seq analysis revealed a 
much larger number of genes with altered expression in CPA-treated GL261(B6) tumors 
compared to LLC and B16F10 tumors. Further, KEGG pathway analysis revealed that the 
predominant immune stimulatory and immune effector pathways were up regulated by 
CPA/6d in the GL261(B6) model, whereas steroid biosynthesis, terpenoid backbone 
biosynthesis, base excision repair, and other tumor cell survival pathways were down 
regulated. 
Molecular mechanisms associated with minor responses of LLC tumors to CPA  
UPR analysis indicated that CPA/6d uniquely activated many factors in 
GL261(B6) tumors that activate immune responses or inhibit tumor cell proliferation. In 
contrast, few unique UPRs were associated with B16F10 tumors, and even fewer UPRs 
were associated with LLC tumors. Indeed, the one unique UPR associated with LLC 
tumors relative to GL261(B6) tumors, the pro-angiogenic factor VEGFA, was predicted 
by IPA to be inhibited by CPA/6d treatment in LLC tumors but activated in GL261(B6) 
tumors. The differential activation status of VEGFA (as a UPR) between LLC and 
GL261(B6) tumors correlates with the level of immune cell recruitment in each tumor 
model and is consistent with our earlier finding that signaling by the VEGFA receptor 
VEGFR2 is required for CPA/6d to activate immune cell recruitment in responding 
gliomas [55]. This finding is also consistent with the anti-angiogenic activity of 
metronomic CPA in LLC tumors reported by Browder et al. [95]. Further, KEGG 
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pathway analysis indicated that drug metabolism was up regulated significantly by CPA 
in LLC tumors. In contrast, only two KEGG pathways were down regulated in LLC 
tumors - cell adhesion molecules and leukocyte transendothelial migration - both of 
which are critical for immune cell infiltration into the tumor compartment. Thus, our data 
suggest that the low metronomic CPA responsiveness of LLC tumors has at least two 
components: 1) up regulation of drug metabolism, which dampens the cytotoxicity and 
corresponding immunogenic tumor cell death induced by CPA; and 2) anti-angiogenesis 
associated with the residual CPA activity, which blocks the route of anti-tumor immune 
cell recruitment by down regulating cell adhesion molecules and leukocyte 
transendothelial migration pathway genes essential for immune cell infiltration. These 
findings suggest that treatments, such as tumor vaccines or oncolytic viruses that can 
target tumor cells that had been selected with up regulated drug metabolism and augment 
immunogenic tumor cell death, may act in a synergistic manner with CPA.  
Molecular mechanisms associated with moderate responses of B16F10 tumors to CPA  
CPA/6d activated only 6 unique UPRs in B16F10 tumors relative to GL261(B6) 
tumors. Three of these six UPRs were identified as activated factors that can promote 
tumor cell survival (KDM5B [162], RBL2 [163], SPARC [218]), and the other 3 UPRs 
were inhibited factors that promote tumor cell survival or tissue repair (FOXM1 
[167],CD24 [168, 169], CSF2 [170]). Depending on cell context, CD24 may increase T 
cell proliferation in a lymphopenic host [219] and CSF2 may facilitate dendritic cell 
maturation and activate anti-tumor T cell responses [171, 172]. In contrast, CSF2 was an 
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activated UPR in GL261(B6) tumors. Thus, while B16F10 tumor responses to CPA/6d 
were characterized by UPRs common to GL261(B6) tumors, including UPRs related to 
immune activation, such as IFNG and IL6 (both activated), and UPRs related to immune 
inhibition, such as TGFB1(activated), no unique immune activation-related UPRs were 
associated with the B16F10 tumor model. Further, gene responses in B16F10 tumors 
were not enriched for any of the immune effector KEGG pathways found in GL261(B6) 
tumors, such as NK cell cytotoxicity and T cell receptor signaling, even though other 
KEGG pathways critical for immune activation were enriched, such as cytokine-cytokine 
receptor interaction, chemokine signaling pathway, and antigen processing and 
presentation. This suggests that CPA/6d, to some degree, induces B16F10 tumor cell 
death, but is not sufficient to induce robust anti-tumor immune responses. Notably, only 
three chemokines, CCL5, CCL6, and CCL7, all related to both monocyte and lymphocyte 
recruitment [220], are induced by CPA/6d in B16F10 tumors, while the only one 
chemokine CCL11 induced in LLC tumors recruit eosinophils [221]. In contrast, there 
were at least 18 NK cell and T cell recruitment-related chemokine or chemokine receptor 
genes up regulated in GL261(B6) tumors (CCL3, CCL4, CCL5, CCL22, CX3CL1, 
CX3CR1, CXCL9, CXCL10, CXCL11, CXCR3, CCL7, CCL8, CCR1, CCR2, CCR5, 
CCL17, CXCL16, CXCR6). Therefore, adoptive transfer of activated lymphocytes or 
intratumoral delivery of NK cell or T cell recruitment-related chemokines might have 
synergistic effects with CPA treatment in B16F10 tumors.  
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Differential KEGG pathway relevance to CPA-responsiveness of GL261(B) tumors 
Filtering out gene responses observed in two unresponsive models, we identified 
several KEGG pathways enriched further among the set of gene responses induced by 
CPA/6d in GL261(B6) tumors, including T cell receptor signaling, primary 
immunodeficiency (inhibited), and leukocyte transendothelial migration. In contrast, 
several CPA/6d-induced KEGG pathways became less significant after filtering out gene 
responses seen in both unresponsive tumor models, including lysosome, JAK-STAT 
signaling pathway, ECM-receptor interaction, focal adhesion, complement and 
coagulation cascades, systemic lupus erythematosus, and other glycan degradation. This 
suggests that these pathways have significant overlap with unresponsive tumor models 
and thus are less important for immune activation. Thus, by comparing gene responses in 
the responsive tumor model with the two unresponsive tumor models, we assessed the 
relative importance of various immune activation-related KEGG pathways for CPA-
activated immune responses.  
High basal immune activity associated with immune responsive GL261(B6) tumors as 
compared to LLC and B16F10 tumors 
Other than several markers of immunogenic tumor cell death, little is known 
about what features can predict immune responses induced by chemotherapy, which 
highlights the need to stratify and select tumors for treatment. Here we found that the 
basal expression level of immune stimulatory and immune effector signaling in 
GL261(B6) tumors is significantly higher than in both unresponsive tumor models, 
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consistent with reported low level of MHC I expression in untreated LLC and B16F10 
tumors in B6 mice [101]. This suggests that tumor immunogenicity is predictive of 
CPA/6d-inducible immune response, similar to the correlation of immunotherapy 
efficacy in animal models with the immunogenicity of the tumor [101]. However, studies 
in additional tumor models are required to confirm this finding, in particular, other 
glioma models with lower immunogenicity than GL261, to exclude confounding factors 
such as different mutation status or tumor histology. Further, the genes that are more 
highly expressed in untreated GL261(B6) tumors than in untreated LLC and B16F10 
tumors were significantly enriched for CPA-responsive genes, suggesting that CPA/6d 
treatment activates a pathway(s) that is already primed to be differentially expressed in 
untreated GL261(B6) tumors.   
Genes expressed at a lower level in untreated GL261(B6) tumors than in untreated 
LLC and B16F10 tumors were enriched for glutathione-based drug metabolism, and for 
glycolysis/gluconeogenesis. Given that NAD(P)H generated by glycolysis is required by 
drug metabolizing enzymes [216] and that NAD
+
 is essential for genotoxic damage repair 
[215], it is likely that the lower level of glycolysis and drug metabolism, together with the 
higher basal immune factor level in GL261(B6) tumors, contribute to their strong 
responsiveness to CPA/6d treatment.   
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Expression of negative regulators of immune responses does not account for 
differential CPA-responsiveness of GL261(B6) tumors vs. LLC and B16F10 tumors 
An immune suppressive tumor micro-environment may dampen the efficacy of 
chemotherapy [222]. We found that negative regulators of immune response were more 
commonly up regulated by CPA treatment in responsive GL261(B6) tumors as compared 
to in immune unresponsive LLC and B16F10 tumors. No negative regulators of immune 
response were uniquely up regulated in both LLC and B16F10 tumors by CPA treatment. 
Further, 20 negative regulators of immune response were more highly expressed and only 
one such negative regulator was lower in expression in untreated GL261(B6) tumors as 
compared to LLC and B16F10 tumors. These data suggest that CPA/6d treatment is 
capable of overcoming a potentially immune suppressive tumor micro-environment, and 
that the immune unresponsiveness of LLC and B16F10 tumors is not due to a highly 
immune suppressive environment prior to CPA treatment or to elevated negative immune 
responses after CPA treatment. The up-regulation of negative regulators of immune 
response by CPA in GL261(B6) tumors also suggests  it serves as a negative feedback 
mechanism that prevents over-reaction of immune responses and promotes tissue repair, 
consistent with previous reports from us and other groups [13, 69]. Thus, the up-
regulation of negative regulators of immune response warrants a repetitive, intermittent 
metronomic CPA schedule with an appropriate drug-free break.  
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Immune suppressive KEGG pathways enriched in genes that expressed more lowly in 
CPA-treated GL261(B6) tumors than in CPA-treated LLC and B16F10 tumors 
Comparison of CPA/6d treatment between GL261(B6) tumors and the 
unresponsive LLC and B16F10 tumors further revealed that, in addition to immune 
activation-related KEGG pathways enriched predominantly among genes expressed more 
highly in CPA/6d-treated GL261(B6) tumors, genes expressed at a lower level in 
CPA/6d-treated GL261(B6) tumors than in CPA/6d-treated LLC and B16F10 tumors 
were enriched for three immune suppressive KEGG pathways: steroid biosynthesis [191], 
butanoate metabolism [192], and tryptophan metabolism [193], which can inhibit T cell 
development, proliferation and/or activation, as discussed in Results. It is not known 
whether these three pathways are a consequence of a decreased tumor cell survival 
function mirroring GL261(B6) tumor regression or whether they are de-suppressing 
factors that promote CPA-induced immune responses. Whether corresponding metabolite 
levels, i.e., steroid hormone, butanoate, and tryptophan, can be used as biomarkers needs 
further study.  
Impact of scid immunodeficiency 
The adaptive immune system can greatly impact the strength or sustainability of 
CPA-induced anti-tumor immune response. Thus, in contrast to GL261 tumors implanted 
in syngeneic B6 mice, which are eradicated by CPA/6d in a mechanism dependent on 
Cd8 T cells, CPA/6d treatment of GL261 tumors implanted in scid mice undergo major 
regression but this is followed by tumor growth rebound [57], suggesting that Three 
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activated UPRs associated with immune activation (EIF2AK2 [157], IFNL1 [194], 
MAVS [196]) were identified as being unique to CPA/6d-treated GL261(B6) when 
compared to GL261(scid) tumors, and two activated UPRs (DMD, SPARC) were 
identified as being unique to the GL261(scid) tumor model. DMD may relate to glia cell 
differentiation and thus favor tumor regression [197], but SPARC can promote tumor cell 
invasion [164-166]. Thus, there were no consistent pattern observed in UPRs unique to 
GL261(scid) tumors. In addition, a subset cytokine-cytokine receptor interaction, T cell 
receptor signaling and several other immune-related KEGG pathway genes were found to 
be unique to the GL261(B6) tumor model, suggesting that T cell receptor signaling and 
cytokine-cytokine receptor interaction are critical for anti-tumor responses in GL261(B6) 
tumors. This is consistent with our previous finding that Cd8
+
 T cells are indispensable 
for the complete regression of GL261(B6) tumor induced by CPA/6d treatment [69].  
Impact of extending CPA drug-free break from 6-day to 9-day 
We compared gene responses between GL261(scid) tumors treated with CPA/6d 
vs. CPA/9d, which induce differential NK cell responses [57]. Consistent with the similar 
tumor regression status of these two tumor models at the time of tumor sampling, we 
found only a small number of gene response differences between the two CPA schedules, 
and no unique UPRs were identified in either model.  We found that TM7SF4 [207] and 
PER2 [203, 204], potential negative regulators of immune response, and RETNLA [208], 
a tumorigenic gene that stimulates proliferation of mesenchymal stem cells and promotes 
angiogenesis, was up regulated stringently in CPA/9d-treated GL261(scid) tumors. In 
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contrast, we identified XIST, a gene whose expression is associated with the sensitivity 
of ovarian cancer to Taxol treatment [200], as the only up regulated gene in CPA/6d-
treated GL261(scid) tumors. SMPD3, which promotes angiogenesis and metastasis [201], 
was the only down regulated gene unique to the CPA/6d schedule. Thus, we identified 
several candidate genes that may contribute to the impaired NK cell response seen in 
CPA/9d-treated tumors.  
In addition, we found that an immune inhibitory C-type lectin DAVID cluster was 
enriched among the genes up regulated only on the CPA/9d schedule. In contrast, four 
immune-related KEGG pathways, including cytokine-cytokine receptors, were enriched 
in the up regulated gene responses specific to the CPA/6d schedule, consistent with a 
more sustained NK cell response seen in CPA/6d-treated GL261(scid) tumors [57].  
 Directly comparison of CPA/9d-treated tumors with CPA/6d-treated tumors 
revealed four top enriched pathways, i.e., metabolism of xenobiotic by cytochrome P450, 
drug metabolism, hematopoietic cell lineage and glutathione metabolism, among 151 
genes with higher expression in CPA/9d-treated tumors. While three of these KEGG 
pathways are related to chemotherapy resistance, the genes in hematopoietic cell lineage 
pathway point to tissue repair and resistance to chemotherapy-related immune cells. This 
suggests that the CPA/9d schedule facilitates tumor cell selection of drug resistance, and 
supports our previous findings that CPA/6d is superior to CPA/9d in terms of its 
activation of longer-term immune response [57]. Thus, immunotherapy, such as tumor 
vaccines or adoptive transfer immune cells, that can benefit from immune responses 
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generated by CPA treatment at an early time point might be a good candidate to combine 
with CPA/9d schedule.  
Summary 
 We used genome-wide transcriptional profiling to identify, and compare, gene 
expression pathways and their UPRs associated with differential tumor responses to 
metronomic CPA treatment related to tumor model, mouse model, and drug schedule. We 
found that CPA/6d treatment activated dominant immune stimulatory KEGG pathways 
and UPRs in GL261(B6) tumors in comparison to unresponsive LLC and B16F10 
tumors, consistent with the strikingly different anti-tumor effects that metronomic CPA 
induces in these tumor models. We identified increases in drug metabolism and a low 
level of cell adhesion and transendothelial pathway in association with the low 
responsiveness of LLC tumors to CPA/6d treatment. The absence of anti-tumor immune 
effector pathways in CPA-treated B16F10 tumors was potentially caused by a lack of NK 
cell and T cell recruitment-related chemokines. We further identified high basal immune 
surveillance, low glycolysis and drug metabolism as being associated with the CPA/6d 
responsiveness of GL261(B6) tumors. Comparison of CPA-treated tumors indicated that 
down regulation of steroid biosynthesis, butanoate and tryptophan metabolism was 
associated with CPA-induced tumor regression. In addition, comparison of CPA-treated 
GL261(B6) vs. GL261(scid) tumors revealed that T cell signaling and related cytokine-
cytokine receptor interactions underlie the differential tumor responses to CPA/6d 
treatment between scid mice and B6 mice. Finally, comparison of the CPA/9d vs. 
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CPA/6d treatment schedules suggests that the longer drug-free break favors selection of 
increased expression of drug metabolism genes.  
Since both UPR and KEGG pathway analysis are based on multiple gene changes 
within a network, our approach is more robust than examining individual genes. In 
addition, while other immune profiling studies have focused on bone marrow, spleen, or 
blood in CPA-treated mice or patients [47, 48], we directed our studies to the tumor 
compartment. Further, the UPR analysis carried out here in part addresses the limits of 
gene profiling by discerning UPR activity changes based on downstream gene changes, 
which may capture some potential endocrine or systematic effects induced by CPA. Thus, 
our results may facilitate chemotherapy drug selection, schedule optimization, and the 
development of combinational therapy. 
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Table 4-1. Overview of tumor model, mouse host, CPA schedule, gene response and 
UPR in this study 
RNA-seq were performed on two replicated RNA pools for each condition. Individual tumor # in 
each pool: 5 in each pool of untreated LLC, CPA/6d-treated LLC (day 6 after third CPA 
injection) and untreated B16F10; 4 in one pool and 3 in another pool for CPA/6d-treated B16F10 
(day 6 after third CPA injection), 9 in one pool and 10 in another pool for untreated GL261(B6), 
9 in one pool and 10 in another pool for CPA/6d-treated GL261(B6) (day 6 after second CPA 
injection), 6 for each pool of untreated GL261(scid), 9 for each pool of CPA/6d-treated 
GL261(scid) (day 6 after second CPA injection), 12 for each pool of CPA/9d-treated GL261(scid) 
(day 6 after second CPA injection). # of up or down regulated genes were based on |FC|>2 and 
p<0.001 cut off values. Shown are significant UPRs after filtering default UPRs listed by IPA 
(see Method). *: data set from GL261(scid) tumors treated by CPA/6d and CPA/9d were 
compared, and commonly regulated genes and UPRs in them were shown. 
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Table 4-2. Unique UPRs induced by CPA in GL261(B6), LLC, and B16F10 tumors. 
(A) Three categories of unique UPRs induced by CPA in GL261(B6) tumors relative to both LLC 
and B16F10 tumors. All 180 (App. 4-3A), 855 (App. 4-2B), and 1,394 (App. 4-2C) UPRs 
induced by CPA in GL261(B6) tumors, LLC, and B16F10 tumors, respectively, were used for 
this analysis. See UPR details in App. 4-3G. (B) One unique UPR in LLC tumors relative to 
GL261(B6) tumors. All 6 significant UPRs (App. 4-3B) induced by CPA in LLC tumors and 
2,121 UPRs (App. 4-2A) in GL261(B6) tumors were used for this analysis. (C) Six unique UPRs 
in B16F10 tumors relative to GL261(B6) tumors. All 93 significant UPRs (App. 4-3C) induced 
by CPA in B16F10 tumors and 2,121 UPRs (App. 4-2A) in GL261(B6) tumors were used for this 
analysis. 
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Table 4-2A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Categories
Reported 
function
Predicted 
Activation 
State
Molecule Type Upstream Regulator
complex IL12 (complex),IL7,IL12A,IL12B,CCL11
enzyme TRAF6
kinase MAPK8,MAPKAPK2,MAP3K14,RIPK2
other MOG,TAC1
transcription regulator TBX21,HMGB1,IRF6,HOXA7
transmembrane receptor TLR2,TYROBP,CD2,CD14,OLR1,CD86,BTNL2
transcription regulator PRDM1
other CORT
phosphatase DUSP1
enzyme SCD
growth factor WISP2
kinase PRKAA1
mature microrna miR-155-5p (miRNAs w/seed UAAUGCU)
transcription regulator MAX,BCL3
cytokine CSF2,CXCL8,PF4
g-protein coupled receptor CCR5
other TRADD
enzyme TAB1
kinase MTOR
other PTX3
transcription regulator IRF4
transporter APOA1
C. Glioma 
cell lineage
Brain 
development
Activated transcription regulator SIM1,PAX7
Inhibit immune 
respones
Activated
enzyme PTGS2
enzyme FN1
kinase FGFR2
D. Resist 
tumor 
regression 
A. Facilitate 
tumor 
regression 
either by 
immune 
mediated 
mechanism
s or 
inhibting 
tumor cell 
survival 
function
B. Postive 
or negatve 
regulator 
of immune 
respones 
depending 
on cell 
context
Activate immune 
responses
Activated
Inhibit immune 
responses
Inhibited
Promote tumor 
cell survival
Inhibited
Activate or inhibit 
immunity
Activated
Activate or inhibit 
immunity
Inhibited
Activated
Promote tumor 
cell survival
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Table 4-2B 
 
Table 4-2C 
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Table 4-3. KEGG pathways responded to CPA in GL261(B6) tumors.  
(A) Four categories of KEGG pathways enriched in genes up regulated by CPA in GL261(B6) 
tumors. The 2,119 genes that are up regulated by CPA and used for this analysis are shown in 
App. 4-1A. The original KEGG pathways without sorted category are in App. 4-4A. (B) KEGG 
pathways enriched in genes down regulated by CPA in GL261(B6) tumors. The 809 genes that 
are down regulated by CPA and used for this analysis are in App. 4-1A. See KEGG pathways 
with full results in App. 4-4A. Pathways with p<0.001 are shown. 
Table 4-3A 
 
 
 
Category Term Count % PValue
mmu04060:Cytokine-cytokine receptor interaction 105 5.05 1.36E-30
mmu04142:Lysosome 50 2.41 4.61E-14
mmu04514:Cell adhesion molecules (CAMs) 55 2.65 5.33E-12
mmu04062:Chemokine signaling pathway 59 2.84 7.45E-11
mmu04630:Jak-STAT signaling pathway 50 2.41 1.51E-09
mmu04620:Toll-like receptor signaling pathway 38 1.83 1.71E-09
mmu04512:ECM-receptor interaction 34 1.64 2.09E-09
mmu04621:NOD-like receptor signaling pathway 27 1.30 2.96E-08
mmu04612:Antigen processing and presentation 32 1.54 4.18E-07
mmu04510:Focal adhesion 53 2.55 9.28E-07
mmu04210:Apoptosis 29 1.40 5.42E-06
mmu04610:Complement and coagulation cascades 25 1.20 2.82E-05
mmu05340:Primary immunodeficiency 16 0.77 2.88E-05
mmu04670:Leukocyte transendothelial migration 33 1.59 7.23E-05
mmu04650:Natural killer cell mediated cytotoxicity 56 2.69 7.15E-18
mmu04660:T cell receptor signaling pathway 39 1.88 1.13E-07
mmu04662:B cell receptor signaling pathway 30 1.44 2.18E-07
mmu04640:Hematopoietic cell lineage 45 2.17 1.28E-17
mmu05332:Graft-versus-host disease 31 1.49 3.57E-12
mmu04940:Type I diabetes mellitus 28 1.35 9.06E-09
mmu05330:Allograft rejection 26 1.25 2.82E-08
mmu05416:Viral myocarditis 31 1.49 3.05E-06
mmu04672:Intestinal immune network for IgA production21 1.01 1.16E-05
mmu05320:Autoimmune thyroid disease 25 1.20 1.30E-05
mmu05322:Systemic lupus erythematosus 29 1.40 1.65E-04
mmu00603:Glycosphingolipid biosynthesis 9 0.43 1.54E-04
mmu00511:Other glycan degradation 9 0.43 5.14E-04
mmu05200:Pathways in cancer 65 3.13 7.91E-04
Immuno-
stimulatory 
signalings
Immune 
effector 
activation
Immune 
related 
disease
Tumor cell 
survival
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Table 4-3B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Term Count % PValue Genes
mmu00100:Steroid biosynthesis 10 1.27551 1.45E-09 TM7SF2, CYP51, SQLE, DHCR7, LSS, HSD17B7, SC4MOL, NSDHL, DHCR24, FDFT1
mmu00900:Terpenoid backbone biosynthesis 8 1.020408 1.80E-07 MVD, HMGCR, FDPS, MVK, ACAT2, IDI1, ACAT1, PDSS1
mmu03030:DNA replication 10 1.27551 2.41E-06 PRIM1, MCM7, RFC4, LIG1, POLD2, POLE, POLA1, MCM2, MCM5, MCM6
mmu00240:Pyrimidine metabolism 14 1.785714 2.95E-05 POLR2F, POLR3K, POLR2L, POLE, POLA1, CAD, POLR1B, NME6, NME4, PRIM1, TYMS, NME1, POLD2, DUT
mmu04110:Cell cycle 16 2.040816 4.15E-05 CDC7, CDC6, SKP2, CHEK1, MCM2, CDK4, MCM5, MCM6, CCNE2, RAD21, MCM7, HDAC2, CCND3, BUB1, CCNA2, MYC
mmu00230:Purine metabolism 17 2.168367 1.27E-04 POLR2F, POLR3K, POLR2L, POLE, POLA1, POLR1B, PFAS, PPAT, NME6, NME4, PRIM1, PRUNE, NME1, ADK, POLD2, PAPSS1, IMPDH2
mmu00670:One carbon pool by folate 6 0.765306 1.71E-04 MTHFD1, SHMT1, TYMS, SHMT2, DHFR, MTHFD1L
mmu03410:Base excision repair 8 1.020408 4.45E-04 HMGB1, NEIL3, UNG, LIG1, POLD2, POLE, LIG3, PARP1
mmu00260:Glycine, serine and threonine metabolism 7 0.892857 7.84E-04 CHDH, SHMT1, SHMT2, GATM, GCAT, PSAT1, CBS
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Table 4-4. KEGG pathways responded to CPA in LLC tumors.  
The genes that are up (151 genes, A) or down (70 genes, B) regulated by CPA and used for this 
analysis are in App. 4-1B. See KEGG pathway with full results in App. 4-4B. Pathways with 
p<0.05 are shown. 
Table 4-4A 
 
 
 
 
 
 
Table 4-4B 
 
 
 
 
 
 
 
 
 
  
Term Count % PValue
mmu04510:Focal adhesion 10 6.6 2.12E-04
mmu04512:ECM-receptor interaction 7 4.6 2.25E-04
mmu04610:Complement and coagulation cascades 5 3.3 0.008008
mmu05218:Melanoma 4 2.6 0.039217
mmu00860:Porphyrin and chlorophyll metabolism 3 2 0.039967
mmu00982:Drug metabolism 4 2.6 0.044982
Term Count % PValue
mmu04514:Cell adhesion molecules (CAMs) 8 11.4 6.45E-06
mmu04670:Leukocyte transendothelial migration 4 5.71 0.019534
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Table 4-5. KEGG pathways responded to CPA in B16F10 tumors.  
The genes that are up (663 genes, A) or down (394 genes, B) regulated by CPA and used for this 
analysis are in App. 4-1C. See KEGG pathway with full results in App. 4-4C. Pathways with 
p<0.05 are shown. 
Table 4-5A 
 
 
 
 
 
 
 
 
 
 
Table 4-5B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Term Count % PValue
mmu04142:Lysosome 21 3.21 3.61E-08
mmu04610:Complement and coagulation cascades 16 2.44 1.88E-07
mmu05322:Systemic lupus erythematosus 15 2.29 5.33E-05
mmu04115:p53 signaling pathway 12 1.83 7.88E-05
mmu04060:Cytokine-cytokine receptor interaction 22 3.36 7.00E-04
mmu05020:Prion diseases 7 1.07 0.00237
mmu04630:Jak-STAT signaling pathway 15 2.29 0.00294
mmu04062:Chemokine signaling pathway 15 2.29 0.01403
mmu04612:Antigen processing and presentation 9 1.37 0.02874
mmu04514:Cell adhesion molecules (CAMs) 12 1.83 0.04429
mmu04512:ECM-receptor interaction 8 1.22 0.04781
Term Count % PValue
mmu04110:Cell cycle 26 6.79 6.81E-19
mmu03030:DNA replication 14 3.66 3.42E-14
mmu04914:Progesterone-mediated oocyte maturation 12 3.13 6.65E-07
mmu04114:Oocyte meiosis 13 3.39 2.13E-06
mmu00260:Glycine, serine and threonine metabolism 7 1.83 3.05E-05
mmu00670:One carbon pool by folate 5 1.31 2.16E-04
mmu00100:Steroid biosynthesis 5 1.31 2.78E-04
mmu00900:Terpenoid backbone biosynthesis 4 1.04 0.002311
mmu00240:Pyrimidine metabolism 8 2.09 0.002685
mmu03040:Spliceosome 9 2.35 0.002916
mmu03410:Base excision repair 4 1.04 0.043371
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Table 4-6. Significant UPRs induced by CPA unique in GL261(B6) or GL261(scid) 
tumors relative to each other.  
(A) Three unique UPRs in GL261(B6) tumors. The 180 significant UPRs induced by CPA/6d in 
GL261(B6) tumors in App. 4-3A and the full set of 1,898 UPRs induced by CPA/6d in 
GL261(scid) tumors in App. 4-2D were used for this analysis. (B) Two unique UPRs in 
GL261(scid) tumors relative to GL261(B6) tumors. All 179 significant UPRs that commonly 
induced by CPA/6d and CPA/9d schedules in GL261(scid) tumors in App. 4-3F and the full set of 
2,121 UPRs induced by CPA/6d in GL261(B6) tumors in App. 4-2A were used for this analysis. 
 
Table 4-6A 
 
 
Table 4-6B 
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Table 4-7. KEGG pathways enriched in genes expressed 1.5-fold higher in 
GL261(scid) tumors treated with CPA/9d than those with CPA/6d schedule.  
See App. 4-12E for 155 genes used in this analysis (p<0.001) and App. 4-13F for full results. 
KEGG pathway with p<0.05 were shown here. Pathways with p<0.05 are shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Term Count % PValue Genes
mmu00980:Metabolism of xenobiotics by cytochrome P450 6 4.03 3.53E-04 GSTM1, CYP2F2, ADH1, GSTT1, GSTT2, CYP2E1
mmu00982:Drug metabolism 6 4.03 6.40E-04 GSTM1, ADH1, FMO1, GSTT1, GSTT2, CYP2E1
mmu04640:Hematopoietic cell lineage 5 3.36 0.00775 CD36, H2-EB1, H2-AA, ANPEP, IL7R
mmu00480:Glutathione metabolism 4 2.68 0.01258 GSTM1, GSTT1, ANPEP, GSTT2
mmu05332:Graft-versus-host disease 4 2.68 0.01689 H2-M2, KLRA8, H2-EB1, H2-AA
mmu00010:Glycolysis / Gluconeogenesis 4 2.68 0.02569 ADH1, ENO3, PGAM2, PFKM
mmu04020:Calcium signaling pathway 6 4.03 0.03283 TNNC2, ATP2A1, RYR1, CAMK2A, CACNA1S, CACNA1A
mmu04512:ECM-receptor interaction 4 2.68 0.0427 CD36, TNXB, COL6A6, THBS4
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Fig. 4-1. Identification of stringent UPRs.  
All up regulated and down regulated genes by CPA at |FC|>2 and p<0.001 were uploaded to IPA 
for UPR identification. Then, UPRs that are 1) chemicals except endogenous mammalian 
chemicals; 2) group UPRs; and 3) redundant UPRs between species with lower |Z-score| are 
excluded from study. Further, UPRs studied that are p value of overlapping <0.0001, # of targeted 
genes > 10, and |Z score| (both bias-corrected and default) > 2 are considered as stringent. 
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Fig. 4-2. Identification of stringent UPRs that are unique to one tumor model (model 
A) as compared to a second tumor model (model B).  
“X” refers to a stringent UPR identified in model A (see Fig. 4-1) 
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Fig. 4-3. Diagram showing UPR analysis comparing GL261(B6) tumors vs. LLC and 
B16F10 tumors and comparing GL261(B6) tumors vs. GL261(scid) tumors.  
Number of genes that respond to CPA treatment at |FC|>2 and p<0.001 were shown with up (red) 
and down (green) arrows on side indicating up and down regulation by CPA, respectively. These 
genes were uploaded to IPA and get UPRs studied (see Fig. 4-1 for definition), which derived a 
set of stringent UPRs (see Fig. 4-1 for stringency definition). Comparison of “Stringent UPRs” in 
one tumor model with “UPRs studied” in a second model (dash purple line) derived a set of 
unique UPRs to one tumor model. Red arrow indicates activated UPRs and green arrow indicates 
inhibited UPRs, respectively. See Fig. 4-2 for strategies used in identification of stringent UPRs 
that are unique to one tumor model as compared to a second tumor model. Significant genes or 
stringent UPRs that have same regulated direction, i.e., up or down, activated or inhibited, are 
shown in blue rectangular by comparison of two sets parental genes or UPRs, which were 
indicated by blue lines. The tables or supplementary spreadsheets (App) that contain 
corresponding data sets are shown. 
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Fig. 4-4. Venn diagram showing numbers of genes that responded to CPA 
treatment.  
(A) GL261(B6), LLC, and B16F10 tumors treated on CPA/6d schedule; (B) GL261(scid) tumors 
treated on CPA/6d or CPA/9d schedule and GL261(B6) tumors treated on CPA/6d schedule. 
Significance cut off values: |FC|>2, p<0.001. No stringency filter about fold changes between 
different tumor models was applied here. Numbers shown indicate number of genes that respond 
to CPA treatment with up and down arrows indicating up and down regulation by CPA, 
respectively; ; no arrow indicates inconsistent regulation pattern. See lists of genes responded to 
CPA in above models in App 4-1.   
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Fig. 4-5. Diagram showing stringent gene responses to CPA treatment in GL261(B6) 
tumors relative to B16F10 and LLC tumors.  
The 2,119 up (red arrow) and 809 down (green arrow) regulated genes by CPA in GL261(B6) 
tumors were identified using cutoff values |FC| > 2 and p < 0.001. These genes were compared to 
corresponding genes in B16F16 tumors to keep genes whose |(FC for GL261(B6) )/ (FC for 
B16F10 )| >2. The genes kept were further compared to LLC tumors to keep genes whose |(FC 
for GL261(B6)) / (FC for LLC|) >2. The resultant gene responses are stringent or unique to 
GL261(B6) tumors relative to B16F10 and LLC tumors. Tables or supplementary spreadsheets 
(App) that contain corresponding gene sets or KEGG pathway analysis results were shown. 
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Fig. 4-6. Diagram showing the identification of stringent gene responses to either 
GL261(B6) or GL261(scid) tumors.  
The 2,352 up and 1,176 down regulated genes by CPA/6d and CPA/9d treatment commonly (|FC| 
> 2 and p < 0.001) in GL261(scid) tumors were used , taking a conservative approach, to compare 
corresponding genes in GL261(B6) tumors. This comparison identified 372 up and 38 down 
regulated genes with |FC for GL261(scid) / FC for (B6) | > 2 as stringent response to CPA in 
GL261(scid) tumors relative to GL261(B6) tumors. On GL261(B6) side, 2,119 up and 809 down 
regulated genes (|FC| > 2 and p < 0.001) were compared to genes in GL261(scid) tumors  treated 
with CPA/6d, which identified 130 up and 24 down regulated genes (|FC-GL261(B6) / FC-
GL261(scid)|>2 as stringent in GL261(B6) tumors relative to GL261(scid) tumors. Up-regulation, 
red arrows; down-regulation, green arrows. Comparisons of two datasets that lead to a common 
dataset (blue rectangular) between them were indicated by blue lines. The tables or 
supplementary spreadsheets (App) that contain corresponding data sets are shown. 
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Fig. 4-7. Diagram showing differential gene expression comparing untreated 
GL261(B6) vs. LLC and B16F10 tumors.  
(A) UT: untreated tumors. Genes expressed more highly or lowly at |FC| > 2 and p < 0.001 were 
indicated by red or green arrows. Genes up or down regulated by CPA were also indicated by red 
or green arrows. The supplementary spreadsheets (App) that contain corresponding dataset were 
shown. (B) Venn diagram showing differential expression pattern from A. The supplementary 
spreadsheet files (App) that contain corresponding datasets were shown. 
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Fig. 4-8. Diagram showing number of negative regulators of immune responses 
expressed in untreated or CPA-treated GL261(B6), LLC and B16F10 tumors.  
Comparisons of negative regulator of immune response (App. 4-5A) with (A) CPA-
responsiveness, (B) Untreated tumors,or (C) CPA-treated tumors. Significance cutoff values: 
|FC>2|, p<0.001. The number of negative regulators of immune response that were up regulated 
(or expressed more highly, red arrows) or down regulated (or expressed more lowly, green 
arrows) were indicated, respectively. The supplementary spreadsheet files (App) that contain 
corresponding datasets were shown. 
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Fig. 4-9. Diagram showing differential gene expression comparing CPA-treated 
GL261(B6) vs. LLC and B16F10 tumors.  
(A) Genes expressed more highly or lowly at |FC| > 2 and p < 0.001 in CPA-treated GL261(B6) 
vs. both CPA-treated LLC and B16F10 tumors were indicated by red or green arrows. The 
supplementary spreadsheets (App) that contain corresponding dataset were shown; (B) Venn 
diagram showing differential expression pattern from A. Red and green arrows indicate more 
highly or lowly expressed in CPA-treated as compared to both CPA-treated LLC and B16F10 
tumors, respectively. 
 
 
 
 
 
  
 170 
 
Fig. 4-10. Primary immunodeficiency pathway inhibited uniquely in GL261(B6) 
model relative to GL261(scid) model. 
 Matched genes in the pathway were labeled with red star. This was one of pathways (App. 4-
11D) that enriched among 130 genes (App. 4-10E) showing stringent up regulation only in 
GL261(B6) tumor model. 
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Fig. 4-11. Diagram showing differential gene responses to CPA/6d and CPA/9d 
schedules in GL261(scid) tumors.  
Blue square region in both A and B shows that 1) the numbers of genes responding significantly 
at |FC|>2 and p<0.001 comparing CPA-treated tumors vs untreated tumors (UT); and 2) The 
genes significantly induced by one schedule (e.g. CPA/6d) were filtered to remove the genes that 
also responded significantly to another schedule (e.g., CPA/9d) (dash lines). These genes were 
further filtered (dash lines) to only keep genes that have > 2-fold (A) or > 1.33-fold (B) change 
comparing the responses to one CPA schedule to the other CPA schedule. (C) Directly compare 
CPA/9d-treated vs. CPA/6d-treated tumors using cutoff values |FC|>2 and p<0.001. Red and 
green arrows indicate more highly or lowly expressed in CPA-treated tumors as compared to 
untreated tumors (A-B), or in CPA/9d-treated tumors vs CPA/6d-treated tumors (C), respectively. 
The supplementary spreadsheets (App) that contain corresponding datasets were shown 
 
 
 
  
 172 
 
Fig. 4-12. Hematopoietic cell lineage KEGG pathway enriched in genes expressed 
1.5-fold higher in CPA/9d-treated GL261(scid) tumors than CPA/6d-treated.  
Detailed results are in App. 4-13F. Matched genes in the pathway were labeled with red star. 
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CHAPTER FIVE: UNPUBLISHED RESULTS AND FUTURE PLANS 
Section 1. Gene signature associated with NK cell recruitment and activation in 
CPA-treated tumors 
Question: What gene signature is associated with NK cell recruitment and activation in 
CPA-treated tumors?  
Background:  
CPA administered at 140 mg/kg bolus dose, every 6 day repeating metronomic 
schedule (CPA/6d) can induce a major tumor regression in three glioma xenograft, i.e., 
rat 9L, human U251, and mouse GL261 glioma, implanted in scid mouse (three CPA-
sensitive brain tumor models) [55-57]. In contrast, the same CPA regimen can only 
induce tumor growth delay or stasis in PC3 prostate cancer, MDA-MB-231 breast cancer, 
or KM12 colon cancer in scid mouse (three CPA-insensitive tumor models; unpublished 
data, Waxman lab). The CPA-induced tumor regression is correlated with recruitment of 
innate immune cells, including NK cells, DCs, and macrophages. The contribution of NK 
cells to the CPA-induced tumor regression is demonstrated by antibody depletion 
experiments and using mouse models deficient in NK cells or in the NK cell cytotoxic 
effector perforin 1 [55]. 
VEGFR selective inhibitor axitinib blocked CPA-induced U251 and 9L tumor 
regression and immune responses in scid mice [55]. DC101 (28.6 mg/kg, every 3 day 
repeating), an antibody specifically targeting mouse VEGFR2, blocked CPA-induced 9L 
tumor regression and NK cell recruitment in scid mice [58]. In contrast, another anti-
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angiogenesis agent sorafenib, which is much less potent in inhibiting VEGFR2 than 
axitinib, induced anti-angiogenesis in 9L tumors but did not block CPA-induced tumor 
regression and immune response [58]. These data suggest that VEGFR2 signaling is 
required in metronomic CPA-stimulated immune cell recruitment [58]. In immune 
competent B6 mice, axitinib slightly reduced NK cell recruitment and NK cell activation 
and slowed down GL261 tumor regression (unpublished data, Waxman lab). 
Hypothesis:  
Stress molecules, chemokines, cytokines, and adhesion molecules that are 
important for NK cell recruitment and activation should be significantly up regulated and 
immune suppressive factors should be significantly down regulated in CPA/6d treated 
sensitive tumor models, but not in CPA/6d treated-insensitive tumor models. These 
changes should precede NK cell recruitment and activation. VEGFR inhibitors that 
interfere with CPA-induced immune responses might alter CPA-induced stress responses 
[34, 223-225], or chemokine, cytokine, and/or adhesion molecule expression patterns. 
Results:  
1. I found that beta-galactosidase, a marker for senescence, is up regulated in 
CPA/6d-treated insensitive tumor models (PC3 and MDA-MB-231 tumors) but not in 
CPA/6d-treated sensitive tumor models (GL261 and 9L tumors) (Fig. 5-1). This suggests 
that SASP (senescence associated secretory phenotype) might be up regulated in CPA-
treated CPA-insensitive tumor models, leading to low efficacy of CPA in insensitive 
tumor models.  
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2. Tumor-expressed CXCL10 and CXCL11 are significantly up regulated by 
CPA/6d in the sensitive tumor models (see micro array data, Fig. 5-2, and confirmed by 
qPCR, Fig. 5-3A) but not in insensitive tumor models (Fig. 5-3A). Also, the expression 
of CXCL10 and CXCL11-sepcific chemo-receptor Cxcr3 correlates with NK cell 
recruitment in 9L and U251 tumors (Fig. 5-3B). Furthermore, CXCL10 and CXCL11 
expression correlate with the NK cell recruitment level in the MTD CPA-treated U251 
tumors (Fig. 5-3C).Thus, the expression of tumor chemokines, i.e., human and rat 
CXCL10 and CXCL11 in U251 and 9L tumors, respectively, correlates with the level of 
NK cell recruitment across three different models, i.e., CPA/6d-treated sensitive tumor 
models, CPA/6d-treated insensitive tumor models, and MTD CPA-treated U251 tumors 
in scid mice.  
However, Nkp46 (NK cell marker) and Gzmb (NK cell activation marker) 
expression were not compromised in CPA-treated GL261 tumors in Cxcr3 KO B6 mice, 
even though chemokine Cxcl9 and Cxcl11 were activated by CPA treatment (Fig. 5-4). 
Thus, the Cxcl9, 10, 11 - Cxcr3 axis is not responsible for NK cell recruitment in CPA-
treated GL261 tumors in B6 mice. This suggests that Cxcl9, 10, 11 - Cxcr3 axis is not a 
shared mechanism for NK cell recruitment in CPA-treated tumors in both scid and B6 
mice. But it is still unknown whether Cxcl9, 10, 11 - Cxcr3 axis is responsible for CPA-
induced NK cell recruitment in three CPA-sensitive tumors in scid mice.   
3. In addition, mouse-expressed Cx3cl1 and tumor-expressed CCL26 and their 
chemo-receptor Cx3cr1 are significantly up regulated by CPA/6d treatment (Fig. 5-2). 
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However, the expression of Cx3cr1 (Fig. 5-5), the chemoreceptor for Cx3cl1 and CCL26, 
was not up regulated in CPA-treated 9L tumors, even though it was up regulated in 
GL261 and U251 tumors. Thus, The Cx3cl1-Cx3cr1 axis could not be a shared 
mechanism for NK cell recruitment in CPA-treated three sensitive tumors in scid mice. 
4. Adhesion molecules expressed in mouse endothelial cells are important for 
immune cell recruitment to tumors. The fold change of Vcam1 expression stimulated by 
CPA ranges from 4 to 18 in three sensitive tumor models (U251, 9L and GL261) (Fig. 5-
6). This up regulation was inhibited by DC101 or axitinib in U251 and 9Ltumor model 
(Fig. 5-6BC). Icam2 expression was not changed by CPA. axitinib blocked the increase 
in Vcam1 and Icam2 by up to 90%; DC101 inhibited these responses by only 20% to 
60%. This suggests that the adhesion molecules Vcam1 and Icam2 contribute to CPA/6d-
induced NK cell recruitment and are partially responsible for the inhibitory effects of 
VEGFR inhibitors on NK cell recruitment.  
5. Axitinib blocked the expression of CPA-induced tumor-expressed chemokines 
(CXCL10 and CXCL11) in U251 tumors (Fig. 5-7A), whereas DC101 does not (Fig. 5-
7B). This indicates that axitinib has more dramatic suppressive effect on NK cell 
recruitment than DC101. Correspondingly, axitinib block CPA-induced innate immune 
cell recruitment [55], but DC101 had little or no suppressive effects on recruitment of 
macrophages, NK cells or DCs in U251 tumors (Fig. 5-8A), even though DC101 did 
suppress CPA-induced innate immune cell recruitment in 9L tumors [58]. However, 
DC101 did suppress CPA-induced tumor MICB expression (Fig. 5-8B) and NK cell 
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activation in U251 tumors (Fig. 5-8B). DC101 also suppressed CPA-induced immune 
stimulatory cytokine IL15 and stress-sensing TLR4, TLR7, and TLR9 expression (Fig. 5-
8C), which are critical for immune responses. 
6. HMGB1, an immunogenic cell death marker, is enriched in the cytoplasm of 
CPA/6d-treated GL261 tumors compared with untreated tumors (Fig. 5-9), suggesting 
that HMGB1 is important for CPA-induced NK cell recruitment and activation in GL261 
tumors. Whether it is important for other sensitive tumor models is unknown.  
Future experiments:  
1. Study HMGB1 expression pattern in other metronomic CPA-treated sensitive 
and insensitive tumors. 
Hypothesis: Cytoplasmic or extracellular HMGB1 are immunogenic cell death 
markers. Therefore, differential HMGB1 expression pattern might be one of the factors 
that causes differential immune recruitment and tumor regression in above models. 
Approach: Carry out IHC staining of HMGB1 in sensitive tumor models first. If 
the hypothesis is verified, then further study of their expression in insensitive tumor 
models (including LLC and B16F10 tumors in B6 mice). 
2. Study whether CPA up regulated SASP related gene signatures in CPA-
insensitive tumor models (including LLC and B16F10 tumors in B6 mice) by qPCR and 
beta-galactosidase assay. 
3. Study if CPA/6d-induced HMGB1, CXCL10 and CXCL11 and Vcam1 and 
Icam2 expression is altered by co-treatment of axitinib or sorafenib. Approach: qPCR, 
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IHC. If these molecules are important, co-treatment of axitinib, but not sorafenib, should 
perturb their expression. 
4. Investigate how DC101 suppresses NK cell activation in U251-bearing scid 
mice. 
Background: Sorafenib, a muti-RTKI that does not block CPA/6d-induced NK 
cell activation, has been reported to reduce NK cell activation in vitro [226]. Could 
DC101-mediated suppression of NK cell activation be one of the mechanisms for anti-
angiogenesis-mediated immune tolerance?  
Hypothesis: (1) NK cells express VEGFR2, and VEGFR2 has been associated 
with DC maturation [227]. DC101 might inhibit NK cell maturation or activation by 
directly targeting VEGFR2 on NK cells; (2) VEGF increased by DC101 treatment may 
suppress NK cell activation just as VEGF suppress T cell activity [228, 229]; (3) 
Reduced Nkg2d ligand expression by DC101 might reduce NK cell activation. 
Question 4.1: Does DC101 directly target VEGFR2 on NK cells?  
Experimental approach: Treat IL2-primed tumor-free scid or C57CL/B6 mice 
with DC101, then isolate NK cells from peripheral blood and determine if VEGFR2 
phosphorylation and Prf1 and Gzmb expression are reduced by DC101 (FACS or qPCR 
analysis). Alternatively, isolate mouse NK cells from scid mouse, use IL-2 prime them, 
then treat these cells with DC101 over a range of concentrations that approximate the 
doses used in vivo, and determine if VEGFR2 phosphorylation and Prf1 and Gzmb 
expression are reduced by DC101 (FACS or qPCR analysis). 
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Question 4.2: Study if reduced MICB expression in tumors is the cause of 
reduced NK cell activation using in vitro and in vivo approaches.  
Experimental approach: Over express MICB in U251 cells, then test if over 
expression of MICB could stimulate NK92 cell activation in vitro. Alternatively, implant 
MICB over-expressing tumor to scid mice and determine if over expression of MICB will 
resist DC101’s suppression effect upon CPA and DC101 combined treatment in vivo. 
 
Section 2. The perturbation of VEGFR selective inhibitors to CPA-induced immune 
responses or tumor regression 
Question:  
What is the molecular mechanism underlying the DC101-mediated differential 
perturbation of CPA-induced tumor regression in different tumor models.  
Background:  
Huang et al. found that low-dose DC101 (10 or 20 mg/kg/3d) can drive tumor 
vasculature normalization and improve vaccine-induced anti-tumor immunity in immune 
competent FVB mice, whereas high-dose (40 mg/kg/3d) can prune tumor vasculature and 
induce immunosuppressive microenvironment [230].  
Hypothesis:  
Low-dose DC101 might be able to normalize tumor vasculature and become 
synergistic with CPA(90)/6d in treating GL261 tumors in B6 mice. 
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Results:  
I compared the immune responses induced by CPA(90)/6d treatment alone with 
CPA(90)/6d in combination of 10mg/kg/3d DC101 or 28.6mg/kg/3d DC101 in GL261 
tumor-bearing C57BL/6 mice.  
The DC101 treatment alone, either at 10 or 28.6 mg/kg/3d doses, can only induce 
slight GL261 tumor growth delay (Fig. 5-10A). CPA(90)/6d induced major tumor 
regression (Fig. 10B); but a significant subset (5 out of 14) of the CPA(90)/6d-treated 
tumors did not undergo sustained regression (Fig. 10C), which could be explained by the 
lower circulating 4-hydroxy-CPA levels at the lower CPA dose. Interestingly, DC101, 
either at 10 or 28.6 mg/kg/3d doses, in combination of CPA(90)/6d treatment induced 
tumor regression for all 19 tumors, which is significantly different from CPA(90)/6d 
alone (5:9 vs 0:19, 2-tailed Fisher’s exact test, p=0.0084) (Fig. 5-10C).  
DC101 treatment (10 or 28.6 mg/kg/3d) did not interfere CPA(90)/6d-mediated 
increase of tumor recruitment of NK cells and Cd8
+
 T cells in the regressing tumors, as 
well as expression of the NK cell and T cell cytotoxic markers Prf1 and Gzmb (Fig. 5-
11A). CD31 IHC stain shows that DC101 treatment did not induce significant anti-
angiogenesis effects in GL261 tumors in B6 mice 12 days after treatment (Fig. 5-11B).   
Future experiments:  
1. Study if DC101 treatment promoted Hoechst dye perfusion. If it did, DC101 
treatment normalized GL261 tumor vasculature and may improve CPA up take and 
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CPA(90)/6d-induced immune responses. If not, DC101 might work through other 
mechanisms to synergize with CPA(90)/6d. 
2. Will DC101 antagonize with CPA/6d in treating GL261 tumors in B6 mice? 
See question A on diagram on Fig. 5-12. If so, DC101 only synergizes low-dose CPA but 
antagonize CPA/6d in treating GL261 tumors in B6 mice, i.e., it is CPA dose-dependent. 
I can further study if DC101 can synergize with CPA(90)/6d in treating LLC or B16F10 
tumors in B6 mice, see question B on diagram on Fig. 5-12; Otherwise, see below. 
3. If DC101 synergize with CPA/6d in treating GL261 tumors in B6 mice, the 
result will be different from those of DC101 in 9L-bearing scid mice, where DC101 
blocks CPA-induced immune responses and tumor regression. Will it because of different 
mouse model or tumors? See question C on diagram on Fig. 5-12. I will study if DC101 
synergize with CPA/6d in treating GL261 tumors in scid mice. If yes, DC101 specifically 
antagonize CPA/6d in scid mice, but not in B6 mice, i.e,. it is mouse model-dependent; 
otherwise, DC101 specifically antagonize CPA/6d in 9L and U251 tumors, but not in 
mouse GL261 tumors, i.e., it is tumor xenograft-dependent.  
 
Section 3. CPA-induced immune cell changes critical for or indicative of anti-tumor 
responses.  
Question:  
What immune cell or gene changes in peripheral blood or spleen are indicative of 
anti-tumor responses activated by CPA? 
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Background:  
CPA-induced immune response is schedule dependent. While CPA/6d induced 
sustained anti-tumor immune response in U251 tumors in scid mice, MTD CPA only 
induced transient immune responses [55]. However, it is not clear 1) what immune cell or 
gene changes in peripheral blood or spleen are critical for or indicative of anti-tumor 
responses activated by CPA; 2) whether MTD CPA-induced transient immune response 
is due to long drug-free break or high CPA dose.  
Hypothesis:  
I hypothesize that CPA/6d may induce different immune cell or gene changes in 
peripheral blood or spleen in sensitive tumor-bearing mice than those in insensitive 
tumor-bearing mice. Further, CPA/6d may induce immune cell changes in peripheral 
blood different from those induced by MTD CPA. 
Results:  
  1) Overall similar level of anti-tumor immune responses were found between 
GL261 tumors 7 days after MTD-CPA treatment (157.5 mg/kg per injection at days 0 and 
1, followed by a 20-day drug-free break; same below) and GL261 tumors at day 6 and 7 
after the first CPA/6d injection (Fig. 5-13). Of note, lower expressions of CTL marker 
CD8a and immunosuppressive Treg cell marker Foxp3 were associated with MTD-CPA 
treatment. This suggest that higher CPA dose in MTD schedule does exert greater 
cytotoxicity than CPA/6d, which correspondingly leads to greater depletion and slower 
rebound of CTL and Treg cells than in CPA/6d-treated tumors. However, the expression 
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levels of other immune response marker genes were similar. These included NK cell 
marker Nkp46, NK cell and CTL shared effectors Prf1 and Gzmb, macrophage marker 
Emr1, immunostimulatory cytokine IL15, and IFNs responsive chemokine Cxcl11. 
Probably, NK cell anti-tumor activity was increased in response to MTD-CPA-mediated 
depletion of CTLs and Treg cells as observed before [57]. Overall these findings suggest 
that the high CPA dose on MTD schedule does not ablate CPA-induced anti-tumor 
immune responses. 
  2)  I found that CPA/6d-induced immune cell change kinetics in peripheral 
blood of GL261-bearing mice were significantly different from those induced by MTD-
CPA (Fig. 5-14A). Time course assay indicated that 6 days after the first CPA/6d 
injection, while CTL percentage of blood WBC remain unchanged, NK cell percentage 
decreased and macrophage and MDSC percentage increased. This is followed by 
increased CTL and NK cell percentage and decreased macrophage and MDSC percentage 
on day 7 (1 day after the second CPA injection), suggesting that expanded macrophage 
and MDSC are sensitive to the second CPA injection. In contrast, MTD-CPA increased 
macrophage and MDSC percentage of WBC and decreased CTL and NK cell percentage 
on day 7 (6 days after the second injection of MTD CPA). Overall the changes induced 
by MTD CPA on day 7 are greater than those at day 6 induced by the first CPA on 
CPA/6d schedule, consistent with higher CPA dose on MTD schedule. However, while 
the second CPA injection on CPA/6d schedule was given at day 7, the third CPA 
injection on MTD schedule that may potentially reduce macrophage and MDSC 
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proportion will not be given until on day 21. Thus, the high ratio of macrophage and 
MDSC over CTL and NK cells in peripheral blood of MTD CPA-treated mice will 
probably persist for much longer time than in CPA/6d-treated mice. These findings 
suggest that long drug-free break is one of the causes of transient immune responses 
induced by MTD-CPA. 
Comparison of above immune cell percentages in peripheral blood of CPA/6d-
treated tumor-free mice and GL261-bearing mice did not reveal significant differences 
(Fig. 5-14B). However, it is not clear whether CPA could induce differential responses 
between GL261-bearing mice and immune unresponsive LLC or B16F10 bearing mice.  
  3) Decrease and increase in spleen weight of mice treated by CPA may 
reflect the CPA cytotoxicity to mouse host and mouse recovery from cytotoxicity, 
respectively. Mouse spleen weight decreased significantly at days 1 and 3 after CPA/6d 
treatment or at days 2 and 4 after MTD-CPA treatment (Fig. 5-15), both of which were 
followed by a significant rebound at day 6 (CPA/6d) or day 7 (MTD-CPA). Spleen 
weights of GL261-bearing mice at day 7 (MTD CPA) were not significantly different 
from those of CPA/6d-treated mice at days 6 or 7. Of note, the spleen weight increase 
rate from MTD-CPA-treated mice (increase 101.2% from 26.8 mg at day 4 to 54.0 mg at 
day 7) is much greater than that of CPA/6d-treated mice (increase 54.1% from 44.4 mg at 
day 3 to 68.4 mg at day 6). Thus, while MTD-CPA-treated mouse spleen had greater 
weight decrease, MTD-CPA-treated mouse spleen seems recover at a faster rate than 
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CPA/6d-treated mice. Overall, these data suggest that MTD-CPA-treated mice might be 
able to sustain CPA chemotherapy with drug-free break much shorter than 20 days.  
  4) Spleen immune response to CPA treatment might be critical for the 
induction of anti-tumor responses seen in tumors. U251-bearing scid mice were treated 
by CPA(170)/6d, a metronomic CPA regimen similar to CPA/6d. I found that CPA 
induced three types of differential gene expression changes in spleen vs. in tumors (Fig. 
5-16A): 1) Early and transient up regulation in spleen at days 1 and 3 followed by 
decrease at day 6 after CPA treatment vs. only mild increase at days 3 and 6 in tumors, 
e.g., mIL15 and Emr1; 2) Early and sustained up regulation in spleen at days 1, 3, and 6 
vs. up regulation at days 3 and 6 in tumors after CPA treatment, e.g., Cxcl10 and 11; 3) 
Similar responses in spleen and tumors, e.g., Gzmb and Prf1. This suggests that 
metronomic CPA-induced early immune responses in spleen, such as mIL15, Emr1, 
Cxcl10 and Cxcl11 up regulation, are critical for stimulation of anti-tumor immune 
responses in tumors.  
However, similar CPA/6d regimen did not induce early up regulation of these 
immune stimulatory molecules in spleen of GL261-bearing B6 mice (Fig. 5-16B), 
suggesting that CPA-induced immune responses have different kinetics between scid and 
B6 mice.  
Future experiments:  
Study if MTD CPA can induce complete GL261 tumor regression in B6 mice. If 
it does, the immune cell change in peripheral blood induced by MTD CPA in GL261-
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bearing B6 mice may not be indicative of CPA-induced tumor regression. Otherwise, 
CPA-induced immune cell change in peripheral blood may be served as prognostic 
markers, and I need to sample a few additional points within a MTD cycle, i.e., days 14 
and 21 after CPA treatment, to reflect both immune responses in blood and tumors in the 
whole 21-day MTD CPA cycle. I may need to quantify absolute numbers of immune cell 
assayed. I may also do BrdU incorporation or apoptosis assay to confirm the differential 
cytotoxicity of CPA to different immune cell types. I may further study if CPA/6d can 
induce similar pattern of immune cell change in peripheral blood in CPA-unresponsive 
LLC or B16F10-bearing B6 mice.  
 
Section 4: Future plans 
Goal:  
Identify genes important for CPA/6d-induced tumor regression and immune 
responses using Crispr-Cas9-mediated mutagenesis.  
Background and approach:  
There are many cell types involved regarding how a particular tumor cell 
population interacts with stromal cells, gains survival advantage, and responds to CPA 
treatment, and it is challenging to identify all genes important for CPA/6d-induced tumor 
regression and immune responses using conventional approaches. Unbiased high-
throughput screen system is a good approach to this problem. However, in vitro systems 
usually do not fully represent the dynamics and complexity of in vivo tumors. On the 
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other hand, a mouse-based in vivo screen assay is usually limited by resources and 
technical difficulties of engineering a screen reporter, which make it very difficult to 
carry out a high-throughput in vivo screening.  
One approach to address this problem is to employ an unbiased genome-wide 
mutation in tumor cells. Each cell will ideally have one gene mutated and thus lose its 
function. If the gene mutated is important for tumor cell survival through interaction with 
stromal cells or by other mechanisms, this particular tumor cell will die, or vice versa. If 
the gene mutated is dispensable for survival but is required to sensitize tumor cell to 
chemotherapy-mediated killing, the tumor cell bearing this mutated gene will survive 
from chemotherapy, or vice versa.  
RNA interference(RNAi)-mediated gene knock down technology can be used to 
implement a largely unbiased genome-wide knock down screen [231], but has a relatively 
high level of off-target effects and variable knock down effects. Retrovirus-mediated 
insertion mutation can only knock out one genome copy of gene, thus is only useful for 
the haplo-insufficient genes or in haploid cells [232]. The recently developed CRISPR 
(clustered regularly interspaced short palindrome repeats)–associated nuclease Cas9 
technology provide a new set of genome-wide editing or LOF mutation tools [233-236]. 
Briefly, CRISPR is a DNA locus with an array of repetitive sequences interspaced by 
short non-repetitive sequences which are called spacers. Spacers could come from 
previous exposures of bacteriophage DNA fragments called “protospacer” in case of an 
original CRISPR from bacteria [237], or from synthesized oliogos that match the gene of 
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interest in case of a genome-editing tool.  A well characterized type II CRISPR from 
Streptococcus pyogenes SF370 includes a nuclease Cas9 and two non-coding crRNAs 
(CRISPR RNAs) (or one chimeric single guided RNA, sgRNA, in some modified 
versions) containing one or several spacers. The crRNA is transcribed as a pre-crRNA 
and processed into the mature crRNA by a host RNase III with the help of a separate 
trans-activating crRNA (tracrRNA) transcribed from the CRISPR locus. Then, mature 
crRNA:tracrRNA complex directs Cas9 to the target DNA of interest via Wastson-Crick 
base-pairing between individual spacer on the crRNA (or guided RNA in some articles) 
and the 20-bp protospacer sequence on the target. The protospacer sequence is followed 
by an NGG motif, termed the protospacer-adjacent motif, which results in a site selection 
of 23-bp sequences in total. Cas9-mediated cleavage of target DNA is then used to create 
a double-stranded break within the protospacer sequence, which causes frame shift 
insertion/deletion (indel) mutations that result in a LOF allele [234, 236].  
A method such as Golden Gate cloning enables one to construct massive gene-
targeting CRISPR cassettes easily on lentiviral vectors [238]. Lentiviral vectors can have 
a GFP transfection marker and an anti-puromycin selection marker. Each CRISPR 
cassette can be served as a distinct DNA barcode for each mutant cell and be counted in a 
mixed cell population using high-throughput sequencing. Thus, the CRISPR-Cas9 system 
can generate a pool of mutant cells each with one distinct gene mutated [234, 236].  
Take GL261 glioma tumor cells as one example. While tumors seeded with wild 
type GL261 cells are 100% cured by metronomic CPA treatment, some mutant GL261 
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cells will survive from metronomic CPA treatment and eventually be selected and 
enriched in rebound tumors if the mutated genes are important for CPA-mediated tumor 
regression. Candidate genes discovered in this manner could relate to drug uptake, tumor 
angiogenesis, DDR responses, anti-tumor immune responses, or other unknown pathways 
that contribute to metronomic CPA-induced tumor regression. Then, we may sort out 
tumor cells using the GFP marker and sequence the CRISPR cassette to see which 
spacers are enriched. The genes knocked out by spacers are essential for metronomic 
CPA-induced tumor regression. Then, we can do a single gene LOF mutation and expand 
the clone to confirm the resistance phenotype and study what related defect(s) enable it to 
confer resistance to tumor regression.   
Applying same mutation-based screen approach to metronomic CPA 
unresponsive B16-F10 melanoma or LLC lewis lung carcinoma cells, we may negatively 
select mutant clones that confer sensitivity to metronomic CPA treatment. Different from 
CPA responsive GL261 tumor cells, these LOF B16-F10 or LLC clones will be depleted 
during metronomic CPA treatment. By recovering survived mutant cells treated by CPA 
and comparing them with untreated mutant pools, we may find the specific spacers that 
are depleted. Correspondingly, the genes knocked out by these spacers are responsible to 
unresponsiveness to metronomic CPA treatment in these two tumor models. 
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Fig. 5-1 CPA/6d-induced senescence-associated beta-galactosidase is expressed in 
insensitive tumors (PC3 and MDA-MB-231 tumors) but not in sensitive tumors (9L 
and GL261 tumors).  
Beta-galactosidase staining was done on cryo-section made from 2 to 3 regions from each tumor. 
From 2 to 4 tumors untreated or treated with CPA/6d were assayed, respectively. 
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Fig. 5-2. Cytokines and chemokine genes significantly changed in U251 tumors. 
Data were extracted by microarray analysis at d6 after second or third CPA treatment (what 
shown is at d6 after third CPA) in U251 tumors (p Value < 0.0001; Fold change > 1.5). Tumor-
expressed CXCL9, 10, 11 (ligands) and mouse Cxcr3 (receptor) and Cx3cl1, CCL26 (ligands) 
and Cx3cr1 (receptor), important for NK cell recruitment, are highlighted by blue or red 
underline, respectively. 
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Fig. 5-3. CPA/6d up regulated tumor-expressed CXCL10 and CXCL11 gene 
expression.  
(A)Tumor CXCL10 and CXCL11 gene expression is up regulated by the CPA/6d treatment in 
sensitive U251 and 9L tumors but not in insensitive KM12 and PC3 tumors. (B) CXCL10 and 
CXCL11-specific chemo-receptor Cxcr3 gene expression is up regulated in CPA/6d-treated U251 
and 9L tumors. (C) Tumor CXCL10 and CXCL11 gene expression are persistently up regulated 
by CPA/6d (Metro CPA, red arrow) treatment but only transiently up regulated by MTD CPA 
(150 mg/kg, blue arrow) treatment in the U251 tumors. 
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Fig.5-4. The expression of Nkp46 and Gzmb and tumor regression in CPA/6d-
treated GL261 tumors in Cxcr3 KO mice.  
NK cell marker Nkp46 and NK cell activation marker Gzmb expression and tumor regression 
were not compromised in CPA/6d-treated GL261 tumors in Cxcr3 KO mice. Chemokine Cxcl9 
and Cxcl11 expression was highly up regulated by CPA treatment. 
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Fig. 5-5. The expression of Cx3cr1 was induced in GL261 and U251 tumors but not 
in 9L tumors by CPA/6d treatment. 
Cx3cr1, a chemoreceptor specific for Cx3cl1 and CCL26, were highly induced by CPA treatment 
in sensitive tumors.  
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Fig. 5-6. qPCR analysis of adhesion molecules in CPA-treated GL261, 9L, and U251 
tumors. 
Vcam1 is up regulated by CPA/6d in GL261 (A), 9L (B), and U251 (C) tumors in scid mice and 
suppressed by DC101 in both 9L tumors (B) and U251 tumors (C) and by axitinib (AG) in U251 
tumor (C). Icam2 expression is not changed by CPA but is suppressed by axitinib and DC101 (B, 
C).  
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Fig. 5-7. qPCR analysis of CPA-induced tumor CXCL10 and CXCL11 gene 
expression in U251 tumors in scid mice.  
Co-treatment of axitinib (A) suppresses the relative fold change of up regulation of tumor-
expressed CXCL10 and CXCL11 but DC101 (B) does not. Tumor sampling days were shown on 
X-axis as days after CPA treatment. One the right, blue and red arrows indicates DC101 and CPA 
treatments, respectively. 
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Fig. 5-8. qPCR analysis of immune marker gene expression in U251 tumors treated 
with metronomic CPA or combination treatment of CPA and DC101.  
DC101 did not suppress the CPA-induced immune cell recruitment (NK cells: Nkp46; dendritic 
cells, CD74; macrophages: CD68) but suppress tumor cell stress molecule MICB expression, NK 
cell activation (Prf1 and Gzmb) and the expression of mouse IL15, Tlr7 and Tlr9, molecules 
important for immune responses. Shown are relative fold changes normalized to untreated 
tumors. 
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Fig. 5-9. IHC staining shows that HMGB1 is enriched in the cytoplasm of CPA-
treated GL261 tumors.  
HMGB1 is an immunogenic cell death marker. Black rectangular region from CPA-treated tumor 
was enlarged below. HMGB1 cytoplasmic staining is indicated by red arrows. 
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Fig. 5-10. DC101 improved CPA(90)/6d efficacy in treating GL261 tumors in B6 
mice.  
(A) DC101 alone only slightly delay GL261 tumor growth; (B,C) A subset of GL261 tumor (5 
out of 14) escaped CPA(90)/6d treatment. Combination CPA(90)/6d with DC101, either 10 (L-
DC101) or 28.6 mg/kg (H-DC101) regimen led to sustained tumor regression without tumor 
escape. 
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Fig. 5-11. Non-anti-angiogenesis DC101 doses did not block CPA-induced immune 
responses.  
(A) DC101, either 28.6 or 10 mg/kg, did not block the CPA(90)/6d-induced Nkp46, Prf1 and Cd8 
expression in GL261 tumors in B6 mice. (B) CD31 IHC staining indicated that DC101 did not 
induce anti-angiogenesis effects in GL261 tumors by day 12 after treatment. 
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Fig. 5-12. Diagrams showing possibilities of DC101-mediated perturbation to CPA-
induced immune responses and tumor regression. 
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Fig. 5-13. qPCR analysis of immune marker gene expression in tumors treated by 
CPA/6d or MTD CPA.  
MTD CPA (157.5 mg/kg per injection at days 0 and 1, blue arrow) induced overall similar anti-
tumor immune responses to those induced by CPA/6d (140 mg/kg per injection at days 0 and 6, 
red arrow). Tumors were excised at days 1, 3, 6, and 7 after CPA/6d treatment or at days 2, 4, and 
7 after MTD CPA treatment indicated as x sign in diagrams. 
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Fig. 5-14. Facs analysis of CTL, NK cell, macrophage, and MDSC percentage in 
peripheral blood WBC.  
Mice were treated and sampled as shown in Fig. 5-13. (A) GL261-bearing mice treated with 
CPA/6d or MTD CPA. Untreated mice were shared. (B) Comparison of CPA/6d-treated GL261-
bearing mice with tumor-free mice did not show significant difference. 
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Fig.5-15. Mouse spleen weight changes after CPA/6d or MTD CPA treatment.  
Mice treatment and spleen weight measurement timing were same as in Fig. 5-13. One way 
Anova analysis, ns, p > 0.05; **, p < 0.01; ***, p < 0.001. No significant differences were found 
when spleen weight at day 7 of MTD CPA treatment was compared with those of days 6 or 7 
after CPA/6d treatment. 
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Fig. 5-16. qPCR analysis of immune marker gene expression in spleen or tumors 
from U251-bearing mice  
(A) U251-bearing mice were treated with CPA(170)/6d or GL261-bearing mice (B) treated with 
CPA/6d (CPA-140) or MTD CPA. 
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APPENDIX 
App. 4-1. Signficant gene responses induced by metronomic CPA treatment in four 
different tumor models.   
This appendix and all other 12 appendices are for chapter 4 and provided as 
supplementary files. They are also available upon request.  
Shown are differentially expressed genes between CPA-treated and control (drug-
free) tumors at |FC| > 2 and p-value < 0.001 for GL261(B6) (A), LLC (B), B16F10 (C), 
GL261(scid) tumors (D) (CPA/6d), GL261(scid) tumors (E) (CPA/9d), and GL261(scid) 
tumors (F) (common to CPA/6d and CPA/9d treatment), respectively. See Fig. 4-1 for 
analysis diagram. TFS, total flag sum, indicates the pattern of regulation by CPA in each 
model, with TFS values of 1.1 or 1.2 indicating significant up or down regulation, 
respectively. See venn diagram on Fig. 4-2 for the gene number responded to CPA 
treatment in above models. 
App. 4-2. All CPA-induced upstream regulators (UPRs) in GL261(B6) (A), LLC (B), 
and B16F10 (C), GL261(scid) (D) (CPA/6d), and GL261(scid) (E) (CPA/9d), 
respectively.  
UPRs were identified by IPA based on all significantly up- and down-regulated 
genes shown in App. 4-1A-E, respectively, as described in Methods. Chemical UPRs 
(except endogenous mammalian chemicals) and group UPRs identified by IPA were 
excluded. In few cases where two UPRs with same name, e.g., one from human another 
from mouse, were identified, the UPR with higher activation score was kept. FC, gene 
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fold-change values induced by CPA, if available, for the upstream regulator itself; 
Mechanistic networks, the total number of target genes in each such network and the 
number of upstream regulators in each network in parenthesis. 
App. 4-3. CPA-induced significant UPRs in GL261(B6) (A), LLC (B), and B16F10 (C), 
GL261(scid) (D) (CPA/6d), GL261(scid) (E) (CPA/9d), and GL261(scid) tumors (F) 
(common to CPA/6d and CPA/9d treatment), respectively.  
UPRs were identified by IPA based on all significantly up- and down-regulated 
genes shown in App. 4-1A-E, respectively, as described in Methods. Default UPR lists 
were in App. 4-2A-E. Shown are the significant UPRs that meet the stringent threshold of 
both bias-corrected z-score and activation z-score > 2, # of target genes > 10, and p-value 
of overlap < E-04 with the target gene set. FC, gene fold-change values induced by CPA, 
if available, for the upstream regulator itself; Mechanistic networks, the total number of 
target genes in each such network and the number of upstream regulators in each network 
in parenthesis. 
App. 4-4. KEGG pathways enriched in up regulated or down regulated genes by CPA 
treatment in GL261(B6) (A), LLC (B), and B16F10 (C) tumors, respectively. 
App. 4-5. Comparisons of 124 negative regulators of immune response with various 
gene sets.  
(A) List of 124 negative regulators of immune response. (B-F) Comparisons to 
genes significantly responded to CPA in GL261(B6) tumors (B), LLC (C), B16F10 
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tumors (D), genes expressed at a higher or lower level in untreated GL261(B6) tumors 
than LLC and B16F10 tumors (E), and genes expressed at a higher or lower level in 
CPA-treated GL261(B6) tumors than LLC and B16F10 tumors (F). (G) summary of 
comparisons in App. 4-5A-F. See diagrams on Fig. 4-6. 
App. 4-6. Differential gene responses and KEGG pathways or DAVID clusters induced 
by CPA in GL261(B6), LLC, and B16F10 model.  
Significance cut off values: |FC| > 2; p < 0.001; Stringency filter between 
repsonsive and unresponsive tumor model: > 2 |FC|. (A) 1153 genes showing significant 
up regulation by CPA and stringent in GL261(B6) model relative to LLC and B16F10 
models, including TFS: 1.100, 3.120, 5.102;  (B) 322 genes showing significant down 
regulation by CPA and stringent in GL261(B6) model relative to LLC and B16F10 
models, including TFS: 1.200, 3.210, 5.201, 7.211; (C) 6 genes showing significant up 
regulation by CPA and stringent in LLC and B16F10 models relative to GL261(B6) 
model, including TFS: 6.011, 7.211; (D) 16 genes showing significant up regulation by 
CPA in all 3 models, including TFS: 7.111. No significantly down regulated and stringent 
in LLC and B16F10 models were found; (E) KEGG pathways enriched in genes up 
regulated by CPA significantly and stringently only in GL261(B6) model relative to LLC 
and B16F10 models; (F) Comparisons of three KEGG pathways induced by CPA in 
GL261(B6)  tumors before (App. 4-4A) and after (App. 4-6E) filtering out CPA 
responsive genes detected in LLC and B16F10 models; (G) KEGG pathway enriched in 
genes down regulated by CPA significantly and stringently only in GL261(B6) model 
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relative to LLC and B16F10 model;  (H) DAVID Clusters enriched in 16 genes up 
regulated by CPA in all 3 models in B6 mice. See diagrams on Fig. 4-2A and Fig. 4-3. 
App. 4-7. Gene expressed significantly higher or lower in untreated GL261(B6) tumors 
than both untreated LLC and B16F10 tumors and their responses to CPA. Significance 
cut off values: |FC|>2, p<0.001. See venn diagrams for distribution of numbers of gene 
responded differentially on Fig. 4-5. 
App. 4-8. KEGG pathway or DAVID clusters enriched in genes expressed at a higher 
or lower level in untreated GL261(B6) tumors than those in LLC and B16F10 tumors 
and the genes responded to CPA treatment. 
App. 4-9. List of genes expressed higher or lower in CPA-treated GL261(B6) tumors 
than both CPA-treated LLC and B16F10 tumors and corresponding KEGG pathways 
that enriched in these genes. 
App. 4-10. Differential gene responses to CPA in GL261(scid) and GL261(B6) models.  
Comparisons were done primarily between GL261(B6) and GL261(scid) tumors 
treated with CPA/6d schedule. However, to increase robustness, the genes responded to 
CPA/6d schedule in GL261(scid) tumors but did not respond to CPA/9d schedule 
significantly were excluded from the responsiveness of GL261(scid) tumors to CPA/6d 
schedule. See Method and diagram on Fig. 4-1 and Fig. 4-4 for details. Significance cut 
off values: |FC| > 2; p < 0.001; Stringency filter between GL261(scid) and GL261(B6) 
tumor model: > 2 |FC|. (A) 1,567 genes showing significant up (TFS: 7.111) regulation 
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by CPA in both models. (B) 631 genes (TFS: 7.222) showing significant down regulation 
by CPA in both models. (C) 372 genes (TFS: 3.110, highlighted in blue) that were up 
regulated significantly by CPA and (D) 38 genes (TFS: 3.220, 7.221, highlighted in blue) 
that were down regulated significantly by CPA in GL261(scid) tumors with at least a 2-
fold greater response than those in GL261(B6) tumors; (E) 130 genes (TFS: 4.001, 6.021, 
5.201, 7.221, highlighted in blue) were significantly up regulated and (F) 24 genes (TFS: 
4.002, highlighted in blue) were significantly down regulated in  GL261(B6) tumors with 
at least a 2-fold greater response than those in in GL261(scid) tumors. 
App. 4-11. KEGG pathways enriched in genes commonly or differentially expressed in 
GL261(B6) and GL261(scid) tumors in response to CPA treatment. 
App. 4-12. Differential gene responses in GL261(scid) tumors induced by CPA/9d or 
CPA/6d treatment. 
App. 4-13. KEGG pathway or DAVID cluster associated with differential gene 
responses in GL261(scid) tumors induced by CPA/9d or CPA/6d treatment. 
 See App. 4-12 for genes. 
 
 
 
 
 
 
 
 
  
 211 
 
 
REFERENCE 
1. DuPage, M., et al., Expression of tumour-specific antigens underlies cancer 
immunoediting. Nature, 2012. 482(7385): p. 405-9. 
2. Beatty, P.L., S. Cascio, and E. Lutz, Tumor immunology: basic and clinical 
advances. Cancer Research, 2011. 71(13): p. 4338-43. 
3. Stewart, T.J. and S.I. Abrams, How tumours escape mass destruction. Oncogene, 
2008. 27(45): p. 5894-903. 
4. Chen, Z.S. and A.K. Tiwari, Multidrug resistance proteins (MRPs/ABCCs) in 
cancer chemotherapy and genetic diseases. FEBS Journal, 2011. 278(18): p. 
3226-45. 
5. Zitvogel, L., et al., Mechanism of action of conventional and targeted anticancer 
therapies: reinstating immunosurveillance. Immunity, 2013. 39(1): p. 74-88. 
6. Kreso, A., et al., Variable clonal repopulation dynamics influence chemotherapy 
response in colorectal cancer. Science, 2013. 339(6119): p. 543-8. 
7. Scherz-Shouval, R., et al., The reprogramming of tumor stroma by HSF1 is a 
potent enabler of malignancy. Cell, 2014. 158(3): p. 564-78. 
8. Gilbert, L.A. and M.T. Hemann, DNA damage-mediated induction of a 
chemoresistant niche. Cell, 2010. 143(3): p. 355-66. 
9. Squatrito, M. and E.C. Holland, DNA damage response and growth factor 
signaling pathways in gliomagenesis and therapeutic resistance. Cancer 
Research, 2011. 71(18): p. 5945-9. 
10. Sadun, R.E., et al., Immune signatures of murine and human cancers reveal 
unique mechanisms of tumor escape and new targets for cancer immunotherapy. 
Clinical Cancer Researchearch, 2007. 13(13): p. 4016-25. 
11. McAllister, S.S. and R.A. Weinberg, The tumour-induced systemic environment 
as a critical regulator of cancer progression and metastasis. Nature Cell Biology, 
2014. 16(8): p. 717-27. 
12. Marais, R., et al., Twenty-fourth annual Pezcoller symposium: Molecular basis 
for resistance to targeted agents. Cancer Research, 2013. 73(3): p. 1046-9. 
 212 
 
13. Spranger, S., et al., Up-regulation of PD-L1, IDO, and T(regs) in the melanoma 
tumor microenvironment is driven by CD8(+) T cells. Science Translational 
Medicine, 2013. 5(200): p. 200ra116. 
14. Iannello, A., et al., p53-dependent chemokine production by senescent tumor cells 
supports NKG2D-dependent tumor elimination by natural killer cells. The Journal 
of Experimental Medicine, 2013. 210(10): p. 2057-69. 
15. Fridlender, Z.G., et al., Polarization of tumor-associated neutrophil phenotype by 
TGF-beta: "N1" versus "N2" TAN. Cancer Cell, 2009. 16(3): p. 183-94. 
16. Lujambio, A., et al., Non-cell-autonomous tumor suppression by p53. Cell, 2013. 
153(2): p. 449-60. 
17. Reimann, M., C.A. Schmitt, and S. Lee, Non-cell-autonomous tumor suppression: 
oncogene-provoked apoptosis promotes tumor cell senescence via stromal 
crosstalk. Journal of molecular medicine (Berl), 2011. 89(9): p. 869-75. 
18. Tsuyada, A., et al., CCL2 mediates cross-talk between cancer cells and stromal 
fibroblasts that regulates breast cancer stem cells. Cancer Research, 2012. 
72(11): p. 2768-79. 
19. Barone, I., et al., Leptin mediates tumor-stromal interactions that promote the 
invasive growth of breast cancer cells. Cancer Research, 2012. 72(6): p. 1416-27. 
20. Vail, M.E., et al., Targeting EphA3 inhibits cancer growth by disrupting the 
tumor stromal microenvironment. Cancer Research, 2014. 74(16): p. 4470-81. 
21. Franciszkiewicz, K., et al., Role of chemokines and chemokine receptors in 
shaping the effector phase of the antitumor immune response. Cancer Research, 
2012. 72(24): p. 6325-32. 
22. Martin, O.A., et al., Para-inflammation mediates systemic DNA damage in 
response to tumor growth. Communicative & Integrative Biology, 2011. 4(1): p. 
78-81. 
23. Isenberg, J.S., et al., Hematopoietic stem cells mobilization and immune response 
in tumor-bearing mice. Annals of Plastic Surgery, 2004. 52(5): p. 523-30; 
discussion 531. 
 213 
 
24. Schreiber, R.D., L.J. Old, and M.J. Smyth, Cancer immunoediting: integrating 
immunity's roles in cancer suppression and promotion. Science, 2011. 331(6024): 
p. 1565-70. 
25. Lechner, M.G., et al., Chemokines, costimulatory molecules and fusion proteins 
for the immunotherapy of solid tumors. Immunotherapy, 2011. 3(11): p. 1317-40. 
26. Zhu, Y., et al., CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating 
Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in 
Pancreatic Cancer Models. Cancer Research, 2014. 74(18): p. 5057-69. 
27. Colegio, O.R., et al., Functional polarization of tumour-associated macrophages 
by tumour-derived lactic acid. Nature, 2014. 513(7519): p. 559-63. 
28. Noy, R. and J.W. Pollard, Tumor-associated macrophages: from mechanisms to 
therapy. Immunity, 2014. 41(1): p. 49-61. 
29. Coppe, J.P., et al., The senescence-associated secretory phenotype: the dark side 
of tumor suppression. Annual Review of Pathology Mechanisms of Disease, 
2010. 5: p. 99-118. 
30. Shaked, Y., et al., Therapy-induced acute recruitment of circulating endothelial 
progenitor cells to tumors. Science, 2006. 313(5794): p. 1785-7. 
31. Gingis-Velitski, S., et al., Host response to short-term, single-agent chemotherapy 
induces matrix metalloproteinase-9 expression and accelerates metastasis in 
mice. Cancer Research, 2011. 71(22): p. 6986-96. 
32. Zitvogel, L., et al., Immunological aspects of cancer chemotherapy. Nature 
Reviews Immunology, 2008. 8(1): p. 59-73. 
33. Zitvogel, L., O. Kepp, and G. Kroemer, Immune parameters affecting the efficacy 
of chemotherapeutic regimens. Nature Reviews Clinical Oncology, 2011. 8(3): p. 
151-60. 
34. Obeid, M., et al., Calreticulin exposure dictates the immunogenicity of cancer cell 
death. Nature Medicine, 2007. 13(1): p. 54-61. 
35. Schiavoni, G., et al., Cyclophosphamide synergizes with type I interferons 
through systemic dendritic cell reactivation and induction of immunogenic tumor 
apoptosis. Cancer Research, 2011. 71(3): p. 768-78. 
 214 
 
36. Martins, I., et al., Surface-exposed calreticulin in the interaction between dying 
cells and phagocytes. Annals of the New York Academy of Sciences, 2010. 1209: 
p. 77-82. 
37. Spisek, R., et al., Bortezomib enhances dendritic cell (DC)-mediated induction of 
immunity to human myeloma via exposure of cell surface heat shock protein 90 on 
dying tumor cells: therapeutic implications. Blood, 2007. 109(11): p. 4839-45. 
38. Apetoh, L., et al., Toll-like receptor 4-dependent contribution of the immune 
system to anticancer chemotherapy and radiotherapy. Nature Medicine, 2007. 
13(9): p. 1050-9. 
39. Ghiringhelli, F., et al., Activation of the NLRP3 inflammasome in dendritic cells 
induces IL-1beta-dependent adaptive immunity against tumors. Nature Medicine, 
2009. 15(10): p. 1170-8. 
40. Zitvogel, L., A. Tesniere, and G. Kroemer, Cancer despite immunosurveillance: 
immunoselection and immunosubversion. Nature Reviews Immunology, 2006. 
6(10): p. 715-27. 
41. Gasser, S., et al., The DNA damage pathway regulates innate immune system 
ligands of the NKG2D receptor. Nature, 2005. 436(7054): p. 1186-90. 
42. Soriani, A., et al., ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D 
ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-
cell susceptibility and is associated with a senescent phenotype. Blood, 2009. 
113(15): p. 3503-11. 
43. Fine, J.H., et al., Chemotherapy-induced genotoxic stress promotes sensitivity to 
natural killer cell cytotoxicity by enabling missing-self recognition. Cancer 
Research, 2010. 70(18): p. 7102-13. 
44. Ramakrishnan, R., et al., Autophagy induced by conventional chemotherapy 
mediates tumor cell sensitivity to immunotherapy. Cancer Research, 2012. 72(21): 
p. 5483-93. 
45. van der Most, R.G., et al., Cyclophosphamide chemotherapy sensitizes tumor cells 
to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression 
of tumor growth. PLoS One, 2009. 4(9): p. e6982. 
 215 
 
46. Penel, N., A. Adenis, and G. Bocci, Cyclophosphamide-based metronomic 
chemotherapy: after 10 years of experience, where do we stand and where are we 
going? Critical Reviews in Oncology/Hematology, 2012. 82(1): p. 40-50. 
47. Moschella, F., et al., Unraveling cancer chemoimmunotherapy mechanisms by 
gene and protein expression profiling of responses to cyclophosphamide. Cancer 
Research, 2011. 71(10): p. 3528-39. 
48. Moschella, F., et al., Cyclophosphamide induces a type I interferon-associated 
sterile inflammatory response signature in cancer patients' blood cells: 
implications for cancer chemoimmunotherapy. Clinical Cancer Research, 2013. 
19(15): p. 4249-61. 
49. Ghiringhelli, F., et al., Metronomic cyclophosphamide regimen selectively 
depletes CD4+CD25+ regulatory T cells and restores T and NK effector 
functions in end stage cancer patients. Cancer Immunology, Immunotherapy, 
2007. 56(5): p. 641-8. 
50. Chen, G. and L.A. Emens, Chemoimmunotherapy: reengineering tumor immunity. 
Cancer Immunology, Immunotherapy, 2013. 62(2): p. 203-16. 
51. Bracci, L., et al., Immune-based mechanisms of cytotoxic chemotherapy: 
implications for the design of novel and rationale-based combined treatments 
against cancer. Cell Death & Differentiation, 2014. 21(1): p. 15-25. 
52. Vacchelli, E., et al., Trial Watch: Chemotherapy with immunogenic cell death 
inducers. Oncoimmunology, 2014. 3(1): p. e27878. 
53. Tesniere, A., et al., Immunogenic death of colon cancer cells treated with 
oxaliplatin. Oncogene, 2010. 29(4): p. 482-91. 
54. Fucikova, J., et al., Human tumor cells killed by anthracyclines induce a tumor-
specific immune response. Cancer Research, 2011. 71(14): p. 4821-33. 
55. Doloff, J.C. and D.J. Waxman, VEGF receptor inhibitors block the ability of 
metronomically dosed cyclophosphamide to activate innate immunity-induced 
tumor regression. Cancer Research, 2012. 72(5): p. 1103-15. 
56. Chen, C.S., J.C. Doloff, and D.J. Waxman, Intermittent metronomic drug 
schedule is essential for activating antitumor innate immunity and tumor 
xenograft regression. Neoplasia, 2014. 16(1): p. 84-96. 
 216 
 
57. Wu, J. and D.J. Waxman, Metronomic cyclophosphamide schedule-dependence of 
innate immune cell recruitment and tumor regression in an implanted glioma 
model. Cancer Letters, 2014. 353(2): p. 272-80. 
58. Doloff, J.C., C.S. Chen, and D.J. Waxman, Anti-tumor innate immunity activated 
by intermittent metronomic cyclophosphamide treatment of 9L brain tumor 
xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2. 
Molecular Cancer, 2014. 13: p. 158. 
59. Jia, L. and D.J. Waxman, Thrombospondin-1 and pigment epithelium-derived 
factor enhance responsiveness of KM12 colon tumor to metronomic 
cyclophosphamide but have disparate effects on tumor metastasis. Cancer Letters, 
2013. 330(2): p. 241-9. 
60. Chen, J., et al., Preconditioning chemotherapy with cisplatin enhances the 
antitumor activity of cytokine-induced killer cells in a murine melanoma model. 
Cancer Biotherapy and Radiopharmaceuticals, 2012. 27(3): p. 210-20. 
61. Tanaka, H., et al., Classification of chemotherapeutic agents based on their 
differential in vitro effects on dendritic cells. Cancer Research, 2009. 69(17): p. 
6978-86. 
62. Emadi, A., R.J. Jones, and R.A. Brodsky, Cyclophosphamide and cancer: golden 
anniversary. Nature Reviews Clinical Oncology, 2009. 6(11): p. 638-47. 
63. Lien, K., et al., Low-dose metronomic chemotherapy: a systematic literature 
analysis. European Journal of Cancer, 2013. 49(16): p. 3387-95. 
64. Wada, S., et al., Cyclophosphamide augments antitumor immunity: studies in an 
autochthonous prostate cancer model. Cancer Research, 2009. 69(10): p. 4309-
18. 
65. Tongu, M., et al., Metronomic chemotherapy with low-dose cyclophosphamide 
plus gemcitabine can induce anti-tumor T cell immunity in vivo. Cancer 
Immunology, Immunotherapy, 2013. 62(2): p. 383-91. 
66. Peng, S., et al., Low-dose cyclophosphamide administered as daily or single dose 
enhances the antitumor effects of a therapeutic HPV vaccine. Cancer 
Immunology, Immunotherapy, 2013. 62(1): p. 171-82. 
67. Malvicini, M., et al., Single low-dose cyclophosphamide combined with 
interleukin-12 gene therapy is superior to a metronomic schedule in inducing 
 217 
 
immunity against colorectal carcinoma in mice. Oncoimmunology, 2012. 1(7): p. 
1038-1047. 
68. Stathopoulos, A., et al., Development of immune memory to glial brain tumors 
after tumor regression induced by immunotherapeutic Toll-like receptor 7/8 
activation. Oncoimmunology, 2012. 1(3): p. 298-305. 
69. Wu, J. and D.J. Waxman, Metronomic cyclophosphamide eradicates large 
implanted GL261 gliomas by activating antitumor Cd8
+
 T cell responses and 
immune memory. Oncoimmunology, 2015. 
70. Wu, J. and D.J. Waxman, Metronomic cyclophosphamide schedule-dependence of 
innate immune cell recruitment and tumor regression in an implanted glioma 
model. Cancer Letters, 2014. 
71. O'Connor, R., A review of mechanisms of circumvention and modulation of 
chemotherapeutic drug resistance. Current Cancer Drug Targets, 2009. 9(3): p. 
273-80. 
72. Palucka, K. and J. Banchereau, Cancer immunotherapy via dendritic cells. Nature 
Reviews Cancer, 2012. 12(4): p. 265-77. 
73. Restifo, N.P., M.E. Dudley, and S.A. Rosenberg, Adoptive immunotherapy for 
cancer: harnessing the T cell response. Nature Reviews Immunology, 2012. 
12(4): p. 269-81. 
74. Herber, D.L., et al., Mechanism and therapeutic reversal of immune suppression 
in cancer. Cancer Research, 2007. 67(11): p. 5067-9. 
75. Butt, A.Q. and K.H. Mills, Immunosuppressive networks and checkpoints 
controlling antitumor immunity and their blockade in the development of cancer 
immunotherapeutics and vaccines. Oncogene, 2014. 33(38): p. 4623-31. 
76. Melero, I., et al., Clinical development of immunostimulatory monoclonal 
antibodies and opportunities for combination. Clinical Cancer Research, 2013. 
19(5): p. 997-1008. 
77. Nguyen, A., L. Ho, and Y. Wan, Chemotherapy and Oncolytic Virotherapy: 
Advanced Tactics in the War against Cancer. Frontiers in Oncology, 2014. 4: p. 
145. 
 218 
 
78. Sistigu, A., et al., Immunomodulatory effects of cyclophosphamide and 
implementations for vaccine design. Seminars in Immunopathology, 2011. 33(4): 
p. 369-83. 
79. Ugel, S., et al., Therapeutic targeting of myeloid-derived suppressor cells. Current 
Opinion in Pharmacology, 2009. 9(4): p. 470-81. 
80. Machiels, J.P., et al., Cyclophosphamide, doxorubicin, and paclitaxel enhance the 
antitumor immune response of granulocyte/macrophage-colony stimulating 
factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer 
Research, 2001. 61(9): p. 3689-97. 
81. Banissi, C., et al., Treg depletion with a low-dose metronomic temozolomide 
regimen in a rat glioma model. Cancer Immunology, Immunotherapy, 2009. 
58(10): p. 1627-34. 
82. Salem, M.L., et al., Recovery from cyclophosphamide-induced lymphopenia 
results in expansion of immature dendritic cells which can mediate enhanced 
prime-boost vaccination antitumor responses in vivo when stimulated with the 
TLR3 agonist poly(I:C). The Journal of Immunology, 2009. 182(4): p. 2030-40. 
83. Radojcic, V., et al., Cyclophosphamide resets dendritic cell homeostasis and 
enhances antitumor immunity through effects that extend beyond regulatory T cell 
elimination. Cancer Immunology, Immunotherapy, 2010. 59(1): p. 137-48. 
84. Lasalvia-Prisco, E., et al., Addition of an induction regimen of antiangiogenesis 
and antitumor immunity to standard chemotherapy improves survival in advanced 
malignancies. Medical Oncology, 2012. 29(5): p. 3626-33. 
85. Ellebaek, E., et al., Metastatic melanoma patients treated with dendritic cell 
vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a 
phase II trial. Cancer Immunology, Immunotherapy, 2012. 61(10): p. 1791-804. 
86. Emens, L.A., et al., Timed sequential treatment with cyclophosphamide, 
doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating 
factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial 
study of safety and immune activation. Journal of Clinical Oncology, 2009. 
27(35): p. 5911-8. 
87. Laheru, D., et al., Allogeneic granulocyte macrophage colony-stimulating factor-
secreting tumor immunotherapy alone or in sequence with cyclophosphamide for 
 219 
 
metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune 
activation. Clinical Cancer Research, 2008. 14(5): p. 1455-63. 
88. Connor, J.P., et al., A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) 
immunocytokine with cyclophosphamide in patients with EpCAM-positive 
advanced solid tumors. BMC Cancer, 2013. 13: p. 20. 
89. Filipazzi, P., et al., Limited induction of tumor cross-reactive T cells without a 
measurable clinical benefit in early melanoma patients vaccinated with human 
leukocyte antigen class I-modified peptides. Clinical Cancer Research, 2012. 
18(23): p. 6485-96. 
90. Greten, T.F., et al., A phase II open label trial evaluating safety and efficacy of a 
telomerase peptide vaccination in patients with advanced hepatocellular 
carcinoma. BMC Cancer, 2010. 10: p. 209. 
91. Loven, D., et al., Low-dose metronomic chemotherapy: from past experience to 
new paradigms in the treatment of cancer. Drug Discovery Today, 2013. 18(3-4): 
p. 193-201. 
92. Di Giacomo, A.M., M. Biagioli, and M. Maio, The emerging toxicity profiles of 
anti-CTLA-4 antibodies across clinical indications. Seminars in Oncology, 2010. 
37(5): p. 499-507. 
93. Liseth, K., et al., Combination of intensive chemotherapy and anticancer vaccines 
in the treatment of human malignancies: the hematological experience. Journal of 
Biomedicine and Biotechnology, 2010. 2010: p. 692097. 
94. Kerbel, R.S. and B.A. Kamen, The anti-angiogenic basis of metronomic 
chemotherapy. Nature Reviews Cancer, 2004. 4(6): p. 423-36. 
95. Browder, T., et al., Antiangiogenic scheduling of chemotherapy improves efficacy 
against experimental drug-resistant cancer. Cancer Research, 2000. 60(7): p. 
1878-86. 
96. Ma, J. and D.J. Waxman, Combination of antiangiogenesis with chemotherapy for 
more effective cancer treatment. Molecular Cancer Therapeutics, 2008. 7(12): p. 
3670-84. 
97. Holbeck, S.L., Update on NCI in vitro drug screen utilities. European Journal of 
Cancer, 2004. 40(6): p. 785-93. 
 220 
 
98. Borg, C., et al., Novel mode of action of c-kit tyrosine kinase inhibitors leading to 
NK cell-dependent antitumor effects. Journal of Clinical Investigation, 2004. 
114(3): p. 379-88. 
99. Balachandran, V.P., et al., Imatinib potentiates antitumor T cell responses in 
gastrointestinal stromal tumor through the inhibition of Ido. Nature Medicine, 
2011. 17(9): p. 1094-100. 
100. Martins, I., et al., Restoration of the immunogenicity of cisplatin-induced cancer 
cell death by endoplasmic reticulum stress. Oncogene, 2011. 30(10): p. 1147-58. 
101. Lechner, M.G., et al., Immunogenicity of murine solid tumor models as a defining 
feature of in vivo behavior and response to immunotherapy. Journal of 
Immunotherapy, 2013. 36(9): p. 477-89. 
102. Chen, J., et al., A restricted cell population propagates glioblastoma growth after 
chemotherapy. Nature, 2012. 488(7412): p. 522-6. 
103. Marusyk, A., et al., Non-cell-autonomous driving of tumour growth supports sub-
clonal heterogeneity. Nature, 2014. 
104. Burrell, R.A., et al., The causes and consequences of genetic heterogeneity in 
cancer evolution. Nature, 2013. 501(7467): p. 338-345. 
105. Barkholt, L. and M. Bregni, Current immunotherapy for solid tumors. 
Immunotherapy, 2009. 1(3): p. 483-93. 
106. Gajewski, T.F., et al., Molecular profiling to identify relevant immune resistance 
mechanisms in the tumor microenvironment. Current Opinion in Immunology, 
2011. 23(2): p. 286-92. 
107. Kandalaft, L.E., et al., The emergence of immunomodulation: combinatorial 
immunochemotherapy opportunities for the next decade. Gynecologic Oncology, 
2010. 116(2): p. 222-33. 
108. Ferris, R.L., E.M. Jaffee, and S. Ferrone, Tumor antigen-targeted, monoclonal 
antibody-based immunotherapy: clinical response, cellular immunity, and 
immunoescape. Journal of Clinical Oncology, 2010. 28(28): p. 4390-9. 
109. Rommelfanger, D.M., et al., The efficacy versus toxicity profile of combination 
virotherapy and TLR immunotherapy highlights the danger of administering TLR 
 221 
 
agonists to oncolytic virus-treated mice. Molecular Therapy, 2013. 21(2): p. 348-
57. 
110. Lipson, E.J. and C.G. Drake, Ipilimumab: an anti-CTLA-4 antibody for metastatic 
melanoma. Clinical Cancer Research, 2011. 17(22): p. 6958-62. 
111. Casares, N., et al., Caspase-dependent immunogenicity of doxorubicin-induced 
tumor cell death. The Journal of Experimental Medicine, 2005. 202(12): p. 1691-
701. 
112. Zitvogel, L., et al., The anticancer immune response: indispensable for 
therapeutic success? The Journal of clinical investigation, 2008. 118(6): p. 1991-
2001. 
113. Bracci, L., et al., Cyclophosphamide enhances the antitumor efficacy of 
adoptively transferred immune cells through the induction of cytokine expression, 
B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. 
Clinical Cancer Research, 2007. 13(2 Pt 1): p. 644-53. 
114. Schiavoni, G., et al., Cyclophosphamide induces type I interferon and augments 
the number of CD44(hi) T lymphocytes in mice: implications for strategies of 
chemoimmunotherapy of cancer. Blood, 2000. 95(6): p. 2024-30. 
115. Chang, C.L., et al., Dose-dense chemotherapy improves mechanisms of antitumor 
immune response. Cancer Research, 2013. 73(1): p. 119-27. 
116. Andre, N., M. Carre, and E. Pasquier, Metronomics: towards personalized 
chemotherapy? Nature Reviews Clinical Oncology, 2014. 11(7): p. 413-31. 
117. Doloff, J.C., C.S. Chen, and D.J. Waxman, Anti-tumor innate immunity activated 
by intermittent metronomic cyclophosphamide treatment of 9L brain tumor 
xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2. 
Molecular cancer, 2014. 13: p. 158. 
118. Kagi, D., et al., Cytotoxicity mediated by T cells and natural killer cells is greatly 
impaired in perforin-deficient mice. Nature, 1994. 369(6475): p. 31-7. 
119. Pardo, J., et al., Granzymes are essential for natural killer cell-mediated and perf-
facilitated tumor control. European Journal of Immunology, 2002. 32(10): p. 
2881-7. 
 222 
 
120. Heusel, J.W., et al., Cytotoxic lymphocytes require granzyme B for the rapid 
induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell, 
1994. 76(6): p. 977-87. 
121. Peterson, R.A., Regulatory T-cells: diverse phenotypes integral to immune 
homeostasis and suppression. Toxicologic Pathology, 2012. 40(2): p. 186-204. 
122. Gautron, A.S., et al., Enhanced suppressor function of TIM-3+ FoxP3+ 
regulatory T cells. European Journal of Immunology, 2014. 44(9): p. 2703-11. 
123. Andersen, M.H., et al., Cytotoxic T cells. Journal of Investigative Dermatology, 
2006. 126(1): p. 32-41. 
124. Shevach, E.M., Mechanisms of foxp3+ T regulatory cell-mediated suppression. 
Immunity, 2009. 30(5): p. 636-45. 
125. Soudja, S.M., et al., Inflammatory monocytes activate memory CD8(+) T and 
innate NK lymphocytes independent of cognate antigen during microbial 
pathogen invasion. Immunity, 2012. 37(3): p. 549-62. 
126. Mouchemore, K.A. and F.J. Pixley, CSF-1 signaling in macrophages: pleiotrophy 
through phosphotyrosine-based signaling pathways. Critical Reviews in Clinical 
Laboratory Sciences, 2012. 49(2): p. 49-61. 
127. Noronha, V., et al., Metronomic therapy: chemotherapy revisited. Indian Journal 
of Cancer, 2013. 50(2): p. 142-8. 
128. Emens, L.A., Chemoimmunotherapy. The Cancer Journal, 2010. 16(4): p. 295-
303. 
129. Bouche, G., et al., Lessons from the Fourth Metronomic and Anti-angiogenic 
Therapy Meeting, 24-25 June 2014, Milan. Ecancermedicalscience, 2014. 8: p. 
463. 
130. Goldberg, E.L., et al., Immune memory-boosting dose of rapamycin impairs 
macrophage vesicle acidification and curtails glycolysis in effector CD8 cells, 
impairing defense against acute infections. The Journal of Immunology, 2014. 
193(2): p. 757-63. 
131. Mocikat, R., et al., Natural killer cells activated by MHC class I(low) targets 
prime dendritic cells to induce protective CD8 T cell responses. Immunity, 2003. 
19(4): p. 561-9. 
 223 
 
132. Salem, M.L. and M.S. Hossain, In vivo acute depletion of CD8(+) T cells before 
murine cytomegalovirus infection upregulated innate antiviral activity of natural 
killer cells. International Journal of Immunopharmacology, 2000. 22(9): p. 707-
18. 
133. Alvarez, M., et al., Increased Antitumor Effects Using IL-2 with Anti-TGF-beta 
Reveals Competition between Mouse NK and CD8 T Cells. The Journal of 
Immunology, 2014. 193(4): p. 1709-16. 
134. Fehniger, T.A., M.A. Cooper, and M.A. Caligiuri, Interleukin-2 and interleukin-
15: immunotherapy for cancer. Cytokine Growth Factor Review, 2002. 13(2): p. 
169-83. 
135. Parameswaran, N. and S. Patial, Tumor necrosis factor-alpha signaling in 
macrophages. Critical Review in Eukaryotic Gene Expression, 2010. 20(2): p. 87-
103. 
136. Ding, Z.C. and G. Zhou, Cytotoxic chemotherapy and CD4+ effector T cells: an 
emerging alliance for durable antitumor effects. Journal of Immunology 
Research, 2012. 2012: p. 890178. 
137. Sevko, A., et al., Cyclophosphamide promotes chronic inflammation-dependent 
immunosuppression and prevents antitumor response in melanoma. Journal of 
Investigative Dermatology, 2013. 133(6): p. 1610-9. 
138. Gabrilovich, D.I. and S. Nagaraj, Myeloid-derived suppressor cells as regulators 
of the immune system. Nature Reviews Immunology, 2009. 9(3): p. 162-74. 
139. Berard, M., et al., IL-15 promotes the survival of naive and memory phenotype 
CD8+ T cells. The Journal of Immunology, 2003. 170(10): p. 5018-26. 
140. Rozados, V.R., et al., The immune response and the therapeutic effect of 
metronomic chemotherapy with cyclophosphamide. Oncology Research, 2010. 
18(11-12): p. 601-5. 
141. Denies, S., et al., Combination of interleukin-12 gene therapy, metronomic 
cyclophosphamide and DNA cancer vaccination directs all arms of the immune 
system towards tumor eradication. Journal Control Release, 2014. 187: p. 175-82. 
142. Man, S., et al., Antitumor effects in mice of low-dose (metronomic) 
cyclophosphamide administered continuously through the drinking water. Cancer 
Research, 2002. 62(10): p. 2731-5. 
 224 
 
143. Khan, N., et al., Recurrent low-dose chemotherapy to inhibit and oxygenate head 
and neck tumors. Advances in Experimental Medicine and Biology 2014. 812: p. 
105-11. 
144. Klement, G., et al., Continuous low-dose therapy with vinblastine and VEGF 
receptor-2 antibody induces sustained tumor regression without overt toxicity. 
Journal of Clinical Investigation, 2000. 105(8): p. R15-24. 
145. Lake, R.A. and B.W. Robinson, Immunotherapy and chemotherapy--a practical 
partnership. Nature reviews. Cancer, 2005. 5(5): p. 397-405. 
146. Adair, J.E., et al., Gene therapy enhances chemotherapy tolerance and efficacy in 
glioblastoma patients. Journal of Clinical Investigation, 2014. 
147. Stupp, R., et al., Effects of radiotherapy with concomitant and adjuvant 
temozolomide versus radiotherapy alone on survival in glioblastoma in a 
randomised phase III study: 5-year analysis of the EORTC-NCIC trial. The 
Lancet Oncology, 2009. 10(5): p. 459-66. 
148. Wolff, J.E. and J.L. Finlay, High-dose chemotherapy in childhood brain tumors. 
Onkologie, 2004. 27(3): p. 239-45. 
149. Abrahamsen, T.G., et al., A phase I and II trial of dose-intensified 
cyclophosphamide and GM-CSF in pediatric malignant brain tumors. Journal of 
Pediatric Hematology/Oncology, 1995. 17(2): p. 134-9. 
150. Yule, S.M., et al., High-dose cyclophosphamide for poor-prognosis and recurrent 
pediatric brain tumors: a dose-escalation study. Journal of Clinical Oncology, 
1997. 15(10): p. 3258-65. 
151. Zitvogel, L., et al., The anticancer immune response: indispensable for 
therapeutic success? Journal of Clinical Investigation, 2008. 118(6): p. 1991-
2001. 
152. Guerriero, J.L., et al., Chemotherapy induces tumor clearance independent of 
apoptosis. Cancer Research, 2008. 68(23): p. 9595-600. 
153. Garber, M., et al., Computational methods for transcriptome annotation and 
quantification using RNA-seq. Nature Methods, 2011. 8(6): p. 469-77. 
 225 
 
154. Trapnell, C., et al., Differential gene and transcript expression analysis of RNA-
seq experiments with TopHat and Cufflinks. Nature Protocols, 2012. 7(3): p. 562-
78. 
155. Trapnell, C., et al., Transcript assembly and quantification by RNA-Seq reveals 
unannotated transcripts and isoform switching during cell differentiation. Nature 
Biotechnology, 2010. 28(5): p. 511-5. 
156. Anders, S. and W. Huber, Differential expression analysis for sequence count 
data. Genome Biology, 2010. 11(10): p. R106. 
157. Lu, B., et al., Regulation of HMGB1 release by inflammasomes. Protein Cell, 
2013. 4(3): p. 163-7. 
158. Ramachandrappa, S., et al., Rare variants in single-minded 1 (SIM1) are 
associated with severe obesity. Journal of Clinical Investigation, 2013. 123(7): p. 
3042-50. 
159. Basch, M.L., M. Bronner-Fraser, and M.I. Garcia-Castro, Specification of the 
neural crest occurs during gastrulation and requires Pax7. Nature, 2006. 
441(7090): p. 218-22. 
160. Serres, E., et al., Fibronectin expression in glioblastomas promotes cell cohesion, 
collective invasion of basement membrane in vitro and orthotopic tumor growth 
in mice. Oncogene, 2014. 33(26): p. 3451-62. 
161. Morrison, R.S., et al., Basic fibroblast growth factor and fibroblast growth factor 
receptor I are implicated in the growth of human astrocytomas. Journal of Neuro-
Oncology, 1994. 18(3): p. 207-16. 
162. Li, X., et al., Histone demethylase KDM5B is a key regulator of genome stability. 
Proceedings of the National Academy of Sciences of the United States of 
America, 2014. 111(19): p. 7096-101. 
163. Tonks, I.D., N.K. Hayward, and G.F. Kay, Pocket protein function in melanocyte 
homeostasis and neoplasia. Pigment Cell Research, 2006. 19(4): p. 260-83. 
164. Brekken, R.A. and E.H. Sage, SPARC, a matricellular protein: at the crossroads 
of cell-matrix communication. Matrix Biology, 2001. 19(8): p. 816-27. 
 226 
 
165. Rempel, S.A., et al., SPARC modulates cell growth, attachment and migration of 
U87 glioma cells on brain extracellular matrix proteins. Journal of Neuro-
Oncology, 2001. 53(2): p. 149-60. 
166. Chlenski, A., et al., SPARC is a key Schwannian-derived inhibitor controlling 
neuroblastoma tumor angiogenesis. Cancer Research, 2002. 62(24): p. 7357-63. 
167. Liu, J., et al., Phosphoglycerate dehydrogenase induces glioma cells proliferation 
and invasion by stabilizing forkhead box M1. Journal of Neuro-Oncology, 2013. 
111(3): p. 245-55. 
168. Dou, J., et al., Identifying tumor stem-like cells in mouse melanoma cell lines by 
analyzing the characteristics of side population cells. Cell Biology International, 
2009. 33(8): p. 807-15. 
169. Ehira, N., et al., An embryo-specific expressing TGF-beta family protein, growth-
differentiation factor 3 (GDF3), augments progression of B16 melanoma. Journal 
of Experimental & Clinical Cancer Research, 2010. 29: p. 135. 
170. Egea, L., et al., GM-CSF produced by nonhematopoietic cells is required for 
early epithelial cell proliferation and repair of injured colonic mucosa. The 
Journal of Immunology, 2013. 190(4): p. 1702-13. 
171. Tian, H., et al., Cellular immunotherapy using irradiated lung cancer cell vaccine 
co-expressing GM-CSF and IL-18 can induce significant antitumor effects. BMC 
Cancer, 2014. 14: p. 48. 
172. Choi, Y. and C.W. Kim, Antitumor effects of combined granulocyte macrophage 
colony stimulating factor and macrophage inflammatory protein-3 alpha plasmid 
DNA. Cancer Science, 2010. 101(11): p. 2341-50. 
173. Schmidt, S., M. Moser, and M. Sperandio, The molecular basis of leukocyte 
recruitment and its deficiencies. Molecular Immunology, 2013. 55(1): p. 49-58. 
174. He, Y., et al., Identification of a lysosomal pathway that modulates glucocorticoid 
signaling and the inflammatory response. Science Signaling, 2011. 4(180): p. 
ra44. 
175. Bradford, B.M. and N.A. Mabbott, Prion disease and the innate immune system. 
Viruses, 2012. 4(12): p. 3389-419. 
 227 
 
176. Amelio, I., et al., Serine and glycine metabolism in cancer. Trends in Biochemical 
Sciences, 2014. 39(4): p. 191-8. 
177. Ryu, C.S., et al., Elevation of cysteine consumption in tamoxifen-resistant MCF-7 
cells. Biochemical Pharmacology, 2013. 85(2): p. 197-206. 
178. Shen, J., et al., SULF2 methylation is associated with in vitro cisplatin sensitivity 
and clinical efficacy for gastric cancer patients treated with a modified FOLFOX 
regimen. PLoS One, 2013. 8(10): p. e75564. 
179. Tessema, M., et al., SULF2 methylation is prognostic for lung cancer survival 
and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15. 
Oncogene, 2012. 31(37): p. 4107-16. 
180. Schwarzbich, M.A., et al., The immune inhibitory receptor osteoactivin is 
upregulated in monocyte-derived dendritic cells by BCR-ABL tyrosine kinase 
inhibitors. Cancer Immunology, Immunotherapy, 2012. 61(2): p. 193-202. 
181. Sharda, S.V., et al., Do glutathione-S-transferase polymorphisms influence 
response to intravenous cyclophosphamide therapy in idiopathic nephrotic 
syndrome? Pediatric Nephrology, 2008. 23(11): p. 2001-6. 
182. Oliveira, A.L., et al., GSTT1, GSTM1, and GSTP1 polymorphisms and 
chemotherapy response in locally advanced breast cancer. Genetics and 
molecular research, 2010. 9(2): p. 1045-53. 
183. Tedeschi, M., et al., Glutathione and detoxification. Cancer Treatment Reviews, 
1990. 17(2-3): p. 203-8. 
184. Rouse, K., et al., Glutamine enhances selectivity of chemotherapy through 
changes in glutathione metabolism. Annals of Surgery, 1995. 221(4): p. 420-6. 
185. Settembre, C., et al., Signals from the lysosome: a control centre for cellular 
clearance and energy metabolism. Nature Reviews Molecular Cell Biology, 2013. 
14(5): p. 283-96. 
186. Watts, C., The endosome-lysosome pathway and information generation in the 
immune system. Biochimica et Biophysica Acta , 2012. 1824(1): p. 14-21. 
187. Pieper, C., et al., Brain capillary pericytes contribute to the immune defense in 
response to cytokines or LPS in vitro. Brain Research, 2014. 1550: p. 1-8. 
 228 
 
188. Bridges, E. and A.L. Harris, Vascular-promoting therapy reduced tumor growth 
and progression by improving chemotherapy efficacy. Cancer Cell, 2015. 27(1): 
p. 7-9. 
189. Wong, P.P., et al., Dual-Action Combination Therapy Enhances Angiogenesis 
while Reducing Tumor Growth and Spread. Cancer Cell, 2015. 27(1): p. 123-37. 
190. Ding, Z.C., et al., Chemotherapy rescues tumor-driven aberrant CD4+ T-cell 
differentiation and restores an activated polyfunctional helper phenotype. Blood, 
2010. 115(12): p. 2397-406. 
191. Velardi, E., et al., Sex steroid blockade enhances thymopoiesis by modulating 
Notch signaling. The Journal of Experimental Medicine, 2014. 211(12): p. 2341-
9. 
192. Zimmerman, M.A., et al., Butyrate suppresses colonic inflammation through 
HDAC1-dependent Fas upregulation and Fas-mediated apoptosis of T cells. The 
American Journal of Physiology-Gastrointestinal and Liver Physiology, 2012. 
302(12): p. G1405-15. 
193. Platten, M., W. Wick, and B.J. Van den Eynde, Tryptophan catabolism in cancer: 
beyond IDO and tryptophan depletion. Cancer Research, 2012. 72(21): p. 5435-
40. 
194. Sommereyns, C., et al., IFN-lambda (IFN-lambda) is expressed in a tissue-
dependent fashion and primarily acts on epithelial cells in vivo. PLOS Pathogens, 
2008. 4(3): p. e1000017. 
195. Kanda, T., et al., Different effects of three interferons L on Toll-like receptor-
related gene expression in HepG2 cells. Cytokine, 2013. 64(2): p. 577-83. 
196. Sun, Q., et al., The specific and essential role of MAVS in antiviral innate immune 
responses. Immunity, 2006. 24(5): p. 633-42. 
197. Waite, A., S.C. Brown, and D.J. Blake, The dystrophin-glycoprotein complex in 
brain development and disease. Trends in Neurosciences, 2012. 35(8): p. 487-96. 
198. Wurch, A., et al., Requirement of CD3 complex-associated signaling functions for 
expression of rearranged T cell receptor beta VDJ genes in early thymic 
development. The Journal of Experimental Medicine, 1998. 188(9): p. 1669-78. 
 229 
 
199. Feske, S., Calcium signalling in lymphocyte activation and disease. Nature 
Reviews Immunology, 2007. 7(9): p. 690-702. 
200. Huang, K.C., et al., Relationship of XIST expression and responses of ovarian 
cancer to chemotherapy. Molecular Cancer Therapeutics, 2002. 1(10): p. 769-76. 
201. Kosaka, N., et al., Neutral sphingomyelinase 2 (nSMase2)-dependent exosomal 
transfer of angiogenic microRNAs regulate cancer cell metastasis. The Journal of 
Biological Chemistry, 2013. 288(15): p. 10849-59. 
202. Alexandrou, A.T., et al., Abstract 2168: Per2 (PERIOD 2) mediates low-dose 
radiation-induced adaptive response in human mammary epithelial cells. Cancer 
Research, 2012. 72(8 Supplement): p. 2168-2168. 
203. Bonney, S., et al., Cardiac Per2 functions as novel link between fatty acid 
metabolism and myocardial inflammation during ischemia and reperfusion injury 
of the heart. PLoS One, 2013. 8(8): p. e71493. 
204. Eckle, T., et al., Adora2b-elicited Per2 stabilization promotes a HIF-dependent 
metabolic switch crucial for myocardial adaptation to ischemia. Nature Medicine, 
2012. 18(5): p. 774-82. 
205. Liu, J., et al., The circadian clock Period 2 gene regulates gamma interferon 
production of NK cells in host response to lipopolysaccharide-induced endotoxic 
shock. Infection and Immunity, 2006. 74(8): p. 4750-6. 
206. Silver, A.C., et al., The circadian clock controls toll-like receptor 9-mediated 
innate and adaptive immunity. Immunity, 2012. 36(2): p. 251-61. 
207. Sawatani, Y., et al., The role of DC-STAMP in maintenance of immune tolerance 
through regulation of dendritic cell function. International Immunology, 2008. 
20(10): p. 1259-68. 
208. Yamaji-Kegan, K., et al., Hypoxia-induced mitogenic factor has proangiogenic 
and proinflammatory effects in the lung via VEGF and VEGF receptor-2. 
American journal of physiology. Lung cellular and molecular, 2006. 291(6): p. 
L1159-68. 
209. Kolosova, I.A., et al., Resistin-like molecule alpha stimulates proliferation of 
mesenchymal stem cells while maintaining their multipotency. Stem Cells and 
Development, 2013. 22(2): p. 239-47. 
 230 
 
210. Thebault, P., et al., The C-type lectin-like receptor CLEC-1, expressed by myeloid 
cells and endothelial cells, is up-regulated by immunoregulatory mediators and 
moderates T cell activation. The Journal of Immunology, 2009. 183(5): p. 3099-
108. 
211. Chalifour, A., et al., A Role for cis Interaction between the Inhibitory Ly49A 
receptor and MHC class I for natural killer cell education. Immunity, 2009. 
30(3): p. 337-47. 
212. Sundback, J., et al., NK cell inhibitory receptor Ly-49C residues involved in MHC 
class I binding. The Journal of Immunology, 2002. 168(2): p. 793-800. 
213. McQueen, K.L., et al., Localization of five new Ly49 genes, including three 
closely related to Ly49c. Immunogenetics, 1998. 48(3): p. 174-83. 
214. Raes, G., et al., Macrophage galactose-type C-type lectins as novel markers for 
alternatively activated macrophages elicited by parasitic infections and allergic 
airway inflammation. Journal of Leukocyte Biology, 2005. 77(3): p. 321-7. 
215. Ying, W., et al., NAD+ as a metabolic link between DNA damage and cell death. 
Journal of Neuroscience Research, 2005. 79(1-2): p. 216-23. 
216. Iyanagi, T., Molecular mechanism of phase I and phase II drug-metabolizing 
enzymes: implications for detoxification. International Review of Cytology, 2007. 
260: p. 35-112. 
217. Lacotte, S., et al., CXCR3, inflammation, and autoimmune diseases. Annals of the 
New York Academy of Sciences, 2009. 1173: p. 310-7. 
218. Yusuf, N., et al., SPARC was overexpressed in human endometrial cancer stem-
like cells and promoted migration activity. Gynecologic Oncology, 2014. 134(2): 
p. 356-63. 
219. Li, O., P. Zheng, and Y. Liu, CD24 expression on T cells is required for optimal T 
cell proliferation in lymphopenic host. The Journal of Experimental Medicine, 
2004. 200(8): p. 1083-9. 
220. Griffith, J.W., C.L. Sokol, and A.D. Luster, Chemokines and chemokine 
receptors: positioning cells for host defense and immunity. Annual Review of 
Immunology, 2014. 32: p. 659-702. 
 231 
 
221. Lampinen, M., et al., CD14+CD33+ myeloid cell-CCL11-eosinophil signature in 
ulcerative colitis. Journal of Leukocyte Biology, 2013. 94(5): p. 1061-70. 
222. Alizadeh, D. and N. Larmonier, Chemotherapeutic targeting of cancer-induced 
immunosuppressive cells. Cancer Research, 2014. 74(10): p. 2663-8. 
223. Guerriero, J.L., et al., DNA alkylating therapy induces tumor regression through 
an HMGB1-mediated activation of innate immunity. The Journal of Immunology, 
2011. 186(6): p. 3517-26. 
224. Rodier, F., et al., Persistent DNA damage signalling triggers senescence-
associated inflammatory cytokine secretion. Nature Cell Biology, 2009. 11(8): p. 
973-9. 
225. Ma, J., et al., Antiangiogenesis enhances intratumoral drug retention. Cancer 
Research, 2011. 71(7): p. 2675-85. 
226. Krusch, M., et al., The kinase inhibitors sunitinib and sorafenib differentially 
affect NK cell antitumor reactivity in vitro. The Journal of Immunology, 2009. 
183(12): p. 8286-94. 
227. Dikov, M.M., et al., Differential roles of vascular endothelial growth factor 
receptors 1 and 2 in dendritic cell differentiation. The Journal of Immunology, 
2005. 174(1): p. 215-22. 
228. Bocci, G., et al., Increased plasma vascular endothelial growth factor (VEGF) as 
a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 
monoclonal antibodies. Cancer Research, 2004. 64(18): p. 6616-25. 
229. Shin, J.Y., et al., Vascular endothelial growth factor-induced chemotaxis and IL-
10 from T cells. Cell Immunology, 2009. 256(1-2): p. 72-8. 
230. Huang, Y., et al., Vascular normalizing doses of antiangiogenic treatment 
reprogram the immunosuppressive tumor microenvironment and enhance 
immunotherapy. Proceedings of the National Academy of Sciences of the United 
States of America, 2012. 109(43): p. 17561-6. 
231. Campeau, E. and S. Gobeil, RNA interference in mammals: behind the screen. 
Briefings in Functional Genomics 2011. 10(4): p. 215-26. 
232. Carette, J.E., et al., Haploid genetic screens in human cells identify host factors 
used by pathogens. Science, 2009. 326(5957): p. 1231-5. 
 232 
 
233. Shalem, O., et al., Genome-scale CRISPR-Cas9 knockout screening in human 
cells. Science, 2014. 343(6166): p. 84-7. 
234. Zhou, Y., et al., High-throughput screening of a CRISPR/Cas9 library for 
functional genomics in human cells. Nature, 2014. 509(7501): p. 487-91. 
235. Gupta, R.M. and K. Musunuru, Expanding the genetic editing tool kit: ZFNs, 
TALENs, and CRISPR-Cas9. Journal of Clinical Investigation, 2014. 124(10): p. 
4154-61. 
236. Wang, T., et al., Genetic screens in human cells using the CRISPR-Cas9 system. 
Science, 2014. 343(6166): p. 80-4. 
237. Horvath, P. and R. Barrangou, CRISPR/Cas, the immune system of bacteria and 
archaea. Science, 2010. 327(5962): p. 167-70. 
238. Engler, C., et al., Golden gate shuffling: a one-pot DNA shuffling method based 
on type IIs restriction enzymes. PLoS One, 2009. 4(5): p. e5553. 
 
  
 233 
 
CURRICULUM VITAE  
Junjie Wu 
2 Cummington Mall, Rm 301, Boston, MA 02215     
Tel: (617) 320-8613    Email: wujj2000@gmail.com    Year of Birth: 1976 
Education 
2008 - 2015 expected, Ph.D. in Molecular Medicine, Boston University School of Medicine, USA 
1998 – 2001, M.A. in Plant Pathology, Zhejiang University, Hangzhou, China     
1994 – 1998, B.S. in Tea Science, Zhejiang University, Hangzhou, China 
Research Experience 
Dr. David Waxman lab, Boston University, Boston, MA.                                Sept. 2010 - present  
 Mouse host, dose and schedule dependence of metronomic cyclophosphamide (CPA)-
activated immune responses; 
 Molecular mechanisms underlying schedule, tumor model, adaptive immune-dependence 
of CPA-activated immune responses; 
 The impact of anti-angiogenesis agents on CPA-activated immune responses; 
 Gene signatures responsible for NK cell recruitment in CPA-treated tumors. 
Dr. Jining Lu lab, Boston University School of Medicine, Boston, MA.       Feb 2007 - Aug. 2010  
miR-129 regulates cell cycle by targeting Cdk6: 
 Map miRNA expression: FISH, northern blot; 
 Manipulate miRNA: knock-down by LNA probes, over-expression by lentivirus; 
 miRNA targets: microarray, western blot, luciferase reporter and rescue assay.  
The Blood Center of Zhejiang Province, China.                                              Jul. 2001 - Jan. 2007 
 The 1st comprehensive molecular characterization of the Rhesus D variants in China; 
 Diagnose the hemolytic disease of the newborn, DNA sequencing, and HLA genotyping. 
The Institute of Biotechnology, Zhejiang Univ., China.                                 Sep. 1998 - Jun. 2001 
 Studied the gene determinants of plant virus host range and symptom;  
 Constructed chimeric plant virus infectious clones in plasmid vectors. 
Posters or Presentation 
2009, Third Place of Evans Day Poster Session Award, Boston University School of Medicine 
2009, Poster, Keystone Symposia: MicroRNA and Cancer, Colorado, USA 
2012, Selected speaker in the Workshop on Systems Biology of Tumor Metronomics in Boston. 
Selected Publications 
1. Wu J, Waxman D. Metronomic cyclophosphamide eradicates large implanted GL261 gliomas 
by activating antitumor Cd8
+
 T cell responses and immune memory. (Oncoimmunology, 
accepted;18 Feb 2015 online preview) . 
 234 
 
2. Wu J, Waxman D. Metronomic cyclophosphamide schedule-dependence of innate immune 
cell recruitment and tumor regression in an implanted glioma model. Cancer letter, 2014; 353: 
272-80. 
3. Wu J, Waxman D. Molecular mechanisms underlying metronomic cyclophosphamide tumor 
model, mouse host, and drug schedule dependence on immune responses. (in preparation). 
4. Wu J, Waxman D. Re-visiting immunogenic chemotherapy: dose and schedule dependence 
and a new direction. (in preparation). 
5. Roblyer D, Tabassum S, Istfan R, Zhao Y, Wu J, Waxman D. Preclinical Monitoring of Breast 
and Prostate Chemotherapy Response with Spatial Frequency Domain Imaging. Poster in SPIE 
Photonics West. 2015 Feb. 
6. Cushing L, Kuang PP, Qian J, Shao F, Wu J, et al. miR-29 is a major regulator of genes 
associated with pulmonary fibrosis. Am J Respir Cell Mol Biol. 2011; 45:287-94. 
7. Wu J, Qian J, Li C, et al. miR-129 regulates cell proliferation by down regulating Cdk6 
expression. Cell Cycle. 2010; 9: 1809-18. 
8. Wu J*, Yan L*, Zhu F, Hong X, Xu X. Molecular basis of D variants in Chinese persons. 
Transfusion. 2007 Mar; 47 (3): 471-7. (*: equal contribution) 
9. Yan L, Xu X, Hong X, Wu J, et al. Identification of a novel FUT1 allele derived from the a-
(1,2)-fucosyltransferase gene through a nucleotide substitution 682A>G, Transfusion Medicine. 
2006; 16 (6):447-9.  
10. Wu J, Hong X, Xu X, et al. Establishment of a Direct RHD Gene Sequencing Method 
and its Application to Molecular Identification of Weak D Phenotypes. Chin J Lab Med. 2006, 
29(5): 460-462. 
11. Wu J, Hong X, Xu X, et al. Molecular Basis of Partial D Phenotypes in Chinese. J Exp 
Hemat (Zhong Guo Shi Yan Xue Ye Xue Za Zhi). 2006, 14(3): 587-591. 
12. Wu J, Hong X, Ma K, et al. The establishment of genotyping method for DEL phenotype 
in Zhejiang Han population. J Exp Hemat. 2006, 14(5).1017-1019. 
13. Xu X, Wu J, Hong X, et al. Identification of nine novel alternative splicing isoforms of 
RHD mRNA. HEREDITAS. 2006, 28(10): 1213-1218. 
14. Wu J, Hong X, Xu X, et al. Study on the molecular structure of D VI type III phenotype. 
Natl Med J China. 2006, 86 (36): 2571-2574. 
15. Wu J, Hong X, Xu X, et al. Study of RHD 1227A Allele Frequency Among Rh Negative 
Population and Random Population. J Exp Hemat. 2006 Dec; 14 (6):1234-7. 
16. Wu J, Xu X, Hong X, et al. Serological and molecular characterization of a new RhD 
variant with weak expression in Chinese. Natl Med J China. 2005, 85 (23): 1638-1640. 
17. Yu C, Hu D, Dong J, Cui X, Wu J, et al. The symptom difference induced by tobacco 
mosaic virus and tomato mosaic virus in tobacco plants containing the N gene is determined by 
movement protein gene. Sci China C Life Sci. 2004, 47(6): 503-509. 
18. Wu J, Zhou X. Effects of replacing the movement protein gene of Tobacco mosaic virus 
by that of Tomato mosaic virus. Virus Research. 2002 (87): 61–67. 
19. Zhou X, Xie Y, Zhang Z, Qi Y, Wu J. Molecular characterization of novel defective 
DNA isolated from tobacco tissues infected with tobacco leaf curl virus. Acta Virologica. 2001, 
45(1): 45-50. 
 
Expertise:  
Gene clone and expression, FACS, lentivirus, cell/organ culture, qRT-PCR, northern blot,  
miRNA, RNA-Seq, xenograft, FISH, immunohistochemistry, western blot, ELISA, transfection 
